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ABSTRACT
Cancer is a major health problem in the world today and is expected to become an
even larger one in the future. Although cancer therapy has improved for many cancers
in the last several decades, there is much room for further improvement. Mathematical
modeling has the advantage of being able to test many theoretical therapies without
having to perform clinical trials and experiments. Mathematical oncology will continue
to be an important tool in the future regarding cancer therapies and management.
This dissertation is structured as a growing tumor. Chapters 2 and 3 consider
spheroid models. These models are adept at describing ‘early-time’ tumors, before
the tumor needs to co-opt blood vessels to continue sustained growth. I consider
two partial differential equation (PDE) models for spheroid growth of glioblastoma.
I compare these models to in vitro experimental data for glioblastoma tumor cell
lines and other proposed models. Further, I investigate the conditions under which
traveling wave solutions exist and confirm numerically.
As a tumor grows, it can no longer be approximated by a spheroid, and it becomes
necessary to use in vivo data and more sophisticated modeling to model the growth
and diffusion. In Chapter 4, I explore experimental data and computational models
for describing growth and diffusion of glioblastoma in murine brains. I discuss not only
how the data was obtained, but how the 3D brain geometry is created from Magnetic
Resonance (MR) images. A 3D finite-difference code is used to model tumor growth
using a basic reaction-diffusion equation. I formulate and test hypotheses as to why
there are large differences between the final tumor sizes between the mice.
Once a tumor has reached a detectable size, it is diagnosed, and treatment begins.
Chapter 5 considers modeling the treatment of prostate cancer. I consider a joint
model with hormonal therapy as well as immunotherapy. I consider a timing study
to determine whether changing the vaccine timing has any effect on the outcome of
i
the patient. In addition, I perform basic analysis on the six-dimensional ordinary
differential equation (ODE). I also consider the limiting case, and perform a full global
analysis.
ii
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Chapter 1
INTRODUCTION
1.1 Mathematics in Medicine
Mathematics has been used to model biological phenomena for centuries, although
it was only recently that mathematics was applied to medicine. One of the earliest
mathematical models in medicine is attributed to Bernoulli, who created a model to
investigate the efficacy of inoculation against smallpox (Bernoulli, 1760).
Within the realm of epidemiology, Kermack and McKendrick formulated the
well-known Susceptible-Infective-Recovered (S-I-R) model to explain the dynamics
of communicable diseases, specifically the spread of the bubonic plague in early
20th century Bombay (Kermack and McKendrick, 1927). This S-I-R type model
has birthed many related modeling frameworks such as the Susceptible-Exposed-
Infected-Recovered (S-E-I-R) and Susceptible-Infected-Recovered-Susceptible (S-I-R-
S) modeling frameworks. Researcher use these frameworks to model anything from
current disease outbreaks such as SARS (Ng et al., 2003) and H1N1 (Coburn et al.,
2009) to far more outlandish ideas like hypothetical zombie outbreaks (Munz et al.,
2009) and social disease dynamics from bulimia nervosa spread (Gonza´lez et al., 2003)
to drug addiction (Behrens et al., 1999).
Apart from epidemiology, mathematics has been extremely useful in understanding
disease dynamics on the sub-cellular, cellular, and tissue levels. There are many
resources detailing the types of mathematical models available for disease progression,
healthy organ function, and more (Bellman et al., 1983; Hoppensteadt and Peskin,
2013).
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1.2 Mathematical Oncology
Until approximately 50 years ago, researchers believed that tumor growth was
governed by an exponential process (Laird, 1964). Mayneord (1932) noticed that in
rat sarcomas, plotting the cube root of the total number of cancer cells against time
generated a linear fit, implying that the overall growth slows in the latter stages of
cancer. This finding was corroborated by other researchers for other types of cancers
(Klein and Re´ve´sz, 1953).
Due to the slowing growth in the late stages of cancer, Mendelsohn (1963) proposed
a slight variation on the equation for exponential growth, creating the power-law
growth. Ultimately, this is a generalization of exponential growth, which can produce
sub-exponential growth curves. In fact, if you choose parameters wisely, your solution
will have tumor volume growing approximately as time cubed, similar to that found
in Mayneord (1932).
Shortly thereafter, Laird (1964) applied the Gompertz Equation (Gompertz, 1825),
an equation that was initially used for mortality curves in actuarial practice, to tumor
growth. She keenly observed that growth given by the Gompertz Equation exhibited
retarding of the growth rate as time increased. Laird (1964) generated excellent fits
to over 20 separate experimental cancer studies, fitting the data using least-squares
methods. She used these fits to estimate doubling time and parameters.
Over twenty years prior to these works, von Bertalanffy (1938) developed a growth
equation, originally meant to model the growth of Lebistes Reticulatus, or guppies,
in terms of length and mass. This model has often been used sparingly in cancer
models, although it was suggested by von Bertalanffy himself in the early 1950s ( von
Bertalanffy and Pirozynski, 1953). This is the only example of a biologically-derived
growth model.
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One other model was suggested for growth, although not specifically for cancer
growth. The well-known logistic equation was first proposed by Verhulst (1845),
although mainly forgotten until revived by Pearl and Reed (1920), who used the
equation to model the population growth of the United Sates. The logistic curve
remains prevalent in today’s literature, modeling the growth of many tumor cells.
Recent work (Gerlee, 2013) argues that the von Bertalanffy model is most effective
due to it’s biologically-driven derivation and the fact that it had fit tumor growth
curves better than both the Gompertz and Logistic models, although only in animal
data (Vaidya and Alexandro, 1982). In human tumor data, the logistic curve was
found to be the best-fit (Vaidya and Alexandro, 1982). Recently Sarapata and de Pillis
(2014) compared five phenomenological models (exponential, power law, Gompertz,
logistic, and von Bertalanffy) to 10 types of cancer growths. They were unable to
conclude that one type of phenomenological model was always the best fit, rather
some methods fit the data better than others for certain types of cancers. They were
able to show, however, that the von Bertalanffy model was inferior to the logistic and
Gompertz models in 9 out of 10 cases (Sarapata and de Pillis, 2014). However, in
the same year, Benzekry et al. (2014) compared logistic, exponential, Gompertz, and
von Bertalanffy models (among others) and found the von Bertalanffy model able to
describe tumor data as well as the Gompertz model, but found the logistic model to
be lacking.
What conclusions can be drawn from such seemingly contradictory findings? Firstly,
I would argue that these findings do not contradict one another. Every type of cancer is
different. There is no one way to describe the growth of all types of cancers. Secondly,
the drawback to the previously mentioned works is that, in general, there is no real
physical or biological justification for the equations, although attempts were made for
the Gompertz equation (Xu, 1987). These works, although highly influential, exhibit
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some of the types of modeling which are phenomenological: models which are used to
fit the data rather than explain the underlying processes. In order to try to understand
the underlying processes, we must turn to mechanistic models.
Although mathematical oncology still represents a small amount of the work
performed in the mathematical biology field, it is on the rise. Textbooks aimed at
the upper undergraduate level and graduate level are becoming more commonplace
(Kuang et al., 2016; Wodarz and Komarova, 2014). For excellent reviews on the
progression of cancer modeling in mathematics, see Araujo and McElwain (2004) and
Byrne (2010).
In accordance with current Arizona State University policy, since portions of my
thesis have already been published, or are in the process of being published, I will
detail in this introduction the contributions I made to each of these papers and
projects. Additionally, I will discuss the contributions made by each author within
the publication and discuss the unique attributes I brought to the project and my
interpretation of the results.
1.3 Density-Dependent Diffusion Model of in vitro Spheroid Glioblastoma Growth
The article published in this section, (Stepien et al., 2015), is an article in which I
am the second author. The project investigated a one-dimensional density-dependent
diffusion model of glioblastoma multiforme (GBM) growth. A highly-cited paper,
Stein et al. (2007a), argued that in order to accurately model GBM, the population of
tumor cells must be split into proliferating cells and migrating cells. The explanation
is that cells either phenotypically stay put and proliferate (Grow), or they migrate but
do not proliferate (Go). This ‘Go or Grow’ hypothesis is widely used by mathematical
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modelers in the GBM field.
Dr. Kuang proposed a single equation model based on the biology of GBM. We
used a density-dependent diffusion which allowed for there to be high diffusion when
there is a low population (the migratory cells) and low diffusion when there is a high
population (the proliferating cells). This density-dependent diffusion was inspired by
the data obtained by the experimentalists, which showed a heavy proliferative core
that did not move much along with a very mobile, low-density region. The model
was fully analyzed, by the first author, Dr. Tracy Stepien, including determining
the minimum wave speed. The model was then used to fit the data presented in the
Stein et al. (2007a) paper. We were able to obtain a much higher quality fit than the
original two-equation model proposed by the experimentalists.
My part in this project was the numerical simulations. I performed a sensitivity
analysis of all the parameters present in our model, showing that all were sensitive.
I also estimated the parameters of our model in order to generate the best fit to
the experimental data. Finally, we were interested in numerically corroborating the
minimum wave speed found analytically, which I performed as well. Since I was not
involved in the analysis, I did not include that portion of the work in my thesis, only
stating the final result and citing the paper for those interested in reading the details.
I did, however, perform the stability of the traveling wave solutions, which was not
included in the original paper.
Overall, I initially wrote the introductory section, and the numerics section. All
authors proof-read and edited the paper as necessary. As per ASU regulations, the
full journal article appears in Appendix E.
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1.4 2 Population Model of in vitro Spheroid Glioblastoma Growth
The article in this section is an article in which I will be the second author, currently
in preparation for submission. As in the previous chapter, the project concerns the
experimental data obtained in the Stein et al. (2007a) paper. The original model
proposed by the experimentalists was more phenomenological, rather than mechanistic.
As such, it included terms that were problematic for both analysis and computation.
Dr. Kuang proposed a 2-equation model, with subpopulations of proliferating cells
and migrating cells, which can exhibit switching. In this model we assume a constant
diffusion. The model was analyzed by the first author, Dr. Tracy Stepien, who was
able to determine the minimum wave speed. The model was then used to fit the
experimental data. However, we were only able to obtain a similar fit as the model
proposed by the experimentalists, and much larger than that of our density-dependent
diffusion model, presented in Chapter 2.
My part in this project was again the numerics. I wrote a basic solver, based on
the Crank-Nicolson method, which proved to be more efficient and accurate than
MATLAB’s built-in pde solver pdepe. I performed sensitivity analysis to determine
how each parameter affected the outcome of the solution. I also estimated the
parameters necessary in order to obtain the best fit to the experimental data. In this
paper, the analysis performed (not by me and not included in my thesis) informed us
that there was a possible range of what we could expect the minimum wave speed
to be. I then plotted the theoretical minimum wave speeds versus the computed
minimum wave speeds for a variety of parameter values.
Lastly, we compared all proposed models in their ability to fit the experimental
data. The argument for comparing all of these models is that we are unsure which type
of model fits the data best. Most of the models are derived from biological assumptions
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and conditions. Having a model fit the experimental data, with parameters in their
biologically relevant ranges, leads credence to the underlying biological assumptions
made in constructing the model. Although being able to fit experimental data to a
model does not validate the model, it does help justify the assumptions. In performing
this comparison, we are eager to see if the ‘Go or Grow’ hypothesis is truly biologically
relevant.
Overall, I initially wrote the introductory section and the numerics section. All
authors proof-read and edited the paper as necessary.
1.5 in vivo Murine Model of Glioblastoma Growth
The article published in this chapter is an article in which I am the first author.
This intensive project included obtaining five immune-competent mice, injecting them
with GL261-Luc2 cells (a cell line that shares many characteristics with the human
GBM), imaging these mice at five separate time points after injection using Magnetic
Resonance Imaging (MRI), processing these images to become computational domains,
and finally performing parameter estimations to generate the best fit with our model.
Because this work is so intensive, there are many co-authors involved in this paper.
I will specifically highlight the aspects of this project that I performed. I became
involved in the project just as the imaging was being finished. For the experimental
side, Dr. Adrienne C. Scheck grew the tumor cell lines, which were implanted into the
mice by Eric C. Woolf. The MR protocol was designed by Dr. Gregory Turner, Dr.
Qingwei Liu and Dr. Vikram Kodibagkar. Jonathan Plasencia performed the image
acquisition and trained me for image processing, which was overseen by Dr. David
Frakes. Dr. Mark C. Preul oversaw the experimental portion of this project. I was
involved in the post-processing of the MR images into computational domains as well
as formulating the hypotheses and performing the parameter estimation.
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To start the post-processing of images, I used the medical software Mimics R© (Ma-
terials Inc, Leuven, Belgium). The raw images involved not just the brain, but also
the skull, eyes, and other material that needed to be eliminated in order to obtain the
brain geometry. Each mouse at each time point has approximately 20-25 2D images
that can be stacked to make a 3D brain geometry. To eliminate non-brain matter, I
used thresholding techniques in Mimics R© (Materials Inc, Leuven, Belgium) in order
to segment out a rough brain outline. In order to ensure a computationally-friendly
domain, I smoothed these edges pixel by pixel for each of the 20-35 images, for each
of the five mice, at all five time points. In addition, I segmented the regions of visible
tumor on the MR images, by hand, which was corroborated independently by another
student, Jonathan Plasencia.
From these brain segmentations, I output the brain surface mesh into point-cloud
form for each mouse at each time point. We decided that all brain geometries would
be registered to their third time point. We assume that the overall volume of the
brain does not change over the course of the experiment. However, the placement
of the mouse for each MR scan could have been slightly different, so we must make
sure to register all the brain volumes to their respective third time point. In order
to do this, for each mouse, I input the outputted brain surface mesh from the first
time point and from the third time point into Geomagic Studio (Geomagic Inc, NC),
which calculated the affine matrix describing the rotation, scaling, reflection, and
shearing needed to transform the brain surface at the first time point to match the
brain surface at the registered brain at time point 3. This was done for each mouse at
each time point and MATLAB was then used to apply the affine matrices, using code
written by Jonathan Plasencia.
Once we began looking at the tumor sizes, we realized there was a lot of variation
between the mice. I formulated three distinct hypotheses as to why the variation
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existed. Using a 3D finite-difference code written by Barrett Anderies, I tested these
three hypotheses by performing parameter optimization and comparing my results
with the data. Other aspects of the paper, such as the 2D level set code were performed
by Dr. Tracy Stepien and theerfore not included in my dissertation. Dr. Yang Kuang
and Dr. Eric Kostelich assisted with the modeling aspect of the project.
Overall, I initially wrote the majority of the paper, excepting the sections on
experimental methods (written by Jonathan Plasencia) and the 2D level set results
(written by Dr. Tracy Stepien). All authors assisted in proof-reading and improving
the paper.
1.6 Global Dynamics of a Model of Joint Hormone Treatment with Dendritic Cell
Vaccines for Prostate Cancer
The article published in this chapter is one in which I am the first author. This
project concerns how the timing and dosage of treatment therapies for prostate cancer
influence the dynamics of the disease. The model is an extension of a previous
model, which the other author, Dr. Yang Kuang, suggested could be improved by
incorporating a few key changes such as generalizing the functions. Previous work
had only considered one dosage. Our paper examined how timing dosage affected the
outcome of the disease. Based on our observation that frequent small injections were
much more effective than infrequent large injections, we considered the special case
where the patient is intravenously connected to the vaccine. From here we performed
bifurcation analysis on a personalized parameter for which literature suggests there is
a range of values. We analyzed this system, proving positivity and determining local
stability of the disease-free equilibrium. Finally, we let the model go to quasi-steady
state, which gave a system of two equations. I performed full global analysis on this
system, including conditions necessary for the global stability of both the disease-free
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equilibrium and the endemic equilibrium. We wrapped up the paper by translating
our mathematical conditions for global stability back into biological meaning.
I performed both theoretical and computational work for this project. At the
beginning of the project, I proposed growth functions for the androgen-dependent and
androgen-independent cells that were more biologically likely. I generated all figures
studying the vaccine timing using MATLAB code and the ode45 solver. I created
the bifurcation diagram through one of the parameters and examined the effect of
continual dosing strategies.
In addition to the computational work, I also thoroughly analyzed the model.
For the full model, I performed basic positivity analysis and proved local stability. I
then translated this local stability condition back into a minimum dosage needed to
theoretically eradicate the prostate cancer.
At Dr. Kuang’s suggestion, I then let the model go to quasi-steady state, reducing
the model to a system of two equations. I performed numerical simulation to show
that, in the limit, the full system and the quasi-steady state system exhibit the same
dynamics. I fully analyzed the quasi-steady state system and found global stability
conditions. I also spearheaded the effort to translate these conditions back into
biological meaning.
I wrote the majority of the paper, including background, model introduction and
the results. Dr. Yang Kuang oversaw the writing and double-checked the proofs and
analysis for correctness. This publication has been accepted and, per ASU regulations,
is included in Appendix F.
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Chapter 2
DENSITY-DEPENDENT DIFFUSION MODEL OF IN VITRO SPHEROID
GLIOBLASTOMA GROWTH
2.1 Introduction
In the early stages of cancer, the tumor is initially somewhat self-sufficient. The
tumor is small enough that it is able to acquire nutrients without the growth of new
blood vessels. The growth and spread of this young tumor can be approximated by
spheroids. There is no competition yet for space nor nutrients, and simple models can
be used to approximate the growth of the tumor.
In this chapter, I present a spheroid model of glioblastoma growth, comparing and
contrasting it’s ability to fit experimental in vitro data. I also analyze the model to
determine the stability of traveling waves of the growing spheroid and compare with
the numerically obtained traveling wave speed. Some of the work contained in this
chapter has been previously published and the full journal article is in Appendix E.
2.1.1 Glioblastoma Multiforme (GBM)
Glioblastoma multiforme (GBM) is a malignant form of brain cancer that has a very
negative prognosis. Even with treatment, mean survival time from detection is less than
15 months (Norden and Wen, 2006). Symptoms of GBM include seizures, hemorrhaging,
and tumor necrosis. Additionally tumors are difficult to treat because GBM are
characterized not only by intense proliferation, but also by excessive migration. This is
complicated by the fact that surgical resection is performed on what is visibly identified
as ‘tumor’ in MR images. Only areas of intense proliferation, leaky vasculature, and
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high tumor volume are often visible in MR images. Thus, surgical resection is able
to remove the tumor core, but less effective at identifying areas where there are few
tumor cells. After resection, secondary tumors often occur, which may be fatal.
The dichotomy between proliferation and invasive migration also makes GBM
difficult to model. Early models of GBM growth include reaction-diffusion equations
that are able to accurately capture the proliferating tumor core. Tracqui et al.
formulated the earliest reaction-diffusion model to describe glioblastoma growth and
diffusion, combined with therapeutic intervention (Tracqui et al., 1995). Swanson et al
continued with these reaction-diffusion models, accounting for a spatially-dependent
diffusion function in an attempt to capture the migratory behavior of the tumor
cells (Swanson et al., 2003). However, none of these reaction-diffusion models were
able to accurately model both the proliferating core and the invasive populations.
2.1.2 Stein et al. (2007a) Experimental Data and Model
An influential paper was published by Stein et. al in 2007 where an in vitro cell line
experiment was performed. Two human astrocytoma U87 cell lines were implanted
into gels—one with a wild-type receptor (EGFRwt) and one with an over-expression of
the epidermal growth factor receptor gene (∆EGFR). The resulting spheroids were left
to grow over 7 days and imaged every day. A summary of the results of the experiment
for the invasive and proliferating cell radii on days 0, 1, 3, and 7 is presented in Figure
2.1. The tumor core radius was measured to be where pixels had an intensity of
< 0.12 and the invasive radius as the half-maximum for the image averaged over the
azimuthal angle. From this data, the authors concluded that in order to accurately
model the invasive radius, it was necessary to use two equations to model the tumor
cells: one for the proliferating core cells and one for the migratory cells (Stein et al.,
2007a).
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Day 0 Day 1 Day 3 Day 7
Figure 2.1: The radius of the core proliferating (black) and migratory (red dashed)
cells for the experiment for EGFRwt strain from (Stein et al., 2007a) on days 0, 1, 3,
and 7. The domain is a 3 mm by 3 mm square.
The landmark mathematical model introduced by Stein et al. (Stein et al., 2007a)
advocated for the separation of glioblastoma cells into two separate populations: the
proliferating core cells and the migratory cells. In addition to the standard reaction-
diffusion terms in the equation for migratory cells, the model includes a radially biased
motility term corresponding to convection to account for the situation where cells
detect the location of the tumor core and actively move away from it (Stein et al.,
2007a).
The mathematical model proposed by the experimentalists describes the movement
of the invasive, or migratory, cells (ui) for the EGFRwt cell line and the ∆EGFR cell
line based on the experiment described above. The radius of the tumor core, consisting
of the less mobile cells, is modeled as increasing at a constant rate based on the in
vitro experimental data (Stein et al., 2007a). The model assumes that the proliferating
tumor cells leave the tumor core and become migratory cells and invade the collagen
gel (Stein et al., 2007a). The behavior of invasive cells is described by the model
in a way that can be quantitatively compared to the experimental measurements.
The invasive cell population is governed by the following ad hoc partial differential
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equation:
∂ui(r, t)
∂t
= D∇2ui︸ ︷︷ ︸
diffusion
+ gui
(
1− ui
umax
)
︸ ︷︷ ︸
logistic growth
− νi∇r·ui︸ ︷︷ ︸
taxis
+ sδ(r −R(t))︸ ︷︷ ︸
shed cells from core
(2.1)
where ui represents the invasive cells of the tumor at radius r and time t (Stein
et al., 2007a). The change in invasive cell population is governed by random diffusion,
directed diffusion (taxis), logistic growth, and cells being ‘shed’ from the proliferating
tumor core population. Taxis refers to the active biased motility of invasive cells
away from the tumor core which the authors attribute to possibly chemotaxis or
haptotaxis (Stein et al., 2007a). This taxis term was found to be more necessary for
the highly invasive EGFRwt strain compared to the less invasive ∆EGFR strain. For
our model, I will only consider the EGFRwt strain, as it was more invasive, and thus,
more difficult to model accurately. The shedding term represent the tumor cells at
the front of the invasion: tumor cells which are proliferating may make a phenotypic
switch from proliferating to migrating cells. This is a well-known hypothesis termed
‘Go or Grow’, which stipulates that glioma cells are either growing (proliferating), or
migrating, but cannot be doing both (Hatzikirou et al., 2010).
The parameters of the model are as follows: D is the random diffusion constant,
g is the intrinsic growth rate, umax is the carrying capacity of tumor cells, νi is the
degree at which cells preferentially migrate away from the core, s is the number of
proliferating cells shed per day, and δ is the Dirac delta function. The radius of the
tumor core is modeled by R(t) = R0 + νct, where R0 is the initial radius of the tumor
core on day 0 and νc is the constant velocity at which the tumor core radius increases.
This value of νc was determined by linearly fitting the invasive radii through time.
Additionally, the data on the invasive cell radius also appears to be somewhat linear,
implying that traveling wave speed analysis could be beneficial. However, the existence
of the Dirac delta function makes this model difficult to analyze, both theoretically
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and numerically. Furthermore, the term is somewhat artificial. In order to perform
traveling wave speed analysis on both proliferating and migrating cells, we propose a
model which contains only one cell population, but uses a density dependent diffusion
function.
2.2 Model Introduction
The model is inspired by the data presented in the paper, so we build our model
with a similar base. The population of cells is governed mainly by logistic growth,
taxis, and density-dependent diffusion. The cell-shedding term is not needed, as there
is no separation between the populations of proliferating and migrating cells. Logistic
growth is used because the tumor cells grow in number, and logistic growth is a
sensible choice. The experimental results also suggest the core reaches a capacity
of tumor cells. The undetermined taxis term is kept, since the experimental results
suggest that glioblastoma tumor cells migrate preferentially away from the tumor
core (Stein et al., 2007b). As mentioned earlier, many current cancer cell migration
models are based on reaction-diffusion equations and most of those models consider
diffusion to be a constant or a function of space. There is no reason to assume that
diffusion occurs at a constant rate. Also, many consider spatially dependent diffusion,
to differentiate between cell movement in white matter and grey matter. Since there
is no brain geometry in this model, spatially-dependent diffusion functions are not
applicable. Instead, the diffusion function is based on the density of cells. Some cell
migration models have included density-dependent diffusion, such as wound healing
models (Cai et al., 2007).
The governing equation is a density-dependent convective-reaction-diffusion equa-
tion, which implies that the amount of random diffusion depends on how many cells
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are present. The equation for the tumor cells u(x, t) is:
∂u
∂t
= ∇ ·
(
D
(
u
umax
)
∇u
)
︸ ︷︷ ︸
density-dependent diffusion
+ gu
(
1− u
umax
)
︸ ︷︷ ︸
logistic growth
− sgn(x)νi∇ · u︸ ︷︷ ︸
taxis
(2.2)
where the equation is in Cartesian coordinates but assume there is radial symmetry.
Parameters g and νi are as in equation (2.1), but now they are in relation to the entire
tumor cell population instead of just the invasive cell population.
There are many functions that could serve as the density-dependent diffusion
D(u∗), where u∗ = u
umax
. Experimental work suggests that diffusion is large for areas
where the cell density is small (the migrating tumor cells), but diffusion is small where
the cell density is large (the proliferating tumor cells) (Stein et al., 2007a). This
relation could possibly be explained by cell–cell adhesion (Armstrong et al., 2006). To
capture this behavior, the diffusion is:
D(u∗) = D1 − D2(u
∗)n
an + (u∗)n
. (2.3)
For biologically relevant parameters, positivity is assumed, n > 1, and D2 ≤ D1
to avoid “negative” diffusion, which is a problem both biologically and numerically.
Examples of the density-dependent diffusion function for varying a values and n values
are shown in Figure 2.2. The parameter n governs how steeply the function decreases
and the parameter a governs the u∗ value at which the transition is occurring at
half maximal rate. D1 and D2 govern the range of the function: if D1 and D2 are
far apart, diffusion could be approximated by a constant, however if D1 and D2 are
similar, diffusion is very different when cell populations are low compared to when
cell populations are high.
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Figure 2.2: The density-dependent diffusion function D(u∗), where u∗ = u
umax
, from
Equation (2.3) for D1 = 0.5, D2 = 0.4, and various a and n. As u
∗ increases, D(u∗)
decreases from its maximum D1 to its minimum D1 −D2.
2.3 Analysis
2.3.1 Existence of Traveling Waves
One of the fundamental questions with in vitro tumor growth is how fast is the
tumor growing? Can we estimate how far the tumor will spread after a certain amount
of time? We want to quantify tumor spread, not just computationally, but also
analytically. To this end, we will need to analyze the traveling wave solutions.
Traveling wave solutions have been studied in models of glioblastoma growth
with multiple cell populations and constant diffusion ((Pe´rez-Garc´ıa et al., 2011),
(Harko and Mak, 2015)). Traveling wave solutions also arise in density-dependent
reaction-diffusion equations, and numerous density-dependent diffusion functions have
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been studied ((Atkinson et al., 1981), (Murray, 2002), (Witelski, 1994), (Sa´nchez-
Gardun˜o and Maini, 1995), (Harris, 2004), (Pedersen, 2005), (Maini et al., 2006),
(Sa´nchez-Gardun˜o et al., 2010), (Ngamsaad and Khompurngson, 2012), and (Kengne
et al., 2013)). More generally, traveling wave solutions for convective-reaction-diffusion
equations have also been studied ((Malaguti and Marcelli, 2002), (Malaguti et al.,
2010), (Malaguti et al., 2011), (Gilding and Kersner, 2005)). Minimal speeds for
various diffusion and convective terms were estimated.
For the model (2.2) with density-dependent diffusion function (2.3), the minimum
wave speed is:
k ≥ kmin = 2
√
D1g + νi. (2.4)
For full explanation and details regarding the proof, see Stepien et al. (2015).
2.3.2 Stability of Traveling Waves
I want to investigate the stability of the traveling waves. I follow the methods from
Canosa (1973) to determine what conditions, if any, must be met for wave stability.
Rewriting (2.2) in one-dimensional Cartesian coordinates, the governing equation
is
∂u
∂t
= D
(
u
umax
)
∂2u
∂x2
+
1
umax
D′
(
u
umax
)(
∂u
∂x
)2
− νi∂u
∂x
+ gu
(
1− u
umax
)
. (2.5)
I rescale by writing
t∗ = gt, x∗ = x
√
g, u∗ =
u
umax
,
set
v =
νi√
g
,
and, omitting the asterisks and dividing through by gumax for simplicity, the equation
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(2.5) becomes
∂u
∂t
= D(u)
∂2u
∂x2
+D′(u)
(
∂u
∂x
)2
− v∂u
∂x
+ u (1− u) . (2.6)
In order to investigate the stability of traveling wave solutions, I re-write the
equations in terms of the moving coordinate system: z = x− ct, where c ≥ 0 is the
minimum wave speed. Then the calculated partial derivatives are:
∂u
∂t
=
∂u
∂t
+
∂u
∂z
∂z
∂t
=
∂u
∂r
− c∂z
∂t
∂u
∂x
=
∂u
∂z
∂2u
∂x2
=
∂2u
∂z2
I can then express the equation in the moving coordinate frame:
∂u
∂t
− c∂u
∂z
= D(u)
∂2u
∂z2
+D′(u)
(
∂u
∂z
)2
− v∂u
∂z
+ u(1− u)
∂u
∂t
= D(u)
∂2u
∂z2
+
∂u
∂z
(
D′(u)
∂u
∂z
− v + c
)
+ u(1− u)
Following the work in Canosa (1973), I assume there exists a solution for the
traveling wave in the form u(z, t) = uc(z), meaning that
∂u
∂t
= 0, ∂u
∂z
= u′c,
∂2u
∂z2
= u′′c
and the equation becomes:
0 = D(uc)u
′′
c + u
′
c
(
D′(uc)u′c − v + c
)
+ uc(1− uc) (2.7)
Now I assume a slight perturbation away from the traveling wave speed, y(z, t),
which I assume goes to zero far away from the wave front: y(z, t) = 0 if |y| ≥ L.
Then I can see what happens to the wave speed when it is perturbed by investigating
w = uc + y:
∂w
∂t
=
∂y
∂t
∂w
∂z
=
∂uc
∂z
+
∂y
∂z
∂2w
∂z2
=
∂2uc
∂z2
+
∂2y
∂z2
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We now look to plug in our findings for the equation in terms of w(z, t):
∂w
∂t
= D(w)
∂2w
∂z2
+
∂w
∂z
(
D′(w)
∂w
∂z
− v + c
)
+ w(1− w)
and note in terms of our uc and y:
∂y
∂t
= D(uc + y)
[
∂2uc
∂z2
+
∂2y
∂z2
]
+
[
∂uc
∂z
+
∂y
∂z
] [
D′(uc + y)
(
∂uc
∂z
+
∂y
∂z
)
− v + c
]
+ (uc + y)(1− (uc + y))
and by expanding all terms
∂y
∂t
= D(uc + y)
∂2uc
∂z2
+
∂uc
∂z
[
D′(uc + y)
∂uc
∂z
− v + c
]
+ uc(1− uc)
+D(uc + y)
∂2y
∂z2
+
∂uc
∂z
D′(uc + y)
∂y
∂z
+
∂uc
∂z
D′(uc + y)
∂y
∂z
∂y
∂z
[
D′(uc + y)
∂y
∂z
− v + c
]
+ y(1− y)− 2ucy
Under the assumption that D(uc + y) ≈ D(uc) and D′(uc + y) ≈ D′(uc) and by
Equation (2.7), this simplifies greatly to:
∂y
∂t
= D(uc + y)
∂2y
∂z2
+ 2
∂uc
∂z
D′(uc + y)
∂y
∂z
+
∂y
∂z
[
D′(uc + y)
∂y
∂z
− v + c
]
+ y(1− y)− 2ucy
Now, ignoring all terms which are higher than first order in y generates:
∂y
∂t
= D(uc + y)
∂2y
∂z2
+
[
2D′(uc + y)
∂uc
∂z
− v + c
]
∂y
∂z
+ (1− 2uc)y (2.8)
I will now assume a solution of the form y(z, t) = g(z)e−λt, which means the partial
derivatives are given by the following
∂y
∂t
= −λg(z)e−λt
∂y
∂z
= g′(z)e−λt
∂2y
∂z2
= g′′(z)e−λt
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which, when plugged into Equation (2.8), gives the following relationship:
−λg(z)e−λt = D(uc)g′′(z)e−λt+g′(z)e−λt
[
2D′(uc)u′c − v + c
]
+g(z)e−λt
[
1− 2ucg′′(z)
]
(2.9)
which can be rearranged into terms of g(z) as:
g′′(z)D(uc) + g′(z)
[
2u′cD
′(uc)− v + c
]
+ g(z) [1− 2uc + λ] = 0 (2.10)
In order to simplify the calculation, we assume that g(z) = h(z)ep(z), where
p′(z) = 1
D(uc)
(−u′cD′(uc) + v2 − c2). Then it is apparent that the derivatives are given
by the following:
g(z) = h(z)ep(z)
g′(z) = h′(z)ep(z) + h(z)p′(z)ep(z)
g′′(z) = h′′(z)ep(z) + 2h′(z)p′(z)ep(z) + h(z)p′′(z)ep(z) + h(z)(p′(z))2ep(z)
These can then be substituted into Equation (2.10) to arrive at the expression
involving h(z):
h′′(z)D(uz) + 2h′(z)p′(z)D(uc) + h(z)p′′(z)D(uc) + h(z)(p′(z))2D(uc)+
h′(z)[2u′cD
′(uc)− v + c] + h(z)p′(z)[2u′cD′(uc)− v + c] + h(z)[1− 2uc + λ] = 0
We notice that [2u′cD
′(uc)− v + c] = −2D(uc)p′(z) and we can simplify to:
h′′(z) + h(z)
[
λ
1
D(uc)
− q(z)
]
= 0 (2.11)
where q(z) = (p′(z))2 − p′′(z) + 2uc−1
D(uc)
.
Proposition 1. Equation (2.11) is a regular Sturm-Liouville problem.
Proof. A regular Sturm-Liouville problem is of the form:
d
dz
[
m(z)
dh
dz
]
+ [λw(z)− q(z)]h = 0, a < z < b
α0h(a) + α1h
′(a) = 0
β0h(b) + β1h
′(b) = 0
(2.12)
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where the boundary conditions are unmixed and the following conditions are met:
1. (a, b) is finite
2. m,m′, q, w are all real and continuous on the interval [a, b]
3. m > 0, w > 0 on [a, b].
In our case, m(z) = 1, w(z) = 1
D(uc)
, and q(z) = (p′(z))2 − p′′(z) + 2uc−1
D(uc)
. Let us
examine each condition in detail.
1. (a, b) is finite.
Without loss of generality, the interval of interest for us is (0,L). We could choose
any arbitrary finite end-point to this interval, L <∞.
2. m,m′, q, w are all real and continuous on the interval [a, b]
Since m(z) = 1, both m and m′ are real and continuous on our arbitrary interval
(0,L).
q(z) = (p′(z))2− p′′(z) + 2uc−1
D(uc)
. We need to show that this is real and continuous.
We start by rewriting q(z) by expanding and combining all terms to see exactly
what q(z) is comprised of:
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q(z) = (p′(z))2 − p′′(z) + 2uc − 1
D(uc)
=
1
D(uc)2
[
(u′cD
′(uc))2 − vu′cD′(uc) + cu′cD′(uc)− cv +
c2
4
+
v2
4
]
− 1
D(uc)
[
D(uc)(−u′2c D′′(uc)− u′′cD′(uc))
]
+
1
D(uc)2
[
D′(uc)u′cv
2
− D
′(uc)u′cc
2
− (D′(uc)u′c)2)
]
+
2uc − 1
D(uc)
=
1
D(uc)2
[
D′(uc)u′c
2
(c− v)− cv
2
+
1
4
(v2 + c2)
]
+
1
D(uc)
[2uc − 1 + (u′c)2D′′(uc) + u′′cD′(uc)]
We know that uc, u
′
c, D(uc) and D
′(uc) are all real and continuous functions.
We also know that D(uc) > 0 ∀ uc ≥ 0, so we do not have discontinuities
in our q(z) function. The only possible sources of discontinuity would then
be D′′(uc) = −D2nanu
n−2
c (a
n(n−1)−unc (n+1))
(an+unc )
3 , which obviously does not have any
discontinuities, and u′′c itself, which there is no reason to believe is not continuous.
w(z) = 1
D(uc)
is continuous everywhere on our interval.
3. m > 0, w > 0 on [a, b]
m(z) = 1 > 0 everywhere and w(z) = 1
D(uc)
> 0 everywhere since D(uc) > 0.
Thus, Equation (2.11) is a regular Sturm-Liouville problem.
There are many benefits to a regular Sturm-Liouville problem, including that all
eigenvalues are real and can form an infinite ordered sequence λ1 < λ2 < λ3 < .... We
will use these properties in order to prove the following main result.
Theorem 2.3.1. Traveling wave solutions to Equation (2.6) are stable, assuming that
∂2
∂z2
(
D(uc(z))
)
+ 2uc(z) ≥ 0.
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Proof. We must show that eigenvalues of Equation (2.11) are all positive. If these
eigenvalues are positive, then y(z, t) = g(z)e−λt → 0 as t→∞. This will prove that
the traveling wave solution is asymptotically stable.
I follow along the guidelines set out by Kot (2001), and see that in order to have
positive eigenvalues we need q(z) > 0 by the Raleigh quotient:
λ =
∫ L
0
[h′(z)2 + q(z)h(z)2]dz∫ L
0
h(z)2dz
(2.13)
q(z) > 0 is a sufficient, but not necessary condition. If we examine q(z) in detail, in
terms of signs:
q(z) = (p′(z))2 − p′′(z) + 2uc − 1
D(uc)
=
D′(uc)u′c
2
[c− v]︸ ︷︷ ︸
≥0
−cv
2︸︷︷︸
≤0
+
v2
4︸︷︷︸
≥0
+
c2
4︸︷︷︸
≥0
+ 2D(uc)uc︸ ︷︷ ︸
≥0
−D(uc)︸ ︷︷ ︸
≤0
+ (u′c)
2︸︷︷︸
≥0
D′′(uc)︸ ︷︷ ︸
?
D(uc)︸ ︷︷ ︸
≥0
+ u′′c︸︷︷︸
?
D′(uc)︸ ︷︷ ︸
≤0
D(uc)︸ ︷︷ ︸
≥0
Note that these assumptions are based on the fact that our density-dependent
diffusion D(u) is positive and decreasing, as is our wave solution uc.
According to our theorem assumptions, ∂
2
∂z2
(
D(uc(z))
)
+ 2uc(z) ≥ 0. which implies
that (u′c)
2D′′(uc)D(uc) + u′′cD
′(uc)D(uc) + 2D(uc)uc ≥ 0. Therefore, everything is
nonnegative except − cv
2
−D(uc). We use two other terms to balance this negativity
out.
Under these assumptions, we can look for sufficient, but not necessary conditions
for q(z) > 0.
v2
4
+
c2
4
− cv
2
−D(uc) > 0
Recalling that D(u) = D1 − D2unan+un , we can see that the second part will end up
being positive, so we just investigate v
2
4
+ c
2
4
− cv
2
−D1 > 0. Let us look at what value
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of c must be in oder to have a positive q(z).
v2 + c2 − 2cv > 4D1
(c− v)2 > 4D1
(c− v) > ±2
√
D1
c > ±2
√
D1 + v
We get the stability condition that c > 2
√
D1 + v, which we can translate back
into our dimensionalized units to get c > 2
√
D1g + νi. We use the positive root be-
cause we assume that c > v, meaning the wave speed is larger than the advection term.
Under this condition, all eigenvalues of the Sturm-Liouville problem are positive,
which implies that the traveling wave solution is asymptotically stable.
2.4 Numerics
2.4.1 Parameter Estimation
In order to ensure that the model selection and traveling wave speed analysis is
correct, it is necessary to compare numerical simulations with the experimental data,
and observed wave speed with the minimum traveling wave speed generated in the wave
speed analysis. Before beginning the parameter estimation, I will perform a sensitivity
analysis to ensure that all parameters are indeed important to the model results.
Once this is complete, a parameter optimization using MATLAB’s fminsearch is
performed to determine the biologically relevant parameters that fit the experimental
data best. Finally, using those optimized parameters, I will compare the simulated
wave speed with the minimum wave speed (2.4) derived in the previous section.
The experimental data that is provided includes the density profile of cells on day
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3 and the invasive radius of the cells measured from days 1 through 7 for both the
U87WT and U87∆EGFR cell lines (Stein et al., 2007a) . As I do not have access to
the true data, experimental results and the experimental model results were obtained
via GRABIT (Doke, 2014), a MATLAB program which extracts data points from an
image file. As mentioned previously, only the U87WT cell line is considered because
it is necessary to show the model is effective even for the strongest migratory cells.
All simulations are performed with the U87WT cell line in mind and are compared to
the U87WT data.
The spatial domain for the numerical simulations is large to ensure that the
boundaries do not interfere with the cell growth and diffusion process. The boundary
conditions are u(x, t) = 0 when x = 1 cm, and reflective boundary conditions at x = 0.
When considering the initial conditions, we recall that in the previous model, the tumor
core cells are not modeled, and the invasive cells start out with a initial cell density
of zero everywhere on the domain (Stein et al., 2007a). For the density-dependent
diffusion model, we must decide how to initialize the tumor cell counts. The initial cell
count is not specified in the paper, but we can see that the initial core tumor radius
is 210 µm and the maximum cell density is umax = 4.2 × 108 cells/cm3. Therefore,
we assume that initial cell density is 95% of umax for the initial core tumor radius of
210 µm and zero elsewhere (Stein et al., 2007a).
The governing equation (2.2) is solved numerically using MATLAB’s pdepe solver.
A more original code was not used due to the complex nonlinearity of the diffusion
term. The full code is available in Appendix C. I conducted a limited spatial study to
determine the largest possible spatial step size which still produced accurate results.
pdepe determines the time-stepping scheme, so there was no need to conduct a
time-step size test. The results of the spatial study are provided in Figure 2.3 and in
Table 2.1. We use two different metrics to determine convergence: first visually in
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Figure 2.3: Spatial convergence study performed in pdepe for various values of ∆x.
We see that the convergence is quick.
the Figure 2.3, secondly in comparing the errors generated by the error function in
Equation (3.3).
Resolution (∆x) Error Value % decrease
1
1000
1.3842
1
2000
1.3320 3.92
1
4000
1.3150 1.29
1
8000
1.3084 0.504
1
16000
1.3055 0.222
Table 2.1: Spatial convergence study in terms of error generated by Equation (3.3).
As the size of ∆x halves, the error also halves.
In Figure 2.3, the spatial convergence is very quick. Once ∆x = 1
4000
, there is
little difference in the corresponding solution curves. However, a visual cue is not
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substantial enough to claim convergence, so I examine the errors generated by our
solution to the data, using Equation (3.3) in Table 2.1. I can see that the decrease in
∆x has a corresponding decrease in the error. I chose ∆x = 1
8000
since this generates a
very good fit, and only differs by 0.22% from the solution obtained when halving ∆x
to 1
16000
. There is the expected cost associated with decreasing ∆x, and the doubling
of simulation time for a 0.22% decrease in error seemed fruitless.
In order to perform MATLAB’s fminsearch for optimization, we first must choose
a function that we want to minimize. In this case we base our error function on the
error function used in the original paper, which is based on the χ2 error function (Stein
et al., 2007a). We could not use the exact function because it included information
about the standard deviation in the measurements of cell densities, the value of which
was not provided in the paper. We modified the error function to account for the
experimental data that was made available. It uses relative errors for each point
because the order of magnitude for the cell densities are approximately 107 − 108,
while the invasive radius measurements are on the order of 0.01 cm. The modified
error function, like that of the original error function, takes into account both how
fast the tumor is spreading, by measuring the invasive radius at each day, and also the
density of cells by comparing the spatial profile of cells on day 3. The error function
is given by:
err =
1
(N +M)− q − 1
 N∑
t=1
|rdata(t)− rsimulation(t)|
rdata(t)
+
M∑
i=1
|udata(3, xi)− usimulation(3, xi)|
udata(3, xi)
 , (2.14)
where N is the total number of days for which there is invasive radius data, so
N = 7, M is the total number of cell density data points at day 3, so M = 17,
and q is the number of parameters being optimized which, in this case, q = 6. The
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sums are broken into the comparison of invasive radii and the comparison of cell
density profiles. The first sum compares the invasive radii of the experimental data,
rdata(t), and the simulation, rsimulation(t). The second sum compares the cell density
at day 3 at experimental data point xi for the data, udata(3, xi), and the simulation,
usimulation(3, xi).
The governing equation (2.2) with diffusion function (2.3) has six parameters
that are unknown: D1, D2, a, n, g, and νi. There are estimated ranges for some
of these parameters, which can be obtained from the experimental paper (Stein
et al., 2007a), but others have little biological measurements. In particular, the
migratory diffusion (diffusion when the density u is small), D1, is estimated to be on
the order of 10−4 cm2/day. The growth rate g ∈ (0, 1)/day and the taxis constant
νi ∈ (0, 0.02) cm/day. However, for a and n, there is no precedent to compare with.
We know that an represents the half-maximum of the saturation and that n determines
the steepness of the curve which describes the diffusion for various cell densities. We
perform a sensitivity study to determine if the model error is insensitive to any of the
changing parameters, particularly those which we do not have biological information
about. If we are able to determine that a parameter is insensitive, we will be able to
fix its value and not include it as a free variable for parameter optimization, increasing
the possible accuracy and decreasing the computational time.
The parameter sensitivity analysis was performed for the six parameters D1, D2,
a, n, g, and νi such that each was in a physiologically relevant range. The set of base
parameters chosen that result in a reasonable match to the data were:
D1 = 10
−4 cm2/day, D2 = 9.99× 10−5 cm2/day, a = 1 cells/cm2,
n = 2, g = 1/day, νi = 0.05 cm/day. (2.15)
These base parameters are not chosen for their excellent fit to the data, rather they
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Figure 2.4: Results of a sensitivity analysis with base parameters (2.15) using error
function (3.3) (vertical axis).
are chosen in order to have error that is not too large and to allow for variations to
still remain in biologically relevant ranges. To test the sensitivity of one parameter,
all the other parameters were held constant and the parameter in question was varied.
The results of this sensitivity test is shown in Figure 2.4.
It is apparent that some parameters are much more sensitive than others, in
particular, D1, g, and νi appear to generate the most sensitivity. The results of this
sensitivity analysis inform us that all parameters are sensitive and we must take care
when we perform our optimization.
The parameters are optimized via the MATLAB program fminsearch (Lagarias
et al., 1998) by minimizing Equation (3.3). Various initial parameter guesses were used
as input to ensure that the parameter space was adequately covered. Additionally,
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for those parameters which had estimated ranges, we ensured that our parameters
remain within those ranges. The optimized parameters found are:
D1 = 1.4247× 10−4, cm2/day, D2 = 1.4040× 10−4, cm2/day,
a = 0.0683 cells/cm3, n = 18.6547,
g = 0.6855/day, νi = 1.7843× 10−9 cm/day. (2.16)
Though D1 −D2 is very close to 0, it is still the case that D1 > D2 as necessary.
Having D1 −D2 close to zero implies that the diffusion is very different when the cell
densities are low and high, which adds credence to our hypothesis. We also see that in
our model, νi is very close to 0. We included this term, because the experimentalists
claimed it was necessary to generate a good fit, arguing that there was some type
of tactic term influencing the migratory cells (Stein et al., 2007a). However, it
appears that our density-dependent diffusion negates the need for this tactic term. To
determine the comparable errors to the two population model simulations that use
invasive cells as a separate population, we use GRABIT (Doke, 2014) to obtain the
simulation data points from the experimental paper (Stein et al., 2007a). We present
the results of our simulation with optimized parameters compared to the experimental
data and the model from the experimental paper in Figure 2.5.
In the top left panel of Figure 2.5, the cell density is plotted on the entire domain
and it indicates that the model is successful in capturing the behavior of both the
tumor core cells and the migratory cells. We want to ensure that the model does
not just compare well with the migratory cell population area, but also with the
proliferating core. It is apparent that our simulation matches qualitatively with both
the core and expanding tail of cells. In the top right panel, the cell density is plotted
on a smaller domain, containing the area where the bulk of the migratory cells exist,
and further verifies that our model with one population is relatively as accurate as the
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model which uses separate invasive cell population and proliferating cell population.
The bottom panel displays the invasive radius of the migrating cells for the seven days
that the experiment was performed. We can see that our fit is not as accurate as
the simulations performed by the experimentalist, however, they are still reasonable.
When we examine the fit as a whole, we can see that our simulations with one equation
are indeed a qualitatively good fit. In fact, our total error from (3.3) is approximately
one-half that of the model proposed by the experimentalists (0.19 compared to 0.38)
(Stein et al., 2007a). However, I will point out that our simulation has more points to
fit, since we also fit the central tumor area, so the scaling is different (since M +N is
larger in our error calculation). If we examine just the points that Stein et al. (2007a)
fits, our error is approximately 62% the error.
2.4.2 Numerical Minimum Wave Speed
Now that we have shown that our model can be utilized and fits the data quite
well, we want to verify the analytic minimum wave speed (2.4) obtained in our analysis
above. In order to do this, we compare with the wave speed observed in the simulations.
However, as traveling wave speed analysis is meant to be on an infinite domain, there
are several changes we must performed before we can measure the wave speed. Firstly,
I rearrange the initial conditions. I use a point source at x = 0 of maximum cell
density. Next, we increase the run-time of the simulation to 25 days, which ensures
that the wave will no longer be ‘growing’ to carrying capacity, but rather will only
be spreading. Similarly, we ignore the first few days of the simulation to ensure we
are only capturing when the wave has already reached maximum cell density in the
core. We also want to enlarge the spatial domain to more so mimic an infinite domain,
however, limitations with pdepe force us to keep the same domain. Additionally, this
allows us to not worry about the boundary conditions affecting the wave shape and
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Figure 2.5: Numerical solution of the density-dependent diffusion glioblastoma model
(2.2) with diffusion function (2.3) and optimized parameter values (2.16) compared to
experimental data from Stein et al. (2007a) and their simulations. The density profile
is from day 3 of the experimental data.
speed. To estimate the wave speed, we ignore the first half (in time) of the simulation
so that the tumor core stably reaches maximum cell density, and then measure the
x location where the cell density is last over 4.2× 105 cells/cm3, approximately 1%
of the maximum cell density. We measure this location throughout the time of the
simulation and use the MATLAB’s polyfit to estimate the slope of the curve for a
linear fit.
The results of the wave speed simulation are shown in Figure 2.6. The leading
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Figure 2.6: Numerical solution of the density-dependent diffusion glioblastoma model
(2.2) with diffusion function (2.3) and optimized parameter values (2.16) for days 5,
10, 15, 20, and 25.
edge of the tumor maintains a constant shape and ultimately moves at a constant
rate, once the wave speed shape is built. This is why we only use the latter portion
of the simulation in order to estimate the traveling wave speed. Using the optimized
parameters (2.16), the minimum wave speed (2.4) is kmin ≈ 0.01977 cm/day and the
simulated wave speed k = 0.01921 cm/day. We can see that the simulated wave speed
is very close to the theoretical wave speed, as expected.
Now that we have found our traveling wave profile, we can test the assumption
that was made in Theorem 2.3.1 numerically. The assumption was:
∂2
∂z2
(
D(uc(z))
)
+ 2uc(z) ≥ 0 (2.17)
In order to determine whether our condition is satisfied, we look towards the
numerical solutions. Specifically, we use our numerical wave speed solution from
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Figure 2.7: Examining the condition, given by Equation (2.17) using the wave speed
solution of Figure 2.6 at 25 days as uc. On the left, parameters given by (2.16) and
on the right, parameters given by (2.16) with n = 2, a = 0.25.
Figure 2.6, at 25s as our uc.
We display the condition, in Equation (2.17) in Figure 2.7. On the left, we have the
condition using parameters given by (2.16). We can see that for our chosen parameter
values, the condition does not hold. However, if we examine other sets of parameters,
it is possible to have this condition hold and be guaranteed stability of wave solutions.
On the right panel of Figure 2.7, we examine the case for parameters given by (2.16)
with n = 2 and a = 0.25 in which the condition does hold.
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Chapter 3
2 POPULATION MODEL OF IN VITRO SPHEROID GLIOBLASTOMA
GROWTH
3.1 Introduction
In Chapter 2, I discussed the influential experimental and modeling paper which
began the discussion of the ‘Go or Grow’ hypothesis. Stein et al. (2007a) discovered
from his data that in order to model in vitro GBM-like growth, subpopulations of
proliferating cells and migrating cells must be modeled separately. Our previous work
concluded that a one-Equation model with density-dependent diffusion was able to fit
the data better and was biologically justified.
In this Chapter, we consider a 2-population model of migratory cells and prolifer-
ating cells. We provide a justification for the proposed model, analyze the minimum
traveling wave speed, and fit this model to the experimental data provided in Stein
et al. (2007a). We compare our fit not only to the experimental data, but to the
ad-hoc model proposed by Stein et al. (2007a), Equation (2.1), and to our 1-D
density-dependent diffusion model, Equation (2.2).
3.1.1 Early Models
Early models of GBM invasion were inspired by reaction-diffusion Equations.
Tracqui et al. (1995) formed one of the earliest models of GBM growth. Swanson
has continued using reaction-diffusion Equations with great success. Swanson et. al
discovered that the simple reaction-diffusion model was able to model the growth,
diffusion, and treatment off GBM, noting that there are very differing dynamics when
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low D and high ρ versus high D and low ρ, although these may show identical visible
tumors at the same time point (Swanson et al., 2003). Building upon this idea, they
discovered a method using the two most common types of MR images to estimate the
‘invasivity ratio’ given by D
ρ
and from this be able to classify the tumors and their
expected survival (Swanson et al., 2008; Baldock et al., 2014).
3.1.2 Go or Grow?
While this work was being performed, other researchers decided that the model
was too simple to accurately describe the dynamics of GBM. Based on the Stein et al.
(2007a) paper, researchers were convinced that in order to accurately describe the
behavior of GBM, they needed to separate the tumor population into a migratory
subpopulation and a proliferating subpopulation. Hatzikirou et al. (2010) coined the
term ‘Go or Grow’ to represent the hypothesis that the cells are either proliferating or
migrating, but not both. They argued that the transformation from the proliferating
phenotype to the migrating phenotype was not solely due to mutation, but driven
by hypoxia, which was corroborated experimentally (Godlewski et al., 2010). Other
researchers have posited that a variety of mechanisms might trigger the phenotypic
switch, from chemotaxis to haptotaxis to self-adhesion (Kim et al., 2009). Others
have investigated how changing aspects of the switching rates from proliferating to
migrating and migrating to proliferating affected the dynamics of the tumor growth
(Gerlee and Nelander, 2012). Pham et. al investigated a basic model which only
feature diffusion and phenotypic switching (for the migrating cells) and growth and
phenotypic switching (for the proliferating cells) and were able to observe dynamics
such as fingering (Pham et al., 2012). While these models exhibit behavior consistent
with the GBM invasion, experimentalists have been unable to directly prove the ‘Go
or Grow’ hypothesis (Garay et al., 2013).
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Although the previously cited works have investigated the truth of the so-called
‘Go or Grow’ hypothesis, current researchers often use the hypothesis in their works.
Eikenberry et al. (2009) used two separate sub-populations of tumors in their simula-
tions of growth, diffusion, and treatment of GBM in mathematical models. Kostelich
et al. (2011) used two subpopulations along with extracellular matrix to forecast glioma
growth using data assimilation techniques. Mart´ınez-Gonza´lez et al. (2012) uses the
terms ‘normoxic’ and ‘hypoxic’ to signify the differing dynamics of proliferative and
migratory cells, respectively, while adding necrotic cells and based their switching
rates on the level of oxygen available. Tanaka et al. (2009) investigated a similar
model which had migrating, proliferating and necrotic regions depending on the tumor
volume. Chauviere et al. (2009) used the two subpopulations to characterize cell
migration through the extracellular matrix. Recently Saut et al. (2014) used the
two populations to characterize how GBM would respond to anti-angiogenesis drugs.
Bo¨ttger et al. (2012) determined how invasive, measured in invasion speed and width
of the infiltration zone, glioma can be for the ‘Go or Grow’ hypothesis versus the ‘Go
and Grow’ hypothesis, showing much richer and complex dynamics with the former.
3.2 Mathematical Model
Our model is based on two subpopulations which exhibit vastly differing behavior:
proliferating cells which mainly grow, and migrating cells which mainly migrate. There
is, of course, phenotypic switching from subpopulation to subpopulation, as has been
the norm in many of the previously mentioned models.
Our model concerns migratory cells (M(x, t)), proliferating cells (P (x, t)), and the
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total number of cells (T (x, t) = M(x, t) + P (x, t)):
∂M
∂t
= D1∇2M︸ ︷︷ ︸
diffusion
+ k
T n
T n +KnM
P︸ ︷︷ ︸
switch from proliferating to migratory
− k K
n
P
T n +KnP
M︸ ︷︷ ︸
switch from migratory to proliferating
− µM︸︷︷︸
death
(3.1a)
∂P
∂t
= g
(
1− T
Tmax
)
P︸ ︷︷ ︸
growth
− k T
n
T n +KnM
P︸ ︷︷ ︸
switch from proliferating to migrating
+ k
KnP
T n +KnP
M︸ ︷︷ ︸
switch from migrating to proliferating
(3.1b)
In this model, we are assuming that the migratory cells are governed by diffusion
and changing to and from proliferating cell populations as well as a death term. As for
the proliferating cells, we assume they are growing logistically and switch to and from
migratory cells, but do not diffuse. This model exhibits the ‘Go or Grow’ hypothesis
in which cells are either growing (proliferating) or going (migrating). According to
the premise from Stein et al. (2007a), this model should more accurately fit their
experimental data than a reaction-diffusion Equation.
As in the previous model, the boundary conditions are M(x, t) = 0 = P (x, t) when
x = ±1 cm, which states that there can be no tumor cells at the boundaries. The
initial cell density of the proliferating core cells is 95% of umax for the initial core
tumor radius of 210 µm and zero elsewhere.
3.3 Numerical Method
The numerics for this section of work was implemented in MATLAB. Due to the
prohibitive overhead costs of using pdepe, the code for the resulting numerics was
written by me, featuring Crank-Nicolson for the diffusion term and first-order finite
differencing for the remaining terms, including an advective term, possibly some taxis
term as in Equation (2.2). This was also implemented to have the freedom to include
a diffusion term in the proliferating population, if necessary.
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The Crank-Nicholson method is a stable finite difference method for solving PDE’s.
It is implemented by using the trapezoidal rule, which gives second-order convergence
in time (as opposed to Euler’s method which would only give first-order convergence
in time). For an Equation ∂u
∂t
= F
(
u, x, t, ∂u
∂x
, ∂
2u
∂x2
)
the Crank-Nicolson method is
written as:
un+1i − uni
∆t
=
1
2
F n+1i
(
u, x, t,
∂u
∂x
,
∂2u
∂x2
)
+ F ni
(
u, x, t,
∂u
∂x
,
∂2u
∂x2
) (3.2)
where the subscript denotes spatial coordinates and the superscript denotes the time
steps.
3.3.1 Derivation of Code
We can now discretize the derivatives using centered finite differencing in order to
implement our Crank-Nicolson scheme. We recall the well-known approximations for
first and second derivatives here:
∂u
∂t
=
uj+1 − uj
∆t
∂u
∂x
=
ui+1 − ui−1
2∆x
∂2u
∂x2
=
ui+1 − 2ui + ui−1
(∆x)2
And now we plug the terms into the Crank-Nicolson method:
uj+1i − uji
∆t
=
1
2
F j+1i
(
u, x, t,
∂u
∂x
,
∂2u
∂x2
)
+ F ji
(
u, x, t,
∂u
∂x
,
∂2u
∂x2
)
uj+1i − uji
∆t
=
1
2
[
D
∂2uj+1
∂x2
+D
∂2uj
∂x2
]
uj+1i − uji
∆t
=
1
2
D(uj+1i+1 − 2uj+1i + uj+1i−1
(∆x)2
)
+D
(
uji+1 − 2uji + uji−1
(∆x)2
)
uj+1i = u
j
i +
D∆t
2∆x2
[
uj+1i+1 − 2uj+1i + uj+1i−1 + uji+1 − 2uji + uji−1
]
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In order to see more clearly, we set c = ∆t
2(∆x)2
and separate into the j, j + 1 time
points:
uj+1i − cD
(
uj+1i+1 − 2uj+1i + uj+1i−1
)
= uji + cD
(
uji+1 − 2uji + uji−1
)
Now we can organize by spatial points to get a tridiagonal matrix:
uj+1i+1 [−cD] + uj+1i [1 + 2cD] + uj+1i−1 [−cD] = uji+1 [cD] + uji [1− 2cD] + uji−1 [cD]
This can be solved easily as it is a tridiagonal matrix.
In order to model the full Equation, we want there to be a growth terms, mutation
terms, and the allowance for a chemotactic term as well, so we add these terms so our
final Equation is:
∂u
∂t
= D∇2u+k (u+ v)
n
(u+ v)n +KnM
u−k K
n
P
(u+ v)n +KnP
u−µM+gu
(
1− u
umax
)
−νi∇·u
which effects our computational work by first having adding in the extra terms. We
know that for consistency and stability we need to express the chemotactic term using
forward differencing. We introduce k = ∆t
2∆x
, and our final solve becomes:
uj+1i+1 [−cD ]+uj+1i [1 + 2cD ] + uj+1i−1 [−cD ]
= uji+1 [cD − kνi] + uji [1− 2cD ] + uji−1 [cD + kνi ] + ∆tf(u)
where f(u) is all the remaining terms which do not contain a derivative (growth,
mutation, and death terms).
Our code is set up to handle a system of Equations (since we have proliferating
and migrating subpopulations) and is set up so each of the subpopulations can specify
the value of all parameters. For example, if we restrict the proliferating subpopulation
to be unable to diffuse (D = 0) this can easily be done in the code. The full code is
available in Appendix D.
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3.3.2 Comparison of codes
In order to ensure that the code is accurate, I ran a comparison using MATLAB’s
pdepe and our Crank-Nicolson code. The following simulations use the initial condition
listed above for which the cell density of the proliferating core cells is 95% of umax for
the initial core tumor radius of 210 µm and zero elsewhere. The domain for pdepe is
x ∈ (0, 1), and the boundary conditions are reflective at x = 0 and 0 far away from
the tumor. For the Crank-Nicolson code, we run on a full domain x ∈ (−1, 1) with
boundary conditions of 0 at the ends of the domain.
We compare several sets of parameters to ensure that we did not luckily choose
a parameter set which happened to match both codes. Figure 3.1 shows examples
of comparisons for various parameter sets modeled with both pdepe and the Crank-
Nicolson code, plotted on top of each other at the final time of day 7. It is apparent
that the Crank-Nicolson solver and the pdepe solve share a high amount of agreement
in every one of the cases for which we have tested. One thing that differs between the
two simulations is the appearance of some numerical oscillations only present in the
pdepe simulations, as seen in the fourth panel of Figure 3.1.
Why do we choose to use our Crank-Nicolson code? Ultimately, we notice that
there are some numerical artifacts that arise from MATLAB’s pdepe. Figure 3.2
shows the numerical oscillations at the border of the migratory and proliferating cells
in pdepe versus the Crank-Nicolson code. We can minimize the oscillations but we
would rEquationuire a much finer resolution. Even choosing ∆x = 1
128000
does not
completely clear up the numerical instabilities that arise. For our purposes, running
the Crank-Nicolson code is much faster and does not contain these numerical artifacts.
Although they appear to not affect our simulation results too much, we cannot be
sure that this artifact will not affect the outcome in every type of parameter set. To
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Figure 3.1: Comparisons of MATLAB’s pdepe and the Crank-Nicolson solver. We see
agreement between the two codes, but some issues at the edge where the proliferating
and migrating cells seem to be switching. In the upper left-hand corner solutions
are compared on day 7. The upper right-hand corner shows a zoomed-in portion
where we can see that pdepe generates oscillatory behavior, while our code does
not. The bottom left-hand corner shows the migratory cell profile, which does not
have oscillatory behavior. The bottom right-hand corner shows the proliferating cell
population, which is where the oscillations occur.
43
distance from core (cm)
0.0204 0.0206 0.0208 0.021 0.0212 0.0214
ce
ll 
po
pu
la
tio
n
×108
2.6
2.8
3
3.2
3.4
3.6 ∆x=1/8000
∆x=1/16000
∆x=1/32000
∆x=1/64000
∆x=1/128000
distance from core (cm)
0.0205 0.021 0.0215
ce
ll 
po
pu
la
tio
n
×108
2.6
2.8
3
3.2
3.4
3.6 Dp=0
Dp=10
-16
Dp=10
-12
Dp=10
-10
Dp=10
-8
Figure 3.2: We determine the cause of numerical oscillations using pdepe, by decreasing
∆x (right) and introducing diffusion to proliferating population (left). As we decrease
the value of ∆x in the pdepe simulations, the numerical oscillations decrease slightly,
although they never disappear. When we introduce a small diffusion coefficient into
proliferating population, we are able to eliminate the oscillations.
be safe, we only use the Crank-Nicolson code.
As pdepe is a black-box code, we are unable to exactly determine why these
artifacts arise. However, my hypothesis is that since pdepe is supposed to solve PDE’s
and our proliferating cell population is, in fact, an ODE, this might be where the
issue arises. It appears to be in effect at the boundary of the proliferating cells and
the migrating cells. If we examine the lower panel of Figure 3.1, it is apparent that
the perturbation is only in the proliferating cell population, not the migrating cell
populaion. In order to test this hypothesis, I introduce a very small diffusion constant
for the proliferating population. I am not able to fully eliminate the oscillations until I
allow this diffusion constant to be approximately D = 10−8, which slightly changes the
dynamics of the simulation. Therefore, to simulate our 2 population model (Equations
3.1), we use our code instead of pdepe.
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3.4 Numerical Results
3.4.1 Sensitivity Analysis
We begin our numerical exploration by determining how sensitive the solutions
are to perturbations in the parameters. The reason to investigate this is that if some
parameters are insensitive, we may eliminate them from our parameter estimation.
Our parameter estimation is performed by varying the nominal value of each parameter
from 1/100* nominal value to 100* nominal value. The nominal values were chosen to
have a reasonable fit to the data and are listed below:
D = 3.5 ∗ 10−4 cm2/day, g = 1/day,
Km = 1× Tmax, Kp = 0.1× Tmax,
k = 1,  = 0.5,
µ = 0.01day
From these nominal values, we vary them and calculate the error generated by
Equation (3.3). This allows us to see that there is change, although we do not
characterize exactly what that change entails.
In Figure 3.3, we can see that all parameters appear to be sensitive to solutions.
Although all parameters appear to be sensitive, some are far more sensitive than
others, such as g, , and D. However, we do notice that unless we have large values
of µ, on the order of approximately 0.1 or larger, the solutions remain insensitive for
smaller values of µ.
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Figure 3.3: Sensitivity analysis for all parameters varying from 1/100 nominal value
to 100*nominal value. All parameters appear to be sensitive.
3.4.2 Parameter Estimation
Now that we have ensured that all parameters are sensitive, we begin our parameter
estimation. The error function that we use for the parameter estimation is:
err =
1
(N +M)− q − 1
 N∑
t=1
|rdata(t)− rsimulation(t)|
rdata(t)
+
M∑
i=1
|udata(3, xi)− usimulation(3, xi)|
udata(3, xi)
 , (3.3)
where N is the number of data points available on the day 3 cell density profile, M is
the number of invasive radius measurements, and q is the number of parameters we
optimize over. This is the same error function that was given in Chapter 2.
In order to obtain the best-fit for parameter estimations, we minimize the error
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Figure 3.4: Numerical solution of 2-Equation GBM model with optimized parameter
values compared to experimental data and simulations from Stein et al. (2007a)
.
given by Equation (3.3) using the fminsearch algorithm in MATLAB. In order to
lead credence to our solutions, we make sure to run the parameter estimation from a
variety of input parameter guesses. Our best fit is given in Figure 3.4
The parameters that generate this fit are:
D = 3.512× 10−4 cm2/day, g = 1.020/day,
k = 1.091, µ = 0.01228day,
KM = 0.8120× Tmax, KP = 0.006282× Tmax,
 = 0.1794
We can see that in this instance, we do not have as good of a fit as our one-Equation
density-dependent diffusion model. In fact, our error is on par with that of the model
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proposed in Stein et al. (2007a). Although our model (Equation 3.1) is built upon
biological understanding, as opposed to the rather ad-hoc Stein et al. (2007a), we still
do not generate as good of a fit. We do note, however, that the best-fit generated by
a generic reaction-diffusion Equations is still much, much higher.
3.4.3 Comparison of Multiple Methods
In this next section, we compare all methods used so far in their ability to fit the
experimental data, as well as introduce two more models in necessary for examining
the best fit for the model. Is the ‘Go or Grow’ hypothesis really necessary or accurate?
The whole argument from Stein et al. (2007a) was that the basic reaction-diffusion
Equation was unable to fit the data and so the populations had to be separated into
migrating or proliferating subpopulations. However, the fit for the reaction-diffusion
Equation was never actually shown in the Stein et al. (2007a) paper, so we introduce
the reaction-diffusion Equation for fitting here:
∂u
∂t
= D∇2u︸ ︷︷ ︸
diffusion
+ gu
(
1− u
umax
)
︸ ︷︷ ︸
growth
(3.4)
In order to simulate this Equation, we use the numerical method introduced in Section
3.3.
Since our generic 2 population model did not generate such a good fit, we merge
the ideas of the ‘Go or Grow’ hypothesis with our density-dependent diffusion. We
also want to look at whether it is just the density-dependent diffusion that generated
such a wonderful fit. Therefore, we replace the diffusion constant in Equation (3.1)
with the density-dependent diffusion function in Equation (2.3) in order to get a
48
2-Equation, density-dependent diffusion model given by:
∂M
∂t
= ∇ ·
((
D1 − D2(M)
n
an + (M)n
)
∇M
)
+ k
T
T +KM
P − k KP
T +KP
M − µM
∂P
∂t
= g
(
1− T
Tmax
)
P − k T
T +KM
P + k
KP
T +KP
M
(3.5)
In order to simulate the model given by Equations (3.5), I use pdepe, since the
density-dependent diffusion term complicates the numerical method described in
Section 3.3.
In order to compare the efficacy of all models, I present not only the error results for
the Stein et al. (2007a) mathematical model and the two-population model proposed
here, but also the Stepien et al. (2015) density-dependent diffusion model as well as
the basic reaction-diffusion Equation.
Table 3.1 allows us to see how effective the various models are to fitting the
experimental data in three ways: firstly a weighted error that penalizes additional
parameters given by Equation (3.3), secondly a raw error that is just the summation
of the differences between data and experiment, and finally the raw error divided
by the number of data points fitted (essentially the Equation (3.3) but without
the parameter penalty). This last measure is necessary because the Stein et al.
(2007a) model only fits to the migratory data, not including the proliferating data
in the center (it is fitted to four less points). In any case, the one Equation density-
dependent diffusion model generates the least error from the experimental data. We
note that, as expected, the reaction-diffusion Equation (3.4) generates the largest
error. Coming in at approximately half the error of the reaction-diffusion Equation
is the ad-hoc model proposed by Stein et al. (2007a), given by Equation (2.1). The
one-Equation density-dependent diffusion Equation (2.2) has one quarter of the error
of the reaction-diffusion Equation. Finally, our 2-Equation models with and without
density-dependent diffusion have approximately one third the error of the reaction
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Model Type Error Error Error
(Weighted) (Raw) (per data point)
Reaction-Diffusion 0.7816 16.4140 0.6079
Equation (3.4)
Stein et al. (2007a) 0.3805 7.229 0.3143
Equation (2.1)
Stepien et al. (2015) 0.1918 4.0279 0.1492
Equation (2.2)
2-Equation Model 0.2782 5.5630 0.2060
Equation (3.1)
2-Equation Model with DDD 0.3170 5.3888 0.2000
Equation (3.5)
Table 3.1: Error generated by Equation (3.3) for various models. Error is given
weighted by the number of parameters as well as unweighted (raw) and the error per
data point (raw error/# of data points).
diffusion Equation.
In Table 3.2, we are only examining the migratory cell populations, instead of both
proliferating and migrating cells. Again, we examine both the weighted error given by
Equation (3.3) as well as the raw error. The results are very similar to the previous
table. If we are just interested in examining the migrating cell population, we can still
see that our one-dimensional density-dependent diffusion Equation is still the best fit
(whether weighted or raw). Our proposed 2-Equation models have similar error as
to each other, and generate less error than the Stein et al. (2007a) model, although
when introducing the parameter penalization, the error is not much better.
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Model Type Error (Weighted) Error (Raw)
Reaction-Diffusion 0.8975 15.2573
Equation (3.4)
Stein et al. (2007a) 0.3805 7.229
Equation (2.1)
Stepien et al. (2015) 0.2353 4.0005
Equation (2.2)
2-Equation Model 0.3334 5.3347
Equation (3.1)
2-Equation Model with DDD 0.3035 5.1595
Equation (3.5)
Table 3.2: Error generated by Equation (3.3) for various models over the migratory
cell population only. Error is given weighted by the number of parameters as well as
unweighted (raw).
3.5 Wave Speed
3.5.1 Analysis
As with our previous model, we would like to determine the traveling wave speed.
Through some analysis using methods similar to Chapter 2, a range of minimum wave
speed is estimated:
cm1 = g
√
D
g + k + µ
≤ cm ≤ (g + k)
√
D
g + 2k + µ
= cm2 (3.6)
3.5.2 Numerics
As in Chapter 2, we are interested in whether we can observe the minimum wave
speed in our simulations. We found a range of minimum wave speeds, contingent
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Figure 3.5: Wave speed bounds given by Equation (3.6), the lower bound in black, the
upper bound in red. The circles represent the migrating wave speed and the plusses
are the proliferating wave speed.
on what the fraction of proliferating cells to migrating cells, in Equation (3.6). The
results of the numerical wave speeds are presented in Figure 3.5.
Figure 3.5 has the lower bound of minimum wave speed, cm1 = g
√
D
g+k+µ
given
in the red dashed line and an upper bound of the minimum wave speed cm2 =
(g + k)
√
D
g+2k+µ
given in the black dashed line. The calculated numerical wave speed
for the migrating population is given by blue plusses, and the numerical wave speed
for the proliferating wave speed is given by green circles. Our results indicate that the
true minimum wave speed does lie between the ranges given by Equation (3.6). There
are a few that fall outside the range of the minimal theoretical wave speed range, for
very large g values. Whether this is an artifact of numerics remains to be seen.
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Chapter 4
IN VIVO MURINE MODEL OF GLIOBLASTOMA GROWTH
4.1 Introduction
Once the tumor reaches a certain size, it is no longer able to function independently.
At this time, tumor cells begin to interact with their surrounding environment more.
Specifically, cancer cells begin emitting pro-angiogenic factors which encourage blood
vessels to grow towards them, facilitating further growth and development. As the
tumor growths larger, it begins to compete with the surrounding healthy tissue cells
and its own tumor cells. At this point, the environment and competition for resources
available begin to influence the growth of the cancer. In order to begin to accurately
model this phenomena, we need to consider in vivo data and modeling.
In this chapter, we consider a murine model for glioblastoma growth and diffusion.
Five mice were injected cranially with GL261-Luc2 cell line and imaged over a series
of time points. We then converted the MR images into a computational domain upon
which to run simulations. We observed a large variance between final tumor sizes and
use a simple model to determine whether or not we can easily explain this discrepancy.
4.1.1 GBM
Glioblastoma multiforme (GBM) is an aggressive form of brain cancer with mean
survival time following diagnosis ranging from about 4 months with supportive care
only (Schapira, 2007) to 15 months with standard treatment (Norden and Wen,
2006; Johnson and ONeill, 2012). GBM cells have both proliferative and migratory
characteristics. Although surgical resection may remove the bulk of the original tumor,
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it has long been recognized that GBM cells migrate away from the main mass and
penetrate the brain parenchyma (Scherer, 1940), forming recurrent tumors adjacent
to and/or extending from the previous surgical resection bed.
It is difficult to capture both the invasive behavior as well as the proliferating core
of the tumor in mathematical models. Compounding this issue is the fact that only
high-density proliferative cell regions that are usually considered to be analogous to
areas of increased contrast (i.e., gadolinium) signal are visible on magnetic resonance
imaging (MRI). Further, areas of increased signal from gadolinium may also indicate
edema surrounding the tumor or tumor necrosis.
GBM has been the subject of many previous mathematical modeling attempts
(more details are provided below). One early effort used a reaction–diffusion model to
capture the gross behavior of GBM tumors as well as the effects of treatment (Tracqui
et al., 1995). Work by Hermann Frieboes, John Lowengrub, and their collaborators
(Frieboes et al., 2006, 2007; Bearer et al., 2009) demonstrates the angiogenic and
invasive behavior of growing gliomas at the microscale. Kristin Swanson and her
collaborators have explored the utility of a two-parameter reaction–diffusion equation,
which can be expressed in terms of a normalized tumor cell density as:
∂u
∂t
(x, t) = ∇ · (D∇u(x, t))︸ ︷︷ ︸
diffusion
+ ρu(x, t)
(
1− u(x, t))︸ ︷︷ ︸
growth
, (4.1)
to explore the potential utility of ‘patient specific’ mathematical models to estimate
patient survival (Swanson et al., 2007) and optimize treatment strategies (Jackson
et al., 2015). The parameters D and ρ can be estimated from successive magnetic
resonance (MR) images of individual patients (Jackson et al., 2015).
Mathematical modeling of GBM in human patients is an inherently challenging
enterprise. For one thing, GBM may arise de novo or as a malignant progression
from a preexisting lower-grade lesion (Ohgaki and Kleihues, 2007), and the extent
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of GBM invasion away from the main mass is difficult to ascertain from MRI (Giese
et al., 2003). Thus, the initial conditions that should be used to model an individual
patient case are uncertain. In addition, multiple genetic pathways appear to be
involved in the development and progression of GBM (Ohgaki and Kleihues, 2007),
and genomic expression may affect the rate at which GBM tumors proliferate and
spread (Jackson et al., 2015). GBM invasion may be facilitated by other cell types,
including macrophages and microglia (Coniglio and Segall, 2013). Thus, the ability to
estimate growth and diffusion constants in any mathematical model of an individual
tumor is limited. Finally, models like Equation (4.1) do not explicitly account for
immune response, genetic drift in the tumor, or the effects of treatment. For all of
these reasons, mathematical models of human GBM tumors may fail to replicate the
observed growth patterns in individual patient cases.
These considerations motivated the following laboratory experiment. Five ge-
netically similar, immunocompetent mice were injected with similar initial doses of
murine glioma tumor cells from the same cell line (details provided Section 4.2). The
progression of each tumor was followed in five successive MR imaging sessions designed
to yield high-quality images. Due to issues in processing the images for two of the
mice, imaging data and the resulting mathematical analyses are presented here for
the remaining three. Under these carefully controlled conditions we have sought to
determine how well simple models like Equation (4.1) could predict the future growth
of each mouse’s tumor based on various assumptions of the initial conditions estimated
from the images.
Figure 4.1 shows a representative T2-weighted MR image of each mouse at the last
imaging session, 25 days after implantation. Although each mouse was inoculated with
nearly the same number of cells from the same culture, the visible volumes of the final
tumors range from approximately 12 mm3 to 62 mm3, with considerable differences in
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mass effect. Table 4.1 shows estimated visible tumor volumes in T2-weighted images
for each mouse at each of the five imaging time points. The sizes of the tumors diverge
considerably during the last ten days of growth.
Figure 4.1: T2-weighted MR images taken 25 days after inoculation at the same
location in the brain with respect to the initial needle track of the three mice used in
this study. Despite inoculations with the same volume of tumor cells, the final tumors
varied considerably in size.
Mouse Day 11 Day 15 Day 18 Day 22 Day 25
volume volume volume volume volume
(mm3) (mm3) (mm3) (mm3) (mm3)
1 0.715 1.155 4.980 15.570 25.460
2 0.595 3.025 4.320 8.095 12.340
3 0.970 3.855 16.485 30.675 61.490
Table 4.1: Experimental volumes of visible tumor on MRI of each mouse a each time
point.
The purpose of this chapter is the use the laboratory imaging data to test a
3-dimensional (3D) finite difference method code in order to predict the growth and
diffusion of the tumor. If we are successful in this endeavor, we can build on this
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preliminary work, adding further complexities to the model in the form of mass effect
and anisotropic diffusion (using diffusion tensor imaging). In this way, we hope to
obtain insight into the model errors that arise when attempting to model the more
complicated case of human GBM.
4.2 Methods
Animals and Care
The study followed the guidelines and regulations set by the National Institutes of
Health Guide for the Care and Use of Laboratory Animals Council (2011) and approved
by the Institutional Animal Care and Use Committee at the Barrow Neurological
Institute and St. Joseph’s Hospital and Medical Center. All aspects of the experiments
including animal housing, surgeries, imaging, and euthanasia were carried out at
the Barrow Neurological Institute at St. Joseph’s Hospital and Medical Center. The
animals had continuous free access to food and water.
GL261-Luc2 Model
The GL261 tumor model in the C57BL/6J mouse strain was chosen because it is
an established glioma tumor cell line that is recommended for preclinical GBM therapy
studies Jacobs et al. (2011). GL261 is a syngeneic tumor cell line originally developed
within the immunocompetent C57BL/6J mouse strain Seligman et al. (1939); Ausman
et al. (1970); Jacobs et al. (2011); Martirosyan et al. (2011); Mohammed G et al.
(2011). Seligman and Shear originally promoted the GL261 tumor cell line in the
C57BL/6J mouse by implanting 3-methylcholanthrene pellets into the brains of mice in
the 1930’s Jacobs et al. (2011); Seligman et al. (1939); Mohammed G et al. (2011). The
GL261 cell line within the immunocompetent C57BL/6J mouse strain thus produces a
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more typical immune response to the glioma and is thought to involve a pathological
progression of malignant glioma akin to that in humans. The GL261 cell line is an
aggressive tumor that shares many characteristics similar to the human GBM: tumor
necrosis, hemorrhages, angiogenesis, cellular proliferation, tumoral cell rim, invasion,
and inflammation Mohammed G et al. (2011); Candolfi et al. (2007); Drevelegas
(2010). Although GL261 has a tumoral cell rim, it is not the typical pseudopalisading
architecture seen in human GBM Candolfi et al. (2007). However, gross cellular
proliferation and invasion are the most important biological characteristics for this
study in the context of modeling cellular growth and migration.
GL261 cells were obtained from the DCTD Tumor Repository (NCI, Frederick,
MD) and grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal calf serum (FCS) at 37◦C with 5% CO2. To facilitate a quantitative
measurement of tumor growth rate GL261 cells were stably transfected with the gene
encoding LUC2 using the pGL4.51[luc2/CMV/Neo] vector (Promega Corp, Madison,
WI) and FuGENE R© 6 Transfection Reagent (Roche Applied Science, Indianapolis,
IN) following conditions specified by the manufacturer. Stable transfectants were
selected and maintained in DMEM containing 10% FCS and 100 µg/ml Geneticin
R© (G418, Invitrogen Corp, Carlsbad, CA). These cells were designated GL261-Luc2;
their growth rate is equivalent to the parental GL261 cell line Mohammed G et al.
(2011); Abdelwahab et al. (2012).
Implantation
GL261-Luc2 cells were harvested by trypsinization, washed and resuspended at
a concentration of 1–2 × 107 cells/ml in DMEM without FCS and implanted into
ten-week-old immunocompetent C57BL/6-cBrd/cBrd/Cr (albino C57BL/6) mice (The
Jackson Laboratory, Bar Harbor, ME, USA) with an average weight of 20 g. Briefly, the
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animals were anesthetized by an intraperitoneal injection of ketamine (10 mg/kg) and
xylazine (80 mg/kg), placed in a stereotactic apparatus, and an incision was made over
the cranial midline. A burrhole was made 0.1 mm posterior to the bregma and 2.3 mm
to the right of the midline. A needle was inserted to a depth of 3 mm and withdrawn
0.4 mm to a depth of 2.6 mm. Two µl of GL261-Luc2 cells (1–2× 104 cells/µl) were
infused over the course of 3 minutes. The burrhole was closed with bonewax and the
incision was sutured. Mice were housed in groups of five in the animal care facility
at St. Joseph’s Hospital and Medical Center in rooms with controlled temperature
and humidity under a 12-hour light-dark cycle according to the guidelines outlined in
the NIH Guide for Care and Use of Laboratory Animals Council (2011). Complete
methods describing the GL261-Luc2 implantation into C57BL/6J mice have been
previously published Mohammed G et al. (2011).
Imaging
Tumor bioluminescence and MRI were performed under isoflurane anesthesia on
days 11, 15, 18, 22, and 25, after initial injection of cells. These imaging intervals were
chosen to obtain frequent snapshots of the growing tumor in a manner that, in the
experimentalists’ judgment, would not be detrimental to the health of the mice. For
each imaging session, anesthesia was induced and maintained under isoflurane (1–2%)
in oxygen. Respiration was continually monitored with a pillow sensor position under
the abdomen (SA Instruments, Stony Brook, NY), and normal body temperature was
maintained with a circulating warm water blanket (Thermo Scientific, Rockford, IL).
Animals were stabilized with ear and tooth bars to minimize any motion and to ensure
accurate image-to-anatomy registration. We present full details of the laboratory
imaging here, although we only use the T2W images for this paper. Subsequent work
will use this information to formulate more complex model frameworks.
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Prior to MR imaging, bioluminescent tumor signal was measured. Animals received
a subcutaneous injection of 150 µg luciferin/kg body weight 15 min prior to in vivo
imaging using an IVIS R© Spectrum in vivo imaging system (Perkin Elmer, Waltham,
MA). Images were acquired and analyzed using the system’s Living Image R© 4.0
software.
MR images were acquired using a Bruker BioSpin 7T system in the following
sequential order for each imaging session: high resolution T2-weighted (T2W), diffusion
weighted (DW), T2W series, T1-weighted (T1W) series, dynamic contrast enhancement
(DCE), and post contrast T1W. In the following discussion regarding imaging, we
report the dimensions as axial × sagittal × coronal. High resolution T2W images
(0.1 mm× 0.1 mm× 0.5 mm voxels) were acquired as a reference between time points.
The DWI data series was acquired in 6 diffusion directions with a resolution of 0.2 mm×
0.2 mm × 1.0 mm. The T1W and T2W image series were acquired for T1 and T2
mapping, respectively. The resolution for these images was 0.2 mm×0.2 mm×0.5 mm.
The DCE was continuously acquired for approximately 21 min, with the scientist
needing to enter the MR room at 1.5 min into the acquisition to deliver a subcutaneous
injection of a 1 ml bolus of contrast agent (i.e., Gd-DPTA (0.04 mol/ml)) through a
preset catheter in the neck. The first 1.5 min of the DCE scan series was used as a
pre-contrast baseline. The injections were completed approximately 2 min into the
DCE acquisition. The resolution for these images was 0.2 mm× 0.2 mm× 0.5 mm.
The full set of MRI parameters will be provided in detail in the full paper.
Representative examples of the MR images are displayed in Fig. 4.1.
Tissue Procurement and Histology
The mice were euthanized on day 26 using deep anesthesia with isoflurane followed
by decapitation. The brains were carefully removed to minimize damage and were
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immediately placed in a 4% paraformaldehyde solution for 48 hours. The sample was
then placed in a phosphate-buffered saline and submitted to St. Joseph’s Hospital and
Medical Center’s histology lab for dehydration and paraffin embedding.
Image Preprocessing
The brain, ventricle, and tumor spaces were segmented from the high resolution
T2W images using the medical image processing software Mimics R© (Materials Inc,
Leuven, Belgium). The segmented spaces were then exported as STL files, i.e., as
surface meshes.
The brain surface meshes were used in two subsequent steps. First, the brain
surface mesh from a given time point was imported back into Mimics to identify
and ultimately export point clouds of the intensity values included in all original
images acquired during the same time point’s MR session. Second, brain meshes for a
single animal at different time points were co-registered using the best-fit function in
Geomagic Studio (Geomagic Inc, NC). Specifically, the brain volumes were registered
to the mid time point, day 18. For each time point and for each mouse, Geomagic
exported an affine matrix describing the necessary rotation, scaling, reflection, and
shearing necessary to transform the surface of a given brain to the registered brain
(which is the identity matrix for the third time point, day 18).
The exported affine matrices were then used to transform the corresponding
resulting point clouds in MATLAB, so that the location of the brain for each mouse was
constant. The transformed data points, containing intensity values, were then linearly
interpolated to a uniform grid. The spacing of the grid is 0.1 mm× 0.1 mm× 0.5 mm
to match the T2W image spacing, which allows for easy comparisons. This uniform
grid is then used for the 3D finite difference described below and also in the 2D level
set method that is in the full paper but outside the scope of this thesis.
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4.3 Mathematical Model
Early mathematical modeling of GBM growth and diffusion were based on reaction–
diffusion equations. Tracqui et al. (1995) formulated the earliest reaction–diffusion
model applied to GBM and were able to incorporate the effect of treatment. Oth-
ers expanded upon this basic model, incorporating a spatially-dependent diffusion
coefficient that depended on whether the material was gray or white matter, as cell
diffusion occurs preferentially in white matter (Swanson et al., 2002; Eikenberry et al.,
2009). These models were effective in determining the proliferating core of the tumor
but may not have been as successful at estimating the invasive front. Later modeling
efforts incorporated a ‘Go or Grow’ hypothesis, in which GBM tumor cell populations
are assumed to consist of two phenotypes: a migratory subpopulation and a stationary,
proliferative subpopulation (Stein et al., 2007a; Hatzikirou et al., 2012). A recent
paper showed that in vitro this behavior was able to be explained using one equation
with density-dependent diffusion (Stepien et al., 2015). Recent in vivo modeling efforts
have incorporated anisotropic diffusion and make use of diffusion weighted imaging
(DWI), which maps the diffusion of water molecules. From the 6 (or more) directional
DWI, a diffusion tensor image (DTI) can be created, which is a method to view the
three-dimensional ways in which water diffuses through the brain (Westin et al., 2002).
It is unclear how to directly relate water diffusion from DTI to cell diffusion, though
several groups have proposed various techniques to relate these quantities (Jbabdi
et al., 2005; Clatz et al., 2005; Bondiau et al., 2008; Konukoglu et al., 2010a,c; Painter
and Hillen, 2013). This is still an area for further investigation. For a recent review
on GBM modeling efforts, please see Martirosyan et al. (2015).
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4.3.1 Computational Setup
The mathematical model that we are considering is the dimensionless reaction-
diffusion equation given by:
∂u
∂t
(x, t) = D∇2u(x, t)︸ ︷︷ ︸
diffusion
+u(x, t)
(
1− u(x, t))︸ ︷︷ ︸
growth
, x ∈ Ω (4.2)
where Ω represents the segmented brain geometry. Ω is the brain tissue with the
ventricles segmented out. We use the last scanned time point (day 25) for the
computational domain. This is because for many of the mice, the growing tumor
altered this brain geometry – specifically the location of the ventricles. Thus, at each
time point, the brain geometry would differ. Therefore we chose the last time point,
which aids in the ease of comparing our final tumor with the images of the final tumor.
For this model Ω represents a 3D volume of the entire domain, and x is representative
of a spatial vector, containing three components x = (x, y, z).
The boundary conditions are given by:
∂
∂n
u(x, t) = 0, x ∈ ∂Ω (4.3)
where ∂Ω is the boundary of the segmented brain geometry: this would be the outline
of the brain and the outline of the ventricles. Essentially, we are assuming there is no
diffusion of tumor cells outside of the brain or into the ventricle space.
The initial condition is:
u(x, 0) = f(x), x ∈ Ω (4.4)
where f(x) represents the initial tumor at a given time. We have two proposed
methods for initializing the tumor: firstly, we can estimate the amount of cells initially
injected into the mouse brain, or we can start our simulations on the day of the
first scan (day 11), where tumor is visible. There are advantages and draw backs to
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each method. For the initialization at day 0, there are many uncertainties associated.
Firstly, we must consider that as the tumor cells are injected into the brain, there
may or may not be backsplash occurring, meaning that some of the tumor cells might
ooze out. Secondly, we are not sure what proportion of those cells are actually viable
and, of those that are viable, what proportion will actually take hold and grow into
a tumor. It is possible that these proportions might vary drastically between each
mouse. However, we would be able to compare our computational tumor with the MR
image for all five time points. By using initialization at day 11, we can only use four
time points to compare simulation with MR images. However, there is more ability to
be consistent since we are using the actual image to generate the initial condition.
For the simulations that use day 11 as an initial condition, we consider that any
part that registers ‘tumor’ is in fact at half the carrying capacity. While this may
seem somewhat arbitrary, we must consider that there is currently not much work
performed which relates what percentage of carrying capacity is ‘visible’ in the MR
image. Once histology is returned, we anticipate quantifying this relationship better
to more accurately model the growth and diffusion of the glioblastoma. A section
below will talk about sensitivity of our solutions to the initial condition cell-density.
When the simulations are complete, we create synthetic T2W MR images. Previous
work indicates that 16% of maximum tumor cells is considered the ‘visible’ tumor on
a T2W MR image (Swanson et al., 2008). We display everywhere above 16% carrying
capacity to compare with the MR image.
When segmenting the murine brains and tumors from the MR image, we also
calculated the volume of the tumor present in each mouse at each time point. We
noticed a large variance in the final tumor sizes in the mice, from 12 mm3 to 62 mm3.
We have several hypotheses which we believe might account for the discrepancy in
these final tumor sizes.
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4.3.2 Simulation Hypotheses
We investigate the values of D and ρ necessary to generate the various experimental
tumor volumes. From the segmented tumors in the MR images, we calculated the
volume of the visible tumor in Mimics R© based on the number of pixels that were
segmented as tumor (as seen in Table 4.1). In the mice injected with GL261-Luc2 cell
line, the final tumor size on day 25 varied from approximately 12 mm3 to 62 mm3, so
we explore several hypotheses that may explain this large discrepancy between mice.
• Hypothesis 1: The natural variance in the growth rate ρ and diffusion rate D
account for the large difference in final tumor size. In the first set of simulation
results described below, we initialize the model based on the first MR imaging on
day 11 following implantation. Our goal is to determine how well an optimized
choice of constant (averaged) parameter values fits the observed images on day 25
and how well they agree with values estimated elsewhere in the literature.
• Hypothesis 2: The values of D and ρ are time dependent, corresponding to
morphological changes during the growth of the tumors. A small tumor may
be highly proliferative, but as the tumor grows and resources become scarce,
the growth dynamics may be dominated by cell migration away from the main
mass. In the second set of simulation results below, we attempt to optimize the
values of D and ρ from time point to time point and see whether all of the mice
display similar trends in the variation of these parameters.
• Hypothesis 3: In addition to the selection of optimized model parameters from
one imaging time to the next, updates to the initial conditions at each imaging
time point are made based on the visible tumor in each scan. This ‘predictor-
corrector’ approach is analogous to that used in operational weather forecasting,
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where the initial conditions of the weather model are updated periodically in
view of incoming observations.
To test these hypotheses, we optimize the model parameters D and ρ for each
mouse individually using the fminsearch command in MATLAB. We minimize an
error function based on the average of the sum of the Jaccard distances (4.6):
error =
1
n
n∑
k=1
dJ,k(A,B) (4.5)
over all n imaging time points used in a given simulation. In the simulations, modeled
cell densities in regions of the computational domain that exceed the assumed detection
threshold are ‘visible tumor’ (shown in red in Figures 4.3-4.9, corresponding to set A) in
the synthetic MR images below, and the Jaccard distance is obtained from comparison
with the visible tumor on the actual MR images (set B).
We do not include a comparison between the simulated and experimental boundaries
of the tumor in the error function (4.5) because the extent to which the glioma cells
infiltrate the brain beyond the visible tumor margin in T2W images is unknown.
Konukoglu et al. (2010b) have suggested an estimation procedure based on Equation
(4.1) to extrapolate the tumor cell density distribution beyond the visible margin in
human GBM. However, since we do not have histological data with which to compare
our extrapolations, we concern ourselves with only visible tumor. For the purposes of
the simulations here, we assume that the detection threshold is 0.16 (Swanson et al.,
2008). As the results below suggest, however, there is considerable uncertainty in this
value. In future work, we plan to digitally analyze all the histology slides from the
mouse brains and correlate them to the final images to address this question, which
may provide insight into human cases.
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4.3.3 Relevant Background
The modeling efforts in this paper focus on Equation (4.1), as described in the
introduction. Although Equation (4.1) is simple, it has proven effective in clinical
settings. Tracqui et al. (1995) were able to show agreement with both the initial
growth of the tumor as well as the response to chemotherapy, and Alvord Jr (1991)
was able to estimate the recurrence of GBM after resection using similar models.
Recently, Baldock et al. (2014) estimated the ratio ρ/D, a measure of tumor
invasiveness relative to growth, from successive imaging studies of individual patients.
This measure was used to predict whether resection would significantly prolong the
life of the patient. Other authors have considered a spatially dependent diffusion
coefficient, with different values for regions of gray and white matter (Swanson et al.,
2003). However, since mouse brains have a relatively uneven distribution of gray and
white matter as compared to humans, we consider only a diffusion constant that is
uniform in space.
In Chapter 2, we discussed how the migratory and proliferating core could not
be modeled using Equation (4.1), because it worked well at modeling the core, but
not the migratory cells. Our justification for using this simple model for our current
simulations is that with the MR image, we are only seeing the higher-density material
of the tumor – most likely the proliferating core. Until we receive back the histology,
Equation (4.1) will be adequate for generating a prediction of the visible tumor on an
MR image.
4.4 Computational Methods
As discussed in Section 4.2, the computational domain Ω for each mouse is the
linearly interpolated uniform grid. The uniform grids of the brain and ventricles are
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imported into MATLAB. Then the ventricles are segmented out of the brain geometry
to produce the computational domain. Since the ventricles have been segmented
out, they are ignored in the discretization and no diffusion or growth occurs in the
ventricular space, consistent with the boundary conditions in Section 4.3.1. As the
tumor grows, it begins to displace the surrounding brain tissue. At each scan session,
the ventricles of each mouse brain have shifted slightly from the previous session due
to mass effect. The gross anatomy of the brain has been registered; however, the
internal structures have shifted due to mass effect of the growing tumor. Because
the ventricles are necessary to determine the computational boundary, we set the
ventricles to be constant throughout the simulation. We use the ventricle locations of
the last MR scan in our computational geometry.
The model is discretized using centered finite differences in space, and for our
purposes, MATLAB’s ode45 proved to be a suitable solver. (Explicit schemes for
finite difference methods are not always stable.) The space discretization is chosen
to correspond to the pixel width in the postprocessed images (the scans haves a
resolution of 0.1 mm×0.1 mm×0.5 mm). The computation is vectorized for efficiency.
Code was written by Barrett J. Anderies, a CSUMS student in the summer of 2014
and is publicly available in the murine-GL261-tumors repository located on github,
https://github.com/banderie/murine-GL261-tumors.
As mentioned above, we obtained usable time sequences of images for three mice,
called Mouse 1, 2, and 3 in the results presented below. Due to software difficulties, it
was not possible to segment out the ventricles for the first two time points (days 11
and 15) for Mouse 3, for which the associated simulations are carried out only for a
truncated time period. (It was possible, however, to estimate the total visible tumor
volume in all mice at each time point, so Table. 4.1 gives a complete set of imaging
volumes.)
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We compare the visible tumor volume on the synthetic MR images with that of
the actual T2W MR images using an error function based on the Jaccard distance at
each imaging time point. The Jaccard distance is a measure of the overlap between
two sets A and B at time t, given by
dJ,t(A,B) = 1− |A ∩B||A ∪B| . (4.6)
In this application, A is the set of voxels in the simulated MR image corresponding to
tumor and B is the voxels corresponding to visible tumor. If A and B are disjoint,
then dJ,t(A,B) = 1, and if A = B, then dJ,t(A,B) = 0. Figure 4.2 shows the nonlinear
relationship between Jaccard distance and the percentage of overlap between two sets.
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Figure 4.2: Relationship between the Jaccard distance measure and the overlap
percentage between two sets.
Since the Jaccard distance is a measure of similarity of two sets, we must have
a binary operator which to compare. In our case, for each pixel, if the density is
higher than the predetermined threshold (0.16), that pixel is considered ‘tumor’ (value
=1). Otherwise, that pixel is considered ‘brain’ (value = 0). We then define the
intersection as the number of pixels for which simulation and data both have a value
of 1 (representing tumor). The union is the number of pixels for which simulation or
69
data have a value of 1. These are the values which are used to calculate our Jaccard
distance.
4.5 Simulation Results
Hypothesis 1
Hypothesis 1 states that natural variance in parameters ρ, D, or both account for the
large difference in final tumor size. To test this hypothesis, we vary the parameters and
use parameter estimation techniques to determine best-fit parameters for individual
mouse cases where simulations are initialized using the MR image from time point 1.
As mentioned above, we select initial conditions corresponding to the visible tumor
at the first MR imaging session (day 11 following implantation). We use MATLAB’s
fminsearch function to determine values of D and ρ that minimize the Jaccard
distance over all subsequent images, Equation (4.5). The resulting values of ρ vary
from 0.0167 h−1 to 0.0188 h−1 among the three mice, but D varies from 319.22 µm2/h
(Mouse 2) to 651.17 µm2/h (Mouse 3). (See Tables 4.2, 4.3, and 4.4 for Mouse 1, 2,
and 3, respectively, at the end of this section.)
Figure 4.3 superimposes the simulated tumor in red over representative MR images
at each subsequent imaging time point for Mouse 1. The Jaccard distance error given
by Equation (4.5) is 0.4524, corresponding to a 70.8 percent overlap between the
simulated and actual visible tumors, based on the MR data.
The simulation results of the optimization under Hypothesis 1 are shown in
Figure 4.4 for Mouse 2 and Figure 4.5 for Mouse 3. Similar results were obtained for
Mouse 2 and Mouse 3: unsurprisingly mouse 3, which had the largest final tumor size,
also had larger ρ values than Mouse 1 and Mouse 2.
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Figure 4.3: Simulated tumor (red) superimposed on MR images for Mouse 1 at the
second through fifth imaging time points, using initial conditions estimated from
the first set of MR images. The model parameters D and ρ are assumed constant
(Hypothesis 1). (A) Day 15; (B) Day 18; (C) Day 22, and (D) Day 25 following
implantation.
Hypothesis 2
Hypothesis 2 states that there may be a morphological change that occurs sometime
within the tumor growth process which might change the values of D and ρ. When
the tumor is small, it may be able to grow much faster. However, as time increases
and resources become scarce, we may see instead the migration increase and the
71
A B
C D
Figure 4.4: Representative slices for Mouse 2 under Hypothesis 1. The simulations
are otherwise the same as in Fig. 4.3.
proliferation decrease.
The procedure to testing this hypothesis is comparable to that in Hypothesis 1,
except that the parameter optimizations are done between successive imaging time
points. That is, we take the same initial conditions on Day 11, then run fminsearch
to minimize the error measure in Equation (4.5) at Day 15 only. Then, starting
with the simulated tumor at Day 15, we select parameter values to minimize the
Jaccard distance at Day 18, and so on. Tables 4.2, 4.3, and 4.4 show all the results
for hypothesis 2, for Mouse 1, Mouse 2 and Mouse 3 respectively. For Mouse 1, the
estimates are ρ = 0.0182, 0.0248, 0.0192, 0.0082 h−1, respectively, for the Day 11–15,
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Figure 4.5: Representative slices for Mouse 3 under Hypothesis 1. We use time point 3
(day 18) as the initial condition. The simulations are otherwise the same as in Fig. 4.3.
(A) Time point 4 (day 22); (B) time point 5 (day 25).
15–18, 18–21, and 21–25 time intervals. The respective estimates for diffusion are
D = 139.24, 839.93, 1047.6, 968.75 µm2/h. The sum of the individual Jaccard error
measures (Equation 4.5)) is 0.4365, and the overlap between simulated and actual
tumors varies from 68.6 to 76.6 percent. Figure 4.6 shows the results for Mouse 1.
The results suggest that there is a significant temporal variation in the model
parameters as the tumor evolves. However, the model’s ability to track the visible
tumor is only slightly improved compared to Hypothesis 1. Figures 4.7 and 4.8 are
the results for Hypothesis 2 for Mouse 2 and 3, respectively.
We observe that, similar to Mouse 1, all the remaining mice also exhibit a better
fit using hypothesis 2 than hypothesis 1. This supports our idea that a constant D
and ρ does not accurately describe the behavior. Although we see that the optimal D
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Figure 4.6: Representative simulation results for Mouse 1 under Hypothesis 2. (A)
Using the optimized parameter values from Day 11–15; (B) Day 15–18; (C) Day 18–21;
(D) Day 21–15.
and ρ change for each time point, the pattern in which they change does not remain
constant. For Mouse 1, the diffusion increases drastically from time point 2 to time
point 3 and slightly to time point 4. The growth increases from time point 2 to time
point 3, then falls for the remainder of the simulation. On the other hand, for Mouse
2, the diffusion starts larger and falls from time point 2 to time point 3, increasing
thereafter. Mouse 2 starts with a large growth, falling quickly until rebounding from
time point 4 to time point 5. For Mouse 3, diffusion decreases and the growth increases
as time increases. Even though all optimized parameters changed from time point to
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Figure 4.7: Representative slices for Mouse 2 under Hypothesis 2. The simulations
are otherwise the same as in Fig. 4.6.
time point, between mice, the result was inconsistent.
Hypothesis 3
Hypothesis 3 also considers allowing D and ρ to vary with time; however, these
simulations are corrected by using actual data to initialize each time point. In this
approach, we optimize the parameters from time point to time point as in Hypothesis 2,
but in addition, we reset the initial conditions at each imaging time point, assuming
as usual that tumor cell densities at and above 0.16 correspond to visible tumor
on T2W images. The optimized estimates for Mouse 1 for the growth rate are
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Figure 4.8: Representative slices for Mouse 3 under Hypothesis 2. We use time point 3
(day 18) as the initial condition. The simulations are otherwise the same as in Fig. 4.6.
(A) Time point 4 (day 22); (B) time point 5 (day 25).
ρ = 0.0182, 0.0499, 0.0178, 0.0105 h−1 respectively for the Day 11–15, 15–18, 18–21,
and 21–25 time intervals, and the respective estimates for diffusion coefficient are
D = 139.24, 233.97, 1156.2, 1305.6 µm2/h.
The sum of the individual Jaccard error measures given by Equation (4.5), based
on the predicted images prior to the initial condition updates, is 0.3663, and the
overlap between simulated and actual tumors by Day 25 is 85.2 percent. Figure 4.9
shows the results for Mouse 1. Figures 4.10 and 4.11 are the results for Hypothesis 3
for Mouse 2 and 3, respectively.
76
A B
C D
Figure 4.9: Representative simulation results for Mouse 1 under Hypothesis 3, using
parameter values optimized over each imaging time interval followed by an update of
the initial conditions: (A) Day 11–15; (B) Day 15–18; (C) Day 18–21; (D) Day 21–15.
For two of the three mice (Mouse 1 and Mouse 3), the diffusion coefficient increased
over time, suggesting that the tumor growth dynamics become more diffusive with
time. However, for Mouse 2, the optimized values for D decrease significantly over
the last two time points, but the growth parameter ρ increased sharply. As for the
growth of the other mice, Mouse 1 had large growth early in tumor development, and
then growth decreased in the later stages of the simulation (time points 4 and 5). For
Mouse 3, there was increasing ρ. This result may reflect a biological difference in the
growth dynamics of the Mouse 2 tumor compared to the others.
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Figure 4.10: Representative slices for Mouse 2 under Hypothesis 3. The simulations
are otherwise the same as in Fig. 4.9.
Velocity of Tumor Boundary
Since our analysis of Hypotheses 1–3 in the previous sections indicates that assuming
constant D and ρ is inadequate to accurately model tumor growth and diffusion, we
examine the dependence of the velocity of the visible tumor boundary on the volume
to determine if the estimated parameters correlate with the volume of the tumor.
Originally, we had hypothesized that we would observe similar dynamics in the
changing of D and ρ over time for all three of the mice. However, our analysis
when examining the results of hypothesis 2 and hypothesis 3 indicated that for each
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Figure 4.11: Representative slices for Mouse 3 under Hypothesis 3. We use time
point 3 (day 18) as the initial condition. The simulations are otherwise the same as in
Fig. 4.9. (A) Time point 4 (day 22); (B) time point 5 (day 25).
mouse, there was no consistency in variation of D and ρ over time. The rationale
for re-optimizing the parameters from time point to time point is that there is some
morphological change which occurs, changing how the tumor spreads. The idea is
that when the tumor is small, it should have a very large growth, or ρ value. As the
tumor grows, however, it needs to start spreading in order to gain nutrients so we
would expect a corresponding increase in diffusion, D. However, with this idea, it
makes more sense that the values of D and ρ are dependent on the volume of the
tumor, rather than the time since tumor implantation. Since our mice exhibited such
large differences in tumor volume through time, it makes sense that we do not have
matching dynamics at the same time point.
Model (4.1) implies that the tumor boundary moves as a traveling wave whose
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Hypothesis Time D ρ (h−1) velocity Error Overlap
Point (µm2/h) 2
√
Dρ (µm/h) (%)
1 – 413.77 0.0188 5.5781 0.4524 70.8
2 2 139.24 0.0182 3.1838 0.1196 68.6
3 839.93 0.0248 9.1280 0.1191 68.7
4 1047.6 0.0192 8.9697 0.1029 74.1
5 968.75 0.0082 5.6369 0.0949 76.6
3 2 139.24 0.0182 3.1838 0.1196 68.6
3 233.97 0.0499 6.8338 0.1145 70.3
4 1156.2 0.0178 9.0731 0.0688 84
5 1305.6 0.0105 7.4051 0.0644 85.2
Table 4.2: Values of estimated parameters for Mouse 1 for each hypothesis at each
time point using the 3D finite difference method. Minimization is performed with
respect to Equation (4.5).
wave speed (velocity) is 2
√
Dρ. Figure 4.12 shows a plot of the predicted wave speed
versus the visible tumor boundaries under each set of modeling hypotheses. The data
points are separated by shape and color: blue markers correspond to the wave speeds
calculated for Hypothesis 2 and red markers correspond to the wave speeds generated
from Hypothesis 3. Within these colors, the markers signify the separate mice: Mouse
1 is represented by triangles, Mouse 2 with plusses, and Mouse 3 with circles. At
first glance, it may appear that there is little correlation between the two variables.
However, if we examine the Hypothesis 3 data (red markers), we can see there does
appear to be some relationship between wave speed and visible tumor size. More data
is necessary to quantify the relationship, however.
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Figure 4.12: Dependence of wave speed of tumor on tumor size. The wave speed
(velocity) of the tumor is calculated by 2
√
Dρ. Blue markers show results from
parameters optimized under Hypothesis 2; red markers, Hypothesis 3. Triangles:
Mouse 1; pluses: Mouse 2; circles: Mouse 3.
4.5.1 Initial Condition Sensitivity Analysis
We performed additional analysis to determine the sensitivity of the parameter
estimation procedure to the choice of initial condition. Using Mouse 1, we re-ran the
parameter estimation procedure assuming initial cell densities of 0.3 and 0.7 in voxels
corresponding to visible tumor on MRI. We discovered that our parameter estimations
were rather insensitive to initial starting densities, the results of which are displayed
in a Table 4.5. Although our values of D increase as we increase the initial cell density,
we have a corresponding decrease in ρ. This is logical, because when we have a high
initial density of cells, we would expect more diffusion and less growth. The result
of this is that the optimized wave speed given be 2
√
Dρ are all within a very close
value to each other. Additionally, our errors given by the Jaccard distance and the
percentage overlap are very consistent.
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Hypothesis Time D ρ (h−1) velocity Error Overlap
Point (µm2/h) 2
√
Dρ (µm/h) (%)
1 – 319.22 0.0167 4.6178 0.4528 70.7
2 2 558.74 0.0235 7.2472 0.1151 70.1
3 206.21 0.0100 2.8720 0.1067 72.9
4 346.35 0.0055 2.7604 0.1042 73.7
5 886.07 0.0104 6.0713 0.0979 75.6
3 2 558.74 0.0235 7.2472 0.1151 70.1
3 950.79 0.0051 4.4041 0.0846 79.6
4 77.734 0.0369 3.3873 0.0621 85.8
5 94.161 0.0520 4.4255 0.0643 85.2
Table 4.3: Values of estimated parameters for Mouse 2 for each hypothesis at each
time point using the 3D finite difference method. Minimization is performed with
respect to Equation (4.5).
The same dynamics are observed for Mouse 2. However, Mouse 3 appears to have a
slight difference for the 30% initial cell density case. It is apparent that the wave speed
is much larger for this case. Upon further investigation, I discovered that there were
many sets of parameters that gave approximately the same amount of error for the
30% initial cell density case for Mouse 3. For the remaining sets of parameters, they
were approximately D = 588.1633− 664.1250 µm/h, and ρ = 0.0202− 0.0214 (h−1),
which gives a wave speed of 7.0955− 7.3254, which is much closer to the remaining
wave speeds for Mouse 3. This indicates that there are many parameter sets which
could optimize the fit of simulated data to experimental data.
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Hypothesis Time D ρ (h−1) velocity Error Overlap
Point (µm2/h) 2
√
Dρ (µm/h) (%)
1 – 651.17 0.0177 6.7899 0.2833 83.5
2 4 859.70 0.0127 6.6085 0.1408 83.6
5 454.29 0.0236 6.5487 0.1364 84.2
3 4 859.704 0.0127 6.6085 0.1408 83.6
5 1552.1 0.0200 11.1431 0.1027 88.6
Table 4.4: Values of estimated parameters for Mouse 3 for each hypothesis at each
time point using the 3D finite difference method. Minimization is performed with
respect to Equation (4.5).
4.6 Discussion
In this study, we examine a laboratory murine model of GBM tumor growth,
in which genetically similar, immunocompetent mice received identical intracranial
injections from the same culture of a GL261 tumor line. After 25 days, the growth
patterns of the resulting tumors are significantly different. From experimental MR
images, we investigate two mathematical models and examine their ability to simulate
the laboratory results under various choices of model parameters. The reaction–
diffusion model, Equation (4.1), is numerically integrated using a finite difference
method in three dimensions.
Previous estimates of the growth parameter ρ is approximately in the range 0.014–
0.018 h−1 for in vitro GL261-Luc2cells (Hercbergs et al., 2009) and 0.0096–0.011 h−1
for in vivo GL261-Luc2 cells (Doblas et al., 2010). The estimated values for ρ in our
simulations, presented in Tables 4.2, 4.3, and 4.4 is comparable with these previous
ranges. Although some of our values are larger and smaller than this range, our
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Mouse Initial Condition D ρ (h−1) velocity Error
Cell Density (%) (µm2/h) 2
√
Dρ (µm/h)
1 30 316.43 0.0226 5.3484 0.4510
50 413.77 0.0188 5.5781 0.4524
70 441.52 0.0168 5.4476 0.4592
2 30 220.0783 0.0220 4.4008 0.4678
50 319.22 0.0167 4.6178 0.4528
70 350.2452 0.0146 4.5226 0.4421
3 30 861.3994 0.0190 8.0911 0.2789
50 651.17 0.0177 6.7899 0.2833
70 630.4063 0.0173 6.6049 0.2880
Table 4.5: Values of estimated parameters for Mouse 1, 2, and 3 using various initial
condition cell densities for Hypothesis 1. Minimization is performed with respect to
Equation (4.5).
average values of ρ are in this range.
Measurements of the apparent diffusion constant (ADC) for in vivo GL261-Luc2
cells, which is calculated from diffusion weighted imaging that maps the diffusion of
water molecules, range from 2.2–3.3 mm2/h (Seshadri and Ciesielski, 2009; Laufer
et al., 2014). These values are orders of magnitude larger than the diffusion constant
D estimated from our simulations in Tables 4.2, 4.3 and 4.4, which models the
movement of tumor cells. A more meaningful comparison between the two types of
measurements requires a quantitative correlation between the diffusion of water in
DWI images and the growth of the tumor over time, which likely will require cell
density measurements from histology. Our largest value of D is still considerably less
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than previously published values, which suggests that errors in the initial conditions
and in the assumptions on the correspondence between tumor cell densities and
enhancing regions on MR images are contributing factors. Our assumption regarding
the minimum cell density that is visible on MR may need to be revised significantly.
The 3D finite difference method applied to Equation (4.1) implies that the velocity
of the visible tumor boundary is 2
√
Dρ, Converting to units of centimeters per year
from Table 4.2, 4.3, and 4.4 the 3D finite difference method yields velocity estimates
from 2.789–7.996 cm/yr for Mouse 1, 2.516–6.348 cm/yr for Mouse 2, and 5.737–
9.761 cm/yr for Mouse 3. The velocities are somewhat larger than those obtained
from tumors in rat brains with implanted human glioblastoma cells (Massey et al.,
2012) and are on the low end of the human velocity range (Harpold et al., 2007; Szeto
et al., 2009). Our results suggest that, in this respect, GL261-Luc2 cells implanted in
mice brains appears to be a reasonable proxy of human GBM growth.
In the original work, we also ran simulations in 2D, which are not chronicled here
as they were written and performed by someone else. We noticed that in two and three
dimensions, we find comparable estimates of the model parameters D and ρ from the
experimental data, implying that there does not need to be a scaling factor between
the 2D and 3D simulations. As far as we are aware, this relationship and possible
scaling factor between 2D and 3D simulations has not been previously investigated.
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Chapter 5
GLOBAL DYNAMICS OF A MODEL OF JOINT HORMONE TREATMENT
WITH DENDRITIC CELL VACCINES FOR PROSTATE CANCER
5.1 Introduction
Once cancer has reached a large enough size that the patient begins to experience
symptoms, they are often diagnosed with the disease, at which point they are offered
standard treatment. Depending on the type of cancer, these treatments may include,
but are not limited to, surgical resection, chemotherapy, radiation therapy, and
immunotherapy. Dosing schedules and amounts are rarely questioned by physicians
for these treatments, but they are of great interest to mathematicians. Is there an
optimal dosing strategy for a certain type of cancer? Do we need to individualize
dosing strategies?
An emerging field among mathematical oncology is determining this optimal dosing
strategy. The goal is no longer necessarily to eradicate cancer, but rather to render it
manageable, as in diabetes or HIV. Metronomic therapy, or the use of much lower
dosages of medication, but more frequently, has been mathematically investigated
as an alternative to the popular types of maximal-dosing strategies (Ledzewicz and
Scha¨ttler, 2002; Ledzewicz et al., 2012). The benefits that these therapies offer can
not be overstated: they lower toxicity of the treatment, improving quality of life for
the patient, they lower costs, and increase time until treatment resistance occurs.
In this chapter, we explore the various treatment strategies for late-stage prostate
cancer. We investigate hormonal therapy, both continual and intermittent, in conjunc-
tion with immunotherapy in the form of dendritic cell vaccines. We consider discrete
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injections of dendritic cell vaccines, and determine whether dosing schedules influences
the time to rise of androgen independent cancer relapse. The work contained in this
chapter has been accepted for publication and the accepted version of the article is
located in Appendix F.
5.1.1 Prostate Cancer and Current Treatment
Prostate cancer is one of the most ubiquitous cancers that affect males in the
United States, with an expected one in six men being diagnosed in their lifetime
(Jemal et al., 2008). Current treatment protocol is hormone therapy in the form of
androgen deprivation therapy. Androgens are the male sex hormones, the most known
of which is testosterone. The prostate requires androgens, such as testosterone and 5α-
dihydrotestosteron (DHT) to function and continue proliferation. Thus, restricting the
production of these androgens will lead to inhibited growth of cancerous cells as well.
Although the initial response to this hormonal treatment is excellent, eventually an
androgen-independent form of prostate cancer, which can be extremely fatal (Nelson,
2012).
Androgen deprivation therapy is an unpleasant therapy with many undesirable
side effects such as loss of libido, loss of muscle, and osteoporosis. Recent research
and clinical trials have begun to question whether an intermittent hormone therapy
schedule might be more effective in terms of both quality of life of the patient, as
well as delaying the rise to treatment resistance (Jain and Friedman, 2013; Portz
et al., 2012; Crook et al., 1999; Larry Goldenberg et al., 1995). Intermittent androgen
deprivation therapy considers the level of prostate specific antigen (PSA), a biomarker
of the disease. A patient is kept on hormone therapy until their PSA levels drop below
a pre-determined threshold. Once the patient has reached that threshold, they are
taken off treatment and have their PSA levels monitored. If their PSA levels rise
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above a second predetermined threshold, they are placed back on treatment, and the
cycle begins anew. This treatment still results in overall suppression of androgen, but
can improve the quality of life of the patient (Crook et al., 2012; Hussain et al., 2013).
It is often suggested that IAD may stave off the emergence of castration-resistant
prostate cancer, although this has yet to be shown in clinical trials and meta studies,
although it is accepted that IAD is non inferior to continual ablation therapy (Crook
et al., 2012; Botrel et al., 2014; Sciarra et al., 2013; Tsai et al., 2013). However, there is
still little consensus within the medical community about who and how to administer
IAD therapy to. Certain studies suggest that IAD is suitable for patient groups which
exhibit certain disease characteristics, but determining which characteristics remains
a work in progress (Wolff et al., 2014; Klotz and Toren, 2012). In addition to the
confusion over who may benefit from IAD, there is still no accepted norm within the
medical community regarding the timing of IAD (Gleave et al., 2009). Even recently,
the debate rages on, with many questioning the findings of the previous clinical trials,
saying the studies used to draw conclusions are flawed (Park and Eisenberger, 2016;
Hussain et al., 2016).
5.1.2 Immunotherapy
In recent years, immunotherapy has emerged as a viable disease management
strategy. Immunotherapy relies on using the body’s own immune system to fight
the cancer. There are many different types of immunotherapy, such as nonspecific
antibodies to boost the immune system response, synthetic antibodies, and targeted
therapies. Non-specific antibodies that boost the immune system response can be
suppressive or boosting. One such example are cytokines which can help he immune
system cells grow and divide. However, there are unpleasant side effects such as flu-like
symptoms and, in the case of to high a dose, possibly fatal heart conditions. Synthetic
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antibodies are lab-designed antibodies which specifically attack target antigens found
on cancer cells. However, for many cancers and diseases, the big question is, which
antigen should these synthetic antibodies attack? Finally, targeted therapies use the
patient’s specific tumor to induce a response. In our model, we will use this last type
of immunotherapy.
First, however, some background on the immune system. We begin with cytokines,
which are small proteins which effect cell signaling. Cytokines are produced by immune
cells such as macrophages, T cells, and B cells. They are released to influence other
types of cells and are known to affect maturation, growth, and death of cell populations.
There are several types of cytokines such as chemokines, interferons and interleukins,
among others. Chemokines induce chemotactic responses in nearby cells. Interferons
are released to cause nearby cells to activate their viral defenses, and also interfere
with viral replications. Interleukins stimulate the development and differentiation of
T and B cells. Large doses of these cytokines, however, can have adverse side effects
and can be fatal in large enough doses. The different types of cytokines interact with
each other, keeping the body in homeostasis. We are investigating an interleukin,
specifically interleukin-2 (IL-2). IL-2 directly promotes the differentiation of immature
T cells into regulatory T cells, which prevents attacking of healthy cells. Additionally,
IL-2 promotes the differentiation of native T cells into effector T cells and memory T
cells. Like other cytokines, IL-2 is dangerous if too much exists in the body, eliciting
responses such has seizures, heart complications, and difficulty breathing.
Another class of immune cells are antigen-presenting cells. Antigen-presenting
cells work by traveling through the blood stream in an immature state. Once they
encounter an antigen, they ingest it, and are activated. Once activated, these cells
migrate to the lymph nodes to interact with T and B cells. The antigen presenting
cells then present the antigen material on their cell surface to naive and memory T
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cells, which then target that antigen. The most potent of these antigen-presenting
cells are dendritic cells. Additionally, they secrete co-stimulatory signals.
The actual therapeutic practice that we investigate in this model is dendritic cell
vaccines. These are created first by extracting blood from a patient. The monocytes
are then differentiated into dendritic cells. These dendritic cells are then loaded
with tumor-derived antigens. Ideally, these tumor-derived antigens are proteins from
autologous tumor extracts, i.e. from the patient’s own tumor. If these autologous
tumor extracts are unavailable, as in a case with an inoperable tumor, synthetic,
lab-derived peptides can be used instead. Once these dendritic cells have had the
opportunity to ingest the antigens, they are activated by cytokines. Finally, these
tumor antigen-presenting dendritic cells are re-injected into the patient. For prostate
cancer, the target antigen used in clinical trials is Prostatic Acid Phosphatase (PAP)
(Fong et al., 2001; Small et al., 2000; Burch et al., 2004). PAP is an enzyme that is
produced by the prostate and tends to be elevated in prostate cancer patients. In fact,
PAP used to be a biomarker of the disease until the switch was made to PSA Taira
et al. (2007). The highest levels of PAP are found in patients for whom the cancer has
already metastasized Whitesel et al. (1984). Currently, Spuleucel-T (Provenge) is the
only FDA-approved dendritic cell vaccine treatment for prostate cancer, which has
been clinically shown to extend the life of patients (Cheever and Higano, 2011; Higano
et al., 2009). DC vaccines tend to be very safe with mild limited side effects, such as
flu-like symptoms. DC vaccine efficacy is mitigated by radiation and chemotherapy,
which makes prostate cancer an ideal candidate to test these vaccines on, as treatment
tends to be hormonal. Currently, Provenge is used for advanced prostate cancer that is
no longer helped by hormonal therapy, the androgen-independent cancer. We question
whether it may be more effective if used in conjunction with hormonal therapy, as
opposed to sequentially.
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5.2 Previous and Proposed Models
Many previous mathematical models have been formulated to estimate evolution
and treatment of prostate cancer using androgen deprivation therapy. In a pioneering
paper published in 2004, Jackson formulated a partial differential equation model
that featured both androgen independent and androgen dependent cancer cells. The
resulting dynamics were consistent with experimental data which exhibited androgen
independent relapse (Jackson, 2004). From this landmark paper, many sequential
papers have considered variations on the model to explore further dynamics. We
concentrate on three previous papers: one which models immunotherapy interaction
with tumors, one which models intermittent hormone therapy for prostate cancer, and
one which marries the two models. Our proposed model is a variation on this last
model, with more realistic terms.
5.2.1 Kirschner and Panetta (1998)
Kirschner and Panetta (1998) formulated a model quantifying the anti-tumor
response due to the immune system. Their model contained effector T cell population
E, tumor cell population T , and IL-2 concentration IL. The governing equations are:
dE
dt
= cT︸︷︷︸
recruitment from tumor
− µ2E︸︷︷︸
death
+
p1EIL
g1 + IL︸ ︷︷ ︸
stimulation from IL2
+ s1︸︷︷︸
immunotherapy
(5.1)
dT
dt
= r2(T )T︸ ︷︷ ︸
growth and death
− aET
g2 + T︸ ︷︷ ︸
death from T cells
(5.2)
dIL
dt
=
p2ET
g3 + T︸ ︷︷ ︸
secretion by tumor
− µ3IL︸︷︷︸
degradation
+ s2︸︷︷︸
immunotherapy
(5.3)
The population of effector T cells is governed by a tumor recruitment term, a
death term, a stimulation from IL-2 term, and an additional immunotherapy term.
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The tumor recruitment term is based on the antigenicity of the tumor (represented by
the parameter c), or how different the tumor is from the healthy tissue. The more
‘different’ the tumor is, the faster the growth of T cells. The stimulation term from
IL-2 is a standard Michaelis-Menten term. The last term allows for effector T-cells to
be injected into the patient, as a form of immunotherapy. For standard immunological
response, we would assume s1=0. For the tumor cell population, we see a growth
function r2(T ) which could be something like a logistical growth term. The death
term is due to interaction between tumor cells and T cells and is saturating. The
equation for IL-2 concentration has a secretion by the tumor, which also displays
Michaelis-Menten kinetics. As mentioned earlier, cytokines are regulated by the body,
so it is necessary for there to be self-limiting production of IL-2. There is also the
option for IL-2 to be directly injected as a form of immunotherapy, but for a standard
immunological response, we would take s2 = 0.
5.2.2 Ideta et al. (2008)
In 2008, Ideta et. al created a prostate cancer model that would incorporate
not only continual androgen deprivation therapy, but also intermittent androgen
deprivation therapy. The model incorporated both AD (X1) and AI (X2 cells, as
well as androgen concentration (A). Within the model, AD cells are are governed by
proliferation, death, and mutation to AI, which are all dependent on the androgen
concentration. The AI cells are governed by mutation from AD, proliferation and
death terms, which can also depend on androgen concentration. The androgen level
itself is governed by a homeostasis term and a term which represents whether the
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patient is on or off treatment. Ideta et al. (2008) model is given by:
dX1
dt
= α1p1(A)X1︸ ︷︷ ︸
proliferation
− β1q1(A)X1︸ ︷︷ ︸
apoptosis
− m(A)X1︸ ︷︷ ︸
mutation to AI
(5.4)
dX1
dt
= α2p2(A)X2︸ ︷︷ ︸
proliferation
− β2q2(A)X2︸ ︷︷ ︸
apoptosis
+ m(A)X1︸ ︷︷ ︸
mutation from AD
(5.5)
dA
dt
= γ(a0 − A)︸ ︷︷ ︸
homeostasis of androgen
− γa0u(t)︸ ︷︷ ︸
depletion of androgen if on therapy
(5.6)
where u(t) represents the state of treatment: u(t) = 1 when treatment is on, u(t) = 0
when treatment is off. The value of u(t) depends on the PSA level y(t), which is
calculated depending on the populations of AD and AI cells in addition to how that
level is changing (i.e., a patient would remain on treatment even if they go under
the threshold if their PSA levels are increasing). The summary of this interaction is
shown below:
y(t) = c1X1 + c2X2
u(t) =
 0→ 1 if y(t) > L1 and
dy
dt
> 0
1→ 0 if y(t) < L0 and dydt < 0
(5.7)
Numerical simulations performed by the authors were able to display the cyclical
behavior expected with intermittent therapy.
5.2.3 Portz and Kuang (2012)
The Portz and Kuang model is based on marrying these two previous models
together with an additional equation that represents the dendritic cell levels. Their
model is given by:
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dX1
dt
= r1(A)X1︸ ︷︷ ︸
growth and death
−m1
(
1− A
a0
)
X1︸ ︷︷ ︸
mutation to AI
− e1X1T
g1 +X1︸ ︷︷ ︸
death by T cell
, (5.8)
dX2
dt
= r2X2︸︷︷︸
growth
+m1
(
1− A
a0
)
X1︸ ︷︷ ︸
mutation from AD
− e2X2T
g1 +X2︸ ︷︷ ︸
death by T cell
, (5.9)
dT
dt
=
eD
g +D︸ ︷︷ ︸
activation of T cell by DC
− µT︸︷︷︸
death
+
e3TIL
g3 + IL︸ ︷︷ ︸
activation of T cell by cytokines
, (5.10)
dIL
dt
=
e4T (X1 +X2)
g4 +X1 +X2︸ ︷︷ ︸
secretion by tumor
− ωIL︸︷︷︸
degradation
, (5.11)
dA
dt
= γ(a0 − A)︸ ︷︷ ︸
homeostasis of androgen
− γa0u(t)︸ ︷︷ ︸
depletion of androgen if on therapy
, (5.12)
dD
dt
= − cD︸︷︷︸
death
. (5.13)
where r1(A) = αa
A
A+k1
− β1
(
k2 + (1− k2) AA+k3
)
.
The equation describing the dendritic cells is just a degradation term, as the den-
dritic cells are added only through immunotherapy. This model adequately describes
the tumor-immune interaction, however, there are some shortcomings that inhibit the
reality and analysis of the model. Firstly, growth of the androgen independent cancer
cells is assumed to be exponential, which is unrealistic. Secondly, the terms governing
the death of the AD and AI cells with respect to T should be saturating over the
entire tumor population, as opposed to the individual AD or AI cell populations. For
this reason, we make some changes to create our model.
5.2.4 Previous Mathematical Models
Many have continued the work of the Ideta e.t al model. Hirata et al. (2010a)
extended the model to include two differing types of androgen independent cells. This
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included a subpopulation which has a reversible mutation to AI and subpopulation of
AI for which the mutation is irreversible. They used this model to then characterize
patients into three sub-groups in order to determine if IAD would be a suitable therapy
(Hirata et al., 2012). They have also used this model to optimize patient protocols
(Hirata et al., 2010b, 2014). Recently, for the patient group which is most likely
to benefit form IAD, they found conditions necessary for non-trivial periodic orbits
(Hirata and Aihara, 2015).
Portz et al. (2012) considered androgen to be a limiting nutrient and introduced
stoichiometric ideas into the model using cell quotas. This model incorporated the
dependence of both AI and AD cell populations on the concentration of intracellular
androgen. This model was furthered and compared to the Hirata et. al model described
above (Everett et al., 2014).
In addition to deterministic models, Tanaka et al. (2010) incorporated stochasticity
into the Ideta et. al model, formulating more realistic PSA data.
There has not been as much mathematical modeling work performed on im-
munotherapy in the context of prostate cancer, however. Kronik et al. (2010) inves-
tigated the interaction of prostate cancer with dendritic cell vaccines, using patient
data, but they only considered one population of prostate tumor cells, and did not
incorporate hormone therapy into their treatment model.
5.2.5 Our Model
Our model is heavily influenced by the Portz et. al model, but we incorporate
several key changes which allow more realistic assumptions. Their results showed that
combining dendritic cell vaccines with the hormone treatment was able to delay the
onset of castration-resistant prostate cancer, however they did not consider altering
the dosing schedule or amounts of dendritic cell vaccine injections. A previous
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mathematical model showed very different dynamics, including increase to AI relapse
by changing the dosages and frequencies of the dendritic cell vaccine (Kronik et al.,
2010).
We still consider six populations: androgen-dependent cancer cells (X1), androgen
independent cancer cells (X2), activated T cells (T ), concentration of cytokines (IL),
concentration of androgen (A), and number of dendritic cells (D). However, in our case
now, we consider logistic growth functions, instead of exponential growth. Additionally,
we generalize many of the functions for interactive terms. Finally, we consider that
androgen-independent cells may mutate back to using more androgen if there is an
androgen-rich environment, similar to Hirata et al. (2010a).
dX1
dt
= r1(A,X1, X2)X1︸ ︷︷ ︸
growth and death
− m1(A)X1︸ ︷︷ ︸
mutation to AI
+ m2(A)X2︸ ︷︷ ︸
mutation from AI
−X1 f1(X1, X2, T )︸ ︷︷ ︸
death by T cell
, (5.14)
dX2
dt
= r2(X1, X2)X2︸ ︷︷ ︸
growth and death
+ m1(A)X1︸ ︷︷ ︸
mutation from AD
− m2(A)X2︸ ︷︷ ︸
mutation to AD
−X2 f2(X1, X2, T )︸ ︷︷ ︸
death by T cell
, (5.15)
dT
dt
=
eD
g +D︸ ︷︷ ︸
activation of T cell by DC
− µT︸︷︷︸
death
+ Tf3(IL, T )︸ ︷︷ ︸
activation of T cell by cytokines
, (5.16)
dIL
dt
= Tf4(X1, X2)︸ ︷︷ ︸
secretion by tumor
− ωIL︸︷︷︸
degradation
, (5.17)
dA
dt
= γ(a0 − A)︸ ︷︷ ︸
homeostasis of androgen
− γa0u(t)︸ ︷︷ ︸
depletion of androgen if on therapy
, (5.18)
dD
dt
= − cD︸︷︷︸
death
. (5.19)
The population of androgen-dependent cancer cells is influenced by a growth and
death term, mutation to and from androgen-independent cancer cell populations, and
a death due to interactions with T cells. The population of androgen-independent
cancer cells has a different growth and death term, can also mutate to and from
androgen-dependent cancer cell population, and can also be killed by interacting with
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T cells. The T cell population is activated by the antigen-presenting dendritic cells
as well as the cytokines, and dies linearly. The concentration of IL-2 has a natural
degradation term but is produced by the tumor and T cell interactions. The androgen
concentration depends on whether the patient is on treatment or off treatment, but
has a homeostatic term as well as a depletion term if patient is on therapy. Finally,
the dendritic cells naturally die.
The modeling of the IAD is exhibited in the interaction of u(t), the switch from
on-treatment to off-treatment, which depends on the patient’s PSA levels, y(t). We
note that u(t) governs the androgen deprivation therapy: when u(t) = 1 treatment is
on, when u(t) = 0, treatment is off. We also use the PSA levels to govern whether
or not the patient is put on or off treatment. Following the work of Swanson, we
model the PSA as simple linear relationship for the number of tumor cells. When
the PSA levels decrease below a certain threshold, labeled L0, the patient is taken off
androgen deprivation therapy. When the PSA levels rise above a certain threshold, L1,
the patient is put back on treatment. Note that we require L0 < L1. The equations
governing treatment and PSA are those listed in Ideta et al. (2008), Equations (5.7).
Our model differs from Portz and Kuang (2012) in three major ways: the inclusion
of more realistic growth and death terms, mutation from not only AD to AI but also
from AI to AD, and generalizing the immune system interaction functions. Each of
these changes, and their reasoning, are explained below.
In the original model by Portz and Kuang (2012), the growth for AD cells only
depended on androgen concentration, not current amount of cancer cells and the
growth for AI cells is exponential. In order to consider a more realistic growth function,
we assume both AD and AI cancer cells grow logistically. The growth of AD cells is
also dependent on the current level of androgen: if there is a0, the homeostatic level of
androgen, the AD cells grow at their intrinsic growth rate r1. As the level of androgen
97
decreases, it represents a corresponding decrease in how fast the AD cell population is
growing, finally reaching no growth in the absence of androgen (A = 0). The growth
of AI cells is very much the same, although it always grows at its intrinsic growth
rate r2, not being scaled by androgen levels. We also assume that not only does the
absence of androgen effect the growth, but that it actively kills and AD cells (the
second term below). This assumption is realistic and has been used in other prostate
cancer models (Eikenberry et al., 2010; Jain et al., 2011). We have no extra death
when we are at homeostatic levels, but as the androgen level decreases, we start having
active cell death due to lack of androgen. In the absence of androgen, the growth rate
of the androgen dependent cells is negative, which represents natural death due to
lack of androgen. As the amount of androgen increases, the growth rate also increase,
resulting in it’s maximum when A = a0. The equations are displayed below:
r1(A,X1, X2) = r1AX1
(
1− X1 +X2
K
)
− d1(a0 − A)
r2(X1, X2) = r2X2
(
1− X1 +X2
K
) (5.20)
The next main change is the mutation functions: the original model only had
mutation from AD cells to AI cells in an androgen-depleted environment. It is, however,
a reasonable assumption that in the case of an an androgen-rich environment, cells
might mutated from AI to AD. Hirata et al. (2010a) also included an assumption
that there is a ‘reversible’ phenotype, which may be able to mutate back into AD
cells. We assume that when A = a0, there is no mutation from androgen dependent to
androgen independent because there is no need for the mutation to occur, as androgen
is abundant. As A decreases, the rate at which the cells mutate grows higher and
higher. On the other hand, for mutation from androgen independent to androgen
dependent, we assume that if there is no androgen, A = 0, we will not have any
mutation from androgen independent to androgen dependent. However, as we increase
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the amount of androgen present, the rate at which androgen independent cells mutate
to androgen dependent cells increases as well. The mutation functions are listed below.
m1(A) = m1
(
1− A
a0
)
m2(A) = m2
(
A
A+ k4
) (5.21)
Our last deviation concerns the immune system interactions. As there is little
published about the immune system and the fact that the immune system is a vast
network of many interacting cells, we are at a loss as to how to form a hypothesis on
how the components of the immune system interact with our cancer cells and with
each other. Due to this fact, we use generic functions so that if, in the future, more
information becomes available, our theoretical results will still hold. Although we
lack knowledge about the specifics of these interactions, we do assume that these
functions have certain properties which we would expect. Firstly, we assume that
if the cell populations and concentrations are non-negative, the functions will also
be non-negative. Additionally, if the populations and concentrations are zero, the
function will also be zero: f1(X1, X2, 0) = f2(X1, X2, 0) = f3(0, T ) = f4(0, 0) = 0.
We also assume that the functions are monotonic and have the following partial
derivative conditions: ∂f1
∂X1
≤ 0, ∂f2
∂X2
≤ 0, and ∂f1
∂T
≥ 0, ∂f2
∂T
≥ 0. Similarly, we have
∂f3
∂IL
≥ 0, ∂f4
∂Xi
≥ 0. These assumptions allow for many classes of functions traditionally
used in mathematical biology models such as mass action and Holling type I,II, and
III functions.
With this proposed model, we have both biological and mathematical questions
that need to be answered. We want to quantify how timing of the dendritic cell
vaccine dose effects the time to independent relapse. Since dendritic cell vaccines
are currently used to treat cancers which no longer respond to hormone therapy, we
want to ask if they could be effective in treating cancers which are not androgen
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independent. Mathematical questions we would like to know include whether we can
determine an optimal dosing quantity to stabilize or eradicate the disease. We would
also like to determine global stability conditions mathematically, and then translate
those conditions back into biological meaning.
5.3 Simulation Results
Although we can perform analysis on the system with generalized functions, in
order for simulation, we must choose our fi functions. We propose the following
functions:
f1(X1, X2, T ) =
e1T
g1 +X1 +X2
f2(X1, X2, T ) =
e2T
g2 +X1 +X2
f3(IL, T ) =
e3IL
g3 + IL
f4(X1, X2) =
e4(X1 +X2)
g4 +X1 +X2
(5.22)
We note that these functions all satisfy our requirements. There are many parame-
ters, yet we have no data to use to estimate these parameters. Some of the parameters
have been estimated in literature or other mathematical papers, so we present a table
of parameters values as Table 5.1. In the remaining simulations, we will assume that
e1 = e2: T-cells are just as cytotoxic to AD cells as they are to AI cells. For those
which do not have estimates, we study how sensitive these parameters are to the
solutions obtained.
P Biological Meaning Value Source
r1 AD proliferation rate 0.025/day (Berges et al., 1995)
β1 AD cell death rate 0.008/day (Berges et al., 1995)
K cell carrying capacity 11 billion
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k4
AI to AD mutation 1.7
half-saturation
r2 AI net cell growth rate 0.006/day (Berges et al., 1995)
m1
maximum mutation rate 0.00005/day (Ideta et al., 2008)
from AD to AI
m2
maximum mutation rate 0.00015/day (Portz et al., 2012)
from AI to AD
a0
base level androgen 30 ng/ml (Ideta et al., 2008)
concentration
γ
androgen clearance 0.08/day (Ideta et al., 2008)
and production rate
ω cytokine clearance rate 10/day (Rosenberg and Lotze, 1986)
µ T cell death rate 0.03//day (Kirschner and Panetta, 1998)
c DC death rate 0.14/day (Lotze and Thomson, 2001)
e1
max rate T cells kill 0-1/day (Kirschner and Panetta, 1998)
AD cancer cells
g1
AD cell saturation level 10 x 109 cells (Kirschner and Panetta, 1998)
for T cell kill rate
e2
max rate T cells kill 0-1/day (Kirschner and Panetta, 1998)
AI cancer cells
g2
AI cell saturation level 10 x 109 cells (Kirschner and Panetta, 1998)
for T cell kill rate
e
T cell max 20 x 106 (Kirschner and Panetta, 1998)
activation rate cells/day
g
DC saturation level 400 x 106 cells (Small et al., 2000)
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for T cell activation
e3
max clonal 0.1245/day (Kirschner and Panetta, 1998)
expansion rate
g3
saturation level for 1000 ng/ml (Kirschner and Panetta, 1998)
T cell clonal expansion
e4
max rate T cells 5 x 10−6 (Kirschner and Panetta, 1998)
produce IL-2 ng/ml/cell/day
g4
saturation level 10 x 109 cells (Kirschner and Panetta, 1998)
for T cell stimulation
D1 DC vaccine dosage 300 x 10
6 cells (Small et al., 2000)
c1
AD cell PSA 1 x 10−9 (Ideta et al., 2008)
level correlation ng/ml/cell
c2
AI cell PSA 1 x 10−9 (Ideta et al., 2008)
level correlation ng/ml/cell
Table 5.1: Values of parameters (P), explanations, and cited sources of every parameter
used in this mathematical model.
The parameters which do not have literature-estimated values are K, the carrying
capacity of the tumor cells and k4, the half-saturation of the AI to AD mutation. Our
value for K was obtained by a brief calculation, observing that the mean weight of
a male prostate is 11 grams (7-16 grams) and the average human cell has a mass of
1 ng. Therefore, we arrive at the carrying capacity of 11 billion cells. As for k4, we
perform some simulations to see how sensitive the parameter is to change, the results
of which are in Figure 5.3.
Now that we have fully explained the model, we can begin the simulations. The
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simulations are run using MATLAB, with the basic solver ode45. We have a constant
initial condition, with has an initial androgen dependent cancer cell count of 14 billion
cells, androgen independent cancer cell count of 0.1 billion cells, 0 activated T cells, 0
(ng/mL) concentration of cytokines, 30 nmol/mL concentration of androgen, and 0
dendritic cells. We set the thresholds for treatments: L0 = 5 ng/mL turns treatment
off, and L1 = 15 ng/mL turns treatment back on. We run simulations out past 4000
days in order to more accurately capture the end behavior.
The code I used was adapted from a previous code written by Travis Portz ?, so I
will describe the numerical method rather than include it in the appendices. ode45 is
used to solve the continuous portions of the equation, however there are two discrete
components: the intermittent androgen suppression therapy switch, and the dendritic
cell vaccine injection. The maximum time length the continuous portion of the code
can run is from one dendritic cell vaccine injection to the next. We also use the ’events’
function in MATLAB in order to simulate the intermittent androgen suppression
therapy. The events function measures PSA − L0 if treatment is on (u = 1) and
PSA − L1 if treatment is off (u = 0). This way, the numerical integration stops if
PSA levels drop below L0, when the patient should be switched off therapy (changed
to u = 0), and starts therapy if PSA levels rise above L1, (u = 1). The numerical
integration is then continued until it reaches the next discrete injection of dendritic
cells (stopping to switch on or off androgen deprivation therapy as needed). At this
point, only the value of the D (dendritic cell) equation is changed, to the number of
cells (in billions) injected in each therapy session.
5.3.1 Discrete Injections
In the previous iteration of this immunotherapy model, the hypothetical vaccines
were administered every 30 days with a total dosage of 0.3 billion dendritic cells. In
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order to test accurately the effect timing has, we must keep the total dosage over a
period of time constant, while varying how often and what dosage they receive at each
injection. We considered timing ranging from daily injections to once every 120 days.
Figure 5.1 displays the PSA levels, androgen dependent (X1), and androgen
independent (X2) cell populations through time. From the graph, we can see that
the more frequent injections result in a much longer delay of onset for AI relapse,
although all of these still result in eventual AI relapse.
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Figure 5.1: PSA serum concentration, androgen dependent (AD), and androgen
independent (AI) cell concentrations for various dendritic cell vaccine injection times
with an e1 = e2 of 0.75. More frequent injections result in delay of the rise of fatal
androgen independent cancer.
We would like to better understand this relationship, so we turn to our personalized
parameters e1 and e2. We recall that these are a measure of cytotoxicity of the T-cells
and represent how many cancer cells a T-cell can kill in one day. This is a personalized
parameter that may vary person to person, which is why a range (0-1) is given in
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Table 5.1. We investigate the minimal e1 value for which we have stable disease cycles
– limit cycles – for the various vaccine timings, shown in Figure 5.2. These limit cycles
are determined numerically.
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Figure 5.2: Limit cycle solutions for androgen dependentX1, and androgen independent
X2 cancer cells. The minimal value of e1 = e2 required to produce limit cycle behavior
is noted above each solution. As vaccine timing decreases, minimal e1 = e2 necessary
to have stable disease state decreases.
We can see that the minimal value of e1 = e2 necessary to obtain steady disease
cycling decreases the more frequently we inject the dendritic cell vaccine. Lower, more
frequent doses of dendritic cell vaccines appear to be more effective at delaying the
rise to castration-resistant prostate cancer. In Figure 5.2, we notice that only for
injections which are monthly, or more frequent, do we observe limit cycle behavior.
For less frequent injections, we would need an e1 = e2 value larger than literature
suggests in order to obtain disease cycles. Thus, more frequent injections of smaller
doses appears to increase efficacy of treatment.
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We also examine the sensitivity of the solutions with respect to k4, a parameter
that has no previous literature assumptions. Figure 5.3 shows solution trajectories for
various values of k4. It is apparent that although we vary k4 from our nominal value
by two orders of magnitude in either direction, the outcome of the solution remains
very similar. In conclusion, solutions are insensitive to values of k4, so we are content
with the value given in Table 5.1.
0 500 1000 1500 2000 2500 3000 3500 4000
PS
A 
(ng
/m
L)
0
50
100 k4=0.017
k4=0.17
k4=1.7
k4=17
k4=170
0 500 1000 1500 2000 2500 3000 3500 4000
AD
 c
el
ls
0
10
20
time (days)
0 500 1000 1500 2000 2500 3000 3500 4000
AI
 c
el
ls
10-5
100
105
Figure 5.3: PSA serum concentration, androgen dependent (AD), and androgen
independent (AI) cell concentrations for various values of k4. We can see that the
solutions are not very sensitive to large changes in k4
5.3.2 Continual Injections
Keeping the total amount of vaccine constant, we notice that more frequent
dendritic cell vaccine administrations are more effective at delaying the onset of AI
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relapse. Now we consider the natural extension of this model: continuous injections.
We propose that the patient is always connected to the vaccine through an IV system.
In order to allow for this in our model, we slightly modify the equation representing
dendritic cell population to:
dD
dt
= v − cD (5.23)
where v is the continual injection rate.
We are interested ultimately in how the continual injection rate influences the
emergence of AI prostate cancer. We keep our injection rate constant, but vary
the parameter e1, which can be thought of as the the cytotoxicity of the T cell, or
rather, how many tumor cells a T cells is able to kill on average per day. We have a
biologically relevant range for e1, from 0 to 1, but it is reasonable to assume this is a
somewhat personalized parameter. We can see in Figure 5.4, that for the wide range
of biologically relevant values of e1, we are able to observe all different outcomes of he
disease. For small values of e1, around 0, we observe that the AI relapse occurs. For
slightly larger values of e1, we see that there is stable cyclical disease. As we increase
e1, the cycles become longer, meaning more off-treatment time for the patient. Finally,
if we have high enough e1 values, we observe eradication of the disease.
We see an interesting switch in dynamics as we increase through e1 = e2, so we
create a bifurcation diagram for the parameter, shown in Figure 5.5. When we have
e1 = 0, the carrying capacity equilibrium is stable, for small values of e1 we have stable
disease cycles, and for larger values of e1, those cycles collapse into a single steady
state solution which is stable. For the highest values of e1, this steady state solution
becomes zero, representing the disease-free equilibrium. For smaller values of e1 we
also see jagged solutions, which we think may be due to long transition times before
approaching the limiting periodic state. We also would like to examine e1 ≈ 0.24 in
more detail, as it appears the solution may have a steady state before switching into
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Figure 5.4: PSA serum concentration, androgen dependent (AD), and androgen
independent (AI) cell concentrations for various values of e1. We see stable disease
cycles, disease eradication, and disease growth.
cyclical behavior.
Our model is unique in that we allow mutations back from androgen independent
to androgen dependent. It is a logical assumption that although some cancer cells
mutate to function without androgen, when androgen is resupplied, they may go
back to using androgen to grow. As this is a parameter which there is no accepted
literature value, we can examine the effect in more detail. We vary m2 widely, because
we assume that androgen independent cells did originate from androgen dependent
cells, meaning that it is possible for m2 >> m1. Figure 5.6 displays the results of this
analysis of varying m2 with respect to the value of m1. We examine how the PSA
levels, AD cells, and AI cells change when examining our shift through m2. For these
simulations, we assume e1 = 0.05, which is before stable limit cycles emerge, rather
the behavior is almost chaotic, hence why these simulation have a long run-time. As
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Figure 5.5: Birfurcation digram for parameter e1, a measure of cytotoxicity of T-cells.
Maximum PSA level in black, minimum PSA level in green. Carrying capacity is
stable only for e1 = 0. Immediately after, we have a what appears to be a Hopf
bifurcation and limit cycles, until we reach e1 ≈ 0.66, after which the disease-free
steady state is stable.
we increase to large enough m2, we can see that we are able to stabilize our cyclical
behavior – a trend which holds for larger values of m2 as well. Although the value
of m2 does not drastically alter the outcome of the simulations, we do notice slight
differences in terms of the cycles of on-treatment off-treatment.
We notice that as we increase the ability for an androgen independent cancer cell
to become androgen dependent, m2, we elongate the time until androgen independent
relapse occurs. For small values of m2, on the order of m1, we do not notice any
improvement. However, when m2 >> m1, we can see that androgen independent
cancer does not arise.
It also appears that m2 is only sensitive for some values of e1: when we have
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Figure 5.6: Concentration of PSA levels, AD cell density, and AI cell density in blood
for varying values of m2, mutation from androgen independent back to androgen
dependent. High values of m2 prevent androgen independent cancer.
stable limit cycles or stable disease-free steady-states, m2 does not appear to affect
the solution trajectories much. When we have stable disease-free steady state, the
only difference is that for large values of m2, time to elimination of cancer is slightly
quicker.
5.3.3 Chaotic Regime
During a small subset of parameter values, we observe what appears to be chaotic
behavior. When e1 = e2 < 0.25, before the stable limit cycles emerge, what appears
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to be chaotic behavior emerges. In fact, for certain values of e1, near 0.2, we observe
what appears to be chaotic behavior, where the PSA is fluctuating, but without any
discernible pattern. In order to determine if this is indeed chaotic behavior, we use
the 0-1 chaos test proposed in Gottwald and Melbourne (2004).
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Figure 5.7: Concentration of PSA levels for e1 = 0.1. The solutions appear somewhat
erratic and chaotic.
In order to test ensure that I am applying the 0-1 chaos test correctly, I look at
the value of e1 = 0.5, which has periodic solutions. Using the 0-1 test, I get a value of
0.06420, signifying that the results are not chaotic. Using this same methodology, we
investigate the 0-1 chaos test for e1 = 0.1, the solution which is shown in Figure 5.7.
We obtain values close to 1 (0.9901), which signifies chaotic behavior.
5.4 Analytical Results
It is necessary to study the basic properties of this system. As informative as
simulations can be, it is imperative to fully understand the system. Simulations can
sometimes be misleading, so we would like to analyze the properties that ensure
stability of the disease-free and diseased steady states. For our analytical results, we
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will assume that we are constantly suppressing androgen, so the treatment is always
on. This assumption changes our equation governing the concentration of androgen,
so the full analyzable system becomes:
dX1
dt
= r1(A,X1, X2)X1 −m1(A)X1 +m2(A)X2 −X1f1(X1, X2, T ), (5.24)
dX2
dt
= r2(X1, X2)X2 +m1(A)X1 −m2(A)X2 −X2f2(X1, X2, T ), (5.25)
dT
dt
=
eD
g +D
− µT + Tf3(IL, T ), (5.26)
dIL
dt
= Tf4(X1, X2)− ωIL, (5.27)
dA
dt
= −γA, (5.28)
dD
dt
= v − cD. (5.29)
5.4.1 Full System
We start with basic properties of the full system before we prove any results for
local stability.
Proposition 2. Solutions of (5.24)-(5.29) that start positive remain positive.
Proof. Solutions for D and A can be explicitly solved for, and it is clear that these
solutions will remain positive when the initial conditions are positive. If the solutions
for the remaining parameters do not remain positive, there must be some time t1 > 0
such that X1(t1) = 0, X2(t1) = 0, T (t1) = 0 or IL(t1) = 0. We examine the first
case where X1(t1) = 0. Then X
′
1(t) ≥ −m(A)X1, ∀ t ∈ [0, t1], or more specifically,
X1(t1) ≥ X1(0)e−m(A)t1 > 0, which is a contradiction. Similar arguments can be
extended to the remaining variables, ensuring positivity of all solutions.
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We would also like to analyze the existence of equilibria and their corresponding
stability from the system. By examining the conditions necessary for stability, and
their biological translation, we hope to understand underlying biological processes
which affect prostate cancer.
Proposition 3. The model system (5.24)-(5.29) has a disease-free equilibrium E∗0 =
(0, 0, ev
µ(cg+v)
, 0, 0, v
c
) with growth functions (5.20), mutation functions (5.21), and
generic functions. E∗0 is unstable if r2 > f2(0, 0, T
∗
0 ), where T
∗
0 =
ev
µ(cg+v)
, and locally
asymptotically stable if r2 ≤ f2(0, 0, T ∗0 ). When r2 > f2(0, 0, T ∗0 ), a positive endemic
equilibrium E∗ = (X∗1 , X
∗
2 , T
∗, I∗L, A
∗, D∗) emerges, stability unknown.
Proof. All variables except X2 are easily solved and have only one steady state.
For X2, we can either have X
∗
2 = 0, which exists always, or an X2 that solves
g(X2) := r2 − r2X2K − f2(0, X2, T ∗) = 0. We examine this quantity in more detail by
calculating its sign at X2 = 0:
g(0) = r2 − f2(0, 0, T ∗0 )
where T ∗0 =
ev
µ(cg+v)
is the corresponding T ∗ value when X∗2 = 0. Next we calculate
the sign as X2 → K, its maximum possible value:
g(K) = −f2(0, K, T ∗K) < 0
Thus, if r2 − f2(0, 0, T ∗0 ) < 0, there is no biologically relevant X2 value that solves
g(X∗2 ) = 0, since the function f2 is monotonically decreasing in X2. Therefore, there
is only the trivial, disease-free equilibrium E∗0 = (0, 0,
ev
µ(cg+v)
, 0, 0, v
c
) in our domain.
On the other hand, if r2 − f2(0, 0, T ∗0 ) > 0 then, by the Intermediate Value
Theorem, there must be some X∗2 ∈ (0, K) which solves g(X∗2 ) = 0, giving us an
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endemic equilibrium E∗1 = (0, X
∗
2 , T
∗
1 , I
∗
L1, 0,
v
c
), representing androgen-independent
relapse.
We would now like to examine the stability of the disease-free steady state, which
is exhibited in the Jacobian. For E∗0 , we have the following Jacobian matrix:
−d1a0 −m1 − f1(0, 0, T ∗) 0 0 0 0 0
m1 r2 − f2(0, 0, T ∗) 0 0 0 0
0 0 −µ T ∗ ∂
∂IL
f3(0, T
∗) 0 ceg
cg+v
T ∗ ∂
∂X1
f4(0, 0) T
∗ ∂
∂X2
f4(0, 0) 0 −ω 0 0
0 0 0 0 −γ 0
0 0 0 0 0 −c

The eigenvalues of this matrix are along the diagonal and are given by (−d1a0 −
m1− f1(0, 0, T ∗), r2− f2(0, 0, T ∗),−µ,−ω,−γ,−c). Since parameters are positive and
given our constraints on our generic functions, all eigenvalues are negative except
λ2 = r2 − f2(0, 0, T ∗). In order for local stability, we require r2 < f2(0, 0, T ∗). For an
unstable equilibrium we would have the opposite: r2 > f2(0, 0, T
∗)
If we examine what our condition for local stability entails – r2 < f2(0, 0, T
∗) – we
can see that it boils down to the intrinsic growth rate of AI cells must be less than the
death rate due to T-cells. This is inherently sensible: if the AI cells are being killed
faster than they are reproducing, we would expect the AI cells to die out.
Since our generic functions are monotone, we can take the inverse of f2 in order
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to find an equivalent condition in terms of T ∗. If we recall that T ∗ = ev
µ(cg+v)
, this
means we can solve directly for a condition based on v, the injection rate. If we can
measure all other parameters, some of which may be personalized, we could concoct a
dosage in order to have local stability of the cancer-free equilibrium. If we examine
the function given in Equation (5.22), we can directly solve our condition for stability
to become v > cgg2r2µ
e2e−g2r2µ , which is the critical dosage value.
5.4.2 Reduced System
Global analysis is extremely difficult to perform on large systems of ordinary
differential equations, so we consider the limiting system. We create the quasi-steady
state system since the dynamics of concentrations such as androgen, cytokines, and
dendritic cells, operate on much faster time scales. We use Thieme (1992) to assert
that the asymptotic behavior of the limiting system is identical to the full system.
Again, we assume continual androgen deprivation therapy, and letA,D, IL approach
quasi-steady state to end up with the following equations:
dX1
dt
= −d1a0X1 −m1X1 −X1f1(X1, X2, T ), (5.30)
dX2
dt
= r2X2
(
1− X1 +X2
K
)
+m1X1 −X2f2(X1, X2, T ), (5.31)
dT
dt
=
eD
g +D
− µT + Tf3(X1, X2, T ), (5.32)
IL =
Tf4(X1, X2)
ω
, (5.33)
A = 0, (5.34)
D =
v
c
. (5.35)
Further, since all parameters and functions are non-negative, it is apparent that,
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in the limit, lim
t→∞
X1(t) = 0, as seen below:
dX1
dt
= X1
[−d1a0 −m1 − f1(X1, X2, T )]
≤ X1 [−d1a0 −m1]
≤ −aX1.
(5.36)
Therefore we can reduce the full system of (5.30)-(5.35) to that of two equations
on the subdomain Ω¯ = {(X2, T ) : X2 ≥ 0, T ≥ 0}:
dX2
dt
= r2X2
(
1− X2
K
)
−X2f2(X2, T ),
dT
dt
=
eD
g +D
− µT + Tf3(IL, T ),
(5.37)
Here we eliminate X1 from f2 for easier notation, since X1 = 0 in the limit.
We would like to ensure, before delving into the analysis of the reduced system,
that the dynamics and behavior of the full and reduced system are equivalent. To
that end, we ran the full system ((5.30)-(5.35)) and the quasi-steady state subsystem
(5.37) for various values of e1 = e2 and compared the dynamics. In Figure 5.8, we can
clearly see that for most values of e1 = e2, we observe the same dynamics. With the
exception of e1 = e2 = 0.15, there are no discernible differences between any of the
dynamics. Now that we have determined that long-term dynamics are very similar for
the full system and the quasi-steady state system, we are able to confidently proceed
with our analysis.
Theorem 5.4.1. The disease-free steady state of (5.30)-(5.35) is globally asymptoti-
cally stable under the following conditions:
i) µ > f3(IL, T ),
ii) r2 < f2(0, 0, T
∗
0 ),
iii) µ
2(cg+v)
ev
> ∂
∂T
f3(0, T
∗
0 ).
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Figure 5.8: Comparisons of the full system and quasi-steady state system for various
values of e1: 0, 0.15, 0.25, and 0.65, assuming androgen deprivation therapy is
constantly on. These values of e1 show many differing dynamics. The quasi-steady
state system closely approximates the full system in every case, but shows slight
differences in the case of e1 = 0.15
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In order to simply prove the theorem, we will break the proof into several proposi-
tions: positivity and boundedness, local stability, and global asymptotic stability. We
start with positivity and boundedness:
Proposition 4. If µ > f3(IL, T ) then solutions of (5.30)-(5.35) remain positive and
bounded.
Proof. We begin with the proof for positivity, examining T first. We note that since
we are assuming that T (t0) ≥ 0, in order for T (t) < 0 for some t, we would require that
dT
dt
< 0 when T = 0. However, dT
dt
|T=0 = eDg+D > 0 since all parameters are positive.
For X2, since we are assuming that X2(t0) ≥ 0, in order for X2(t) < 0 for some t, we
would require that dX2
dt
< 0 when X2 = 0. However,
dX2
dt
|X2=0 = m1X1 > 0 since we
have already proved that X1 stays positive and all parameters are positive.
We have already proven that solutions remain nonnegative, so we now look to
boundedness. We begin with T :
dT
dt
=
eD
g +D
+ T (f3(IL, T )− µ)
≤ c− g¯T
(5.38)
where g¯ = min[µ− f3(IL, T )] > 0 by assumption. This implies that T is bounded.
We look towards the boundedness of X2 now. We immediately see that X2 is
bounded above by K.
Next, we examine local stability of the quasi-steady state system:
Proposition 5. The limiting system (5.37) contains two equilibria: the disease-free
equilibrium and a negative equilibrium, under assumption ii): r2 < f2(0, 0, T
∗
0 ). The
disease-free equilibrium is locally asymptotically stable under assumption ii) and iii):
g+D
eD
> ∂
∂T
f3(0, T
∗
0 ).
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Proof. There are two possible equilibria of the system. Following the proof from
Proposition 3: if r2 < f2(0, 0, T
∗
0 ), only the disease-free equilibrium exists, E
∗
0 = (0, T
∗
0 ).
We get that X∗2 = 0. Correspondingly, we get T
∗ = eD
µ(g+D)
, since f3(0, T
∗) = 0 by our
assumption for our generalized functions. Thus, we only concern ourselves with the
disease-free steady state E∗0 = (0,
eD
µ(g+D)
), where D = v
c
.
In order to determine the stability of the disease-free equilibrium, we need to
compute the Jacobian evaluated at E∗0 , which is shown below:
r2 − f2(0, T ∗) 0
T ∗ ∂
∂X2
f3(0, T
∗) −µ+ T ∗ ∂
∂T
f3(0, T
∗)

which has eigenvalues along the diagonal, λ1 = r2 − f2(0, T ∗) and λ2 = −µ +
T ∗ ∂
∂T
f3(0, T
∗). We see that our conditions (ii) and (iii) from our theorem force these
eigenvalues to be negative, showing local stability for the disease-free equilibrium.
Now we are ready to prove the main result of our theorem, stating the disease-free
equilibrium is globally asymptotically stable under our conditions.
Proof of Theorem 5.4.1. Our physically relevant equilibrium is a boundary equilibrium
and since solutions to the system are positive, we conclude that there can be no limit
cycles in our biologically relevant range (X2 ≥ 0, T ≥ 0). Since solutions are positive,
bounded, and contain no limit cycles, by Poincare-Bendixson, all solutions tend
towards our disease free steady state. E∗0 is globally asymptotically stable.
Now that we have proven the conditions under which we have global asymptotic
stability, we would like to see what these conditions mean when translated back into
biological meaning. We look at the conditions and their corresponding meaning below:
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i) µ > f3(IL, T ), : The death of T-cells is greater than the production of T cells
due to the cytokine IL2. This helps keep our T cells at a temperate value.
ii) r2 < f2(0, T ), : The intrinsic growth rate of AI cells needs to be smaller than
the killing rate of AI cells by T cells. This was a condition also present in the
full system and is biologically sensible.
iii) µ
2(g+D)
eD
> ∂
∂T
f3(0, T
∗): Unsure how to interpret this condition in a biological
manner.
In addition to examining the disease-free equilibrium, we would also like to consider
the case when we have an endemic equilibrium and the conditions necessary for global
stability.
Theorem 5.4.2. The diseased steady state of (5.30)-(5.35) is globally asymptotically
stable under the following conditions:
i) µ > f3(IL, T ),
ii) r2 > f2(0, 0, T
∗
0 ),
iii) µ− f3(IL, T ) > −X2 ∂∂X2f2(X1, X2, T ) + T ∂∂T f3(IL, T )− r2X2K ∀ X2, T ≥ 0.
As with the previous proof, we will prove the result with the help of several
propositions in order to be clear: first we will tackle positivity and boundedness, then
local asymptotic stability, followed by the elimination of limit cycles, then we finish
with tying everything together. We begin with positivity and boundedness.
Proposition 6. If condition i) is satisfied, then solutions of (5.30)-(5.35) remain
positive and bounded.
Proof. The proof is identical to that of Proposition 4, assuming condition i).
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We now look to the equilibria and their assorted local stability:
Proposition 7. The limiting system (5.37) contains two equilibria: the disease-free
equilibrium, E∗0 , and a secondary equilibrium, E
∗
1 . The secondary equilibrium is
positive (assuming condition ii)). The disease-free equilibrium is a saddle point (under
conditions ii) and iii)).
Proof. The existence of the equilibria follow from Proposition 3, so we know that
under condition ii), if r2 > f2(0, T
∗
0 ), we will have two biologically relevant equilibria:
E∗0 = (0, T
∗
0 ) = (0,
ev
µ(cg+v)
) and E∗1 = (X
∗
2 , T
∗
1 ).
We will start by showing stability of the disease-free steady state E∗0 by analyzing
the following Jacobian:

r2 − f2(0, T ∗0 ) 0
T ∗0
∂
∂X2
f3(0, T
∗
0 ) −µ+ T ∗0 ∂∂T f3(0, T ∗0 )

and the eigenvalues are given by λ1 = r2 − f2(0, T ∗0 ) > 0 by condition ii) and
λ2 = −µ+ T ∗0 ∂∂T f3(0, T ∗0 ) < 0, by condition iii). Thus, the disease-free equilibrium is
a saddle point.
We now turn towards the stability of the endemic equilibrium E∗1 = (X
∗
2 , T
∗),
which is determined by the Jacobian:

− r2X∗2
K
−X∗2 ∂∂X2f2(X∗2 , T ∗1 ) −X∗2 ∂∂T f2(X∗2 , T ∗1 )
T ∗1
∂
∂X2
f3(I
∗
L, T
∗
1 ) −µ+ T ∗1 ∂∂T f3(I∗L, T ∗1 ) + f3(I∗L, T ∗1 )
 .
121
We look towards the trace τ and determinant ∆ to ascertain the stability of E∗1 .
In order to have a locally stable E∗1 , we need τ < 0,∆ > 0. Thus, the trace is given by
τ = −r2X
∗
2
K
−X∗2
∂
∂X2
f2(X
∗
2 , T
∗
1 )− µ+ T ∗1
∂
∂T
f3(I
∗
L, T
∗
1 ) + f3(I
∗
L, T
∗
1 ) (5.39)
and the determinant is given by
∆ =
(
−r2X
∗
2
K
−X∗2
∂
∂X2
f2(X
∗
2 , T
∗
1 )
)(
−µ+ f3(IL,∗ T ∗1 ) + T ∗1
∂
∂T
f3(I
∗
L, T
∗
1 )
)
+
(
X∗2
∂
∂T
f2(X
∗
2 , T
∗
1 )T
∗
1
∂
∂X2
f3(I
∗
L, T
∗
1 )
)
.
(5.40)
In order for E∗1 to be stable we require τ < 0,∆ > 0. Notice that τ < 0 is given
by assuming condition iii). However, we have no idea about the sign of ∆. Given
our information of τ < 0, we know that E∗1 is either a saddle point or a stable
node/spiral.
Next we move on to proving the preclusion of period orbits and limit cycles.
Proposition 8. The limiting system (5.37) has no limit cycles as long as condition
iii) is satisfied.
Proof. To show that there are no periodic orbits, we will be using the Dulac criterion.
We set h(X2, T ) =
1
X2
, and prove that ∆ = ∂
∂X2
(
h(X2, T )
∂X2
∂t
)
+ ∂
∂T
(
h(X2, T )
∂T
∂t
)
stays positive or stays negative.
∆ =
∂
∂X2
 1
X2
(
r2X2
(
1− X2
K
)
−X2f2(X2, T )
)
+
∂
∂T
[
1
X2
(
eD
g +D
− µT + Tf3(IL, T )
)]
=
∂
∂X2
[
r2 − r2X2
K
− f2(X2, T )
]
+
∂
∂T
[
eD
X2(g +D)
− µT
X2
+
T (f3(IL, T ))
X2
]
= − r2
K
− ∂
∂X2
f2(X2, T )− µ
X2
+
f3(IL, T )
X2
+
T
X2
∂
∂T
f3(IL, T )
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To ensure that there are no periodic orbits, we must prove that this quantity ∆ does
not change sign. We begin by re-writing this condition:
X2∆ = −r2X2
K
−X2 ∂
∂X2
f2(0, X2, T )− µ+ f3(IL, T ) + T ∂
∂T
f3(IL, T ). (5.41)
We know that for X2, T ≥ 0, ∆ < 0 by condition iii). Thus, the Dulac criterion has
ensured that we will have no periodic orbits in our domain.
We are now ready to prove the main result for global asymptotic stability.
Proof of Theorem 5.4.2. By Proposition 8, we can see that there are no limit cycles
present. Solutions are positive and bounded, and the model system has two fixed
points, one of which is a saddle point. By the Poincare-Bendixson theorem, we know
that there are three possibilities: all solutions tends to a fixed point, all solutions tend
to a periodic orbit, or there is a homoclinic or heteroclinic orbit which connects our
two fixed points. We have ruled out periodic orbits by Dulac criterion using condition
iii).
Now we must show there is no homoclinic or heteroclinic orbits connecting our
fixed points.
In order to show there is no heteroclinic orbit connecting the two fixed points,
we look towards the stable manifold of the saddle point. Looking back towards our
Jacobian, we can clearly see that the stable manifold is given by the T -axis X2
T
 =
0
1
 . (5.42)
Due to assumption ii), we notice that near the disease free steady state E∗0 , we
have dX2(t)/dt > 0. These observations preclude the existence of a heteroclinic orbit
connecting E∗0 and E
∗
1 .
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The fact that dX2(t)/dt > 0 near E
∗
0 also implies that there is no homoclinic orbit
originating from E∗0 . There can not be any homoclinic orbits originating from E
∗
1 if it
is stable. The Dulac criteria also rules out homoclinic orbits originating from E∗1 if it
is a saddle.
By Poincare-Bendixson Theorem, the only option remaining is that all solutions of
(5.37) converge to E∗1 . Thus, E
∗
1 is globally asymptotically stable.
Now that we have proven the conditions under which we have global asymptotic
stability, we would like to see what these conditions mean when translated back into
biological meaning. We look at the conditions and their corresponding meaning below:
i) µ > f3(IL, T ),: The death of T-cells is greater than the production of T cells
due to the cytokine IL2. This helps keep our T cells at a temperate value. This
showed up as a condition in Theorem 5.4.1 as well.
ii) r2 > f2(0, 0, T
∗
0 ), : The intrinsic growth rate of AI cells needs to be larger than
the killing rate of AI cells by T cells. This is a logical assumption considering
that we want stability of an equilibrium that has non-zero X2 values.
iii) µ−f3(IL, T ) > −X2 ∂∂X2f2(X1, X2, T )+T ∂∂T f3(IL, T )− r2X2K ∀X2, T ≥ 0.: Unsure
how to interpret this condition in a biological manner.
.
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Chapter 6
CONCLUSIONS AND FURTHER DIRECTIONS
In accordance with current Arizona State University policy, since portions of my
thesis have already been published, or are in the process of being published, I will detail
in this conclusion the conclusions of each of these papers and projects. Additionally, I
will discuss how these papers have shaped and will shape my future research thoughts
and ideas.
6.1 Density-Dependent Diffusion Model of in vitro Spheroid Glioblastoma Growth
We derived a one-equation density-dependent diffusion model for in vitro glioblas-
toma tumor growth that was validated by existing experimental data (Stein et al.,
2007a). With the density-dependent diffusion model, we were able to capture the
behavior of both the proliferating tumor core as well as the invading migratory cells.
Since analysis of one equation is much more accessible, this model has the opportunity
to simplify glioblastoma tumor modeling. Additionally, a one-population model will
simplify and hasten numerical simulations.
The one-population model used phase plane analysis to prove the existence of
traveling wave solutions. The minimum traveling wave speed was corroborated
by simulations and I proved stability of the traveling waves. Finally, the model
incorporated a sensitivity analysis to show that all parameters needed to be optimized.
Parameter optimizations were performed to fit the model to the experimental data
and compared with the original model proposed by the experimentalists.
The governing equation for the one-population model contains density-dependent
diffusion, logistic growth, and taxis which could possibly be due to chemotaxis or
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haptotaxis. The chosen density-dependent diffusion function (2.3) ensures that when
the cell density is large, random diffusion is small, and when the cell density is small,
random diffusion is large, which could possibly be explained by cell–cell adhesion and
is observed in experimental data. This function matches the behavior observed, like
how the migratory cells move further away from the tumor core at a large speed, while
the core remains proliferating and slowly expanding. The logistic term describes the
growth of the total number of cells. The taxis term describes the active and directed
motility of the tumor cells away from the tumor core, possibly in search of nutrients.
The performed sensitivity analysis indicated that all parameters largely influenced
the numerical solutions for the model. We performed a parameter optimization for all
parameters of the model and showed that the error for the best fit was approximately
half that of the error generated by the two-population model of the experimentalist.
This implies that monotone decreasing density-dependent diffusion may better explain
the behavior of tumor spheroid cell migration as opposed to cell shedding of the tumor
core, as was argued by the experimentalist..
Through wave speed analysis we were able to determine a minimum wave speed
and conditions necessary for the existence of traveling wave solutions. I was also
able to show that this condition generated stable traveling wave solutions. Numerical
simulations indicated that the observable wave speed was extremely similar to the
analytic minimum wave speed.
Future studies of glioblastoma growth will focus on comparing this model to
in vivo data. The model will need to be extended to include brain geometry, and
furthermore, comparing the model to in vivo data instead of in vitro data may result
in the need to extend the equations to describe more complex behavior such as tumor
cell necrosis, brain tissue type differentiation, and mass effect. Instead of density-
dependent diffusion, it may be more appropriate to implement anistropy through
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diffusion tensor imaging (DTI), as has been done in other GBM models ((Jbabdi
et al., 2005), (Bondiau et al., 2008), and (Painter and Hillen, 2013)), depending on
the availability of experimental data. Another direction is to consider a non-local
reaction-diffusion equation instead of density-dependent diffusion with proliferating
and dispersing cell groups in which dispersing cells convert proliferating cells into
dispersing ones.
Although I was not involved in the actual analysis of determining the minimum
wave speed, I did follow along with the mathematics. I also performed the stability of
the traveling wave solutions, which ended up being somewhat complicated and very
messy. The fact that I was able to be present and suggestive during the process has
shaped my future in understanding PDE’s. I now feel confident that I can at least
start the analysis for traveling wave speeds for non-traditional PDE’s, and would feel
comfortable examining the stability of those traveling wave solutions..
6.2 2 Population Model of in vitro Spheroid Glioblastoma Growth
The ‘Go or Grow’ hypothesis has often been suggested as a means for explaining
why GBM are so invasive. The idea is that tumor cells are either going (migrating) or
growing (proliferating). However our model suggests that such a distinction is still too
simple to explain the underlying dynamics. While the model fits better than a basic
reaction-diffusion model, it is on par with the Stein et al. (2007a) model. It falls far
short, however, as compared to the one-equation density-dependent diffusion model
results. This suggests that merely incorporating a mutation switch is insufficient.
We also examined the fits of several models: the reaction-diffusion equation, Stein
et al. (2007a), our one equation density-dependent diffusion mode, the two-population
model, and our two population model assuming density-dependent diffusion. Most of
the results were unsurprising: the reaction-diffusion equation generated the worst fit,
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followed by the Stein et al. (2007a) model, and the two population model. However,
we were astonished to see that the one-equation density-dependent diffusion model
generated less error than the two equation model which incorporated density-dependent
diffusion. This result lends credence to our original hypothesis: diffusion of GBM is
governed by the surrounding density. The reason the two-equation density-dependent
diffusion does not fit well is that only the migratory cell population includes density-
dependent diffusion. Although the ‘go or grow’ hypothesis does describe the data
better than the reaction-diffusion equation, it is not the best hypothesis. There is no
biological evidence that there are separate phenotypes. Our work and experimental
data suggest that the movement of cells is controlled by the cell density: those cells
which have a predilection towards proliferation will be in high-density areas and less
likely to diffuse, while those cells which tend to migrate will be in lower-density areas
and will diffuse at a much higher rate.
We also compared our theoretical minimum wave speed calculations with simulated
wave speeds. We discovered bounds for the theoretical minimum wave speed and were
able to show good agreement with our calculated minimum wave speed bounds. More
work will need to be performed in order to tweak our analysis to obtain a theoretical
minimum wave speed.
This project forced me to question the established literature assumptions. As
a mathematician early in my career, I constantly feel overwhelmed by the research
and information that has already been performed, and am intimidated to question
the status quo. Just because a model is able to fit data does not mean that it is an
effective or sensible model. This is compounded by the fact that more complicated
equations generally involve more parameters, increasing the likelihood of a good fit,
regardless of model assumptions. I have now reached the point where I will question
the assumptions that I see made in papers as well as whether or not those assumptions
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are correct. I will also not make the mistake of thinking that just because a model
involves more complications and assumptions, it must be a better model that generates
a good fit.
6.3 in vivo Murine Model of Glioblastoma Growth
We obtained experimental data from injecting mice with GL261-Luc2 cells to
mimic the growth of human GBM. MR images provided information on the location
and movement of tumor boundaries, which we used to fit parameters in mathematical
models based on a reaction–diffusion equation. We found that the murine tumors did
not move symmetrically in general, and that their growth patterns differed considerably
between mice; however, they appeared to match the behavior of rat models of GBM
as well as those of human patient GBM.
Of course, model (4.1) is only an approximation of the tumor dynamics. It does not
account for interactions with the immune system, genetic drift within the tumor cells,
or anisotropy in the brain parenchyma, among other factors. Although the model error
probably is substantial, with reasonable choices of parameters and a crude inference
about the correspondence between tumor visibility on T2W imaging and local cell
density, the model nevertheless produces reasonable short-term predictions of the
future size and location of the tumor. If, after a future careful examination of all the
histology slides derived from each mouse, it proves possible to provide a quantitative
correspondence between the local tumor cell density and MR imaging, then more
sophisticated data assimilation methods can be applied to infer the distribution of
tumor cells in regions beyond the visible tumor boundary (Kostelich et al., 2011).
An improved future modeling framework will incorporate mass effect and spatial
heterogeneity of the model parameters. Associated quantitative histology data may
make possible (via MR imaging) a reliable statistical correlation between tumor
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enhancement and tumor cell densities in and near the visible tumor.
From this project, I learned about the realities of dealing with data. My involvement
in this project gave me a sympathetic understanding for the experimentalists who have
provided data to me in the past. I had hands-on working experience with transforming
the MR images into a computational domain. This long, and often frustrating, process
required me to smooth individual images by hand, ensuring that there are uncertainties
in brain geometry. I had naively assumed, as one that does not perform experiments,
that experimental data is always true. I had not considered these little uncertainties,
which occur for even the most experienced experimentalists. Because of this project, I
have a greater appreciation and understanding of the sheer difficulties involved in any
type of experimental foray. This understanding will continue to influence my work,
and I hope to learn more sophisticated methods for coping with these uncertainties in
the future.
6.4 Global Dynamics of a Model of Joint Hormone Treatment with Dendritic Cell
Vaccines for Prostate Cancer
Current treatment options for late-stage prostate cancer are sub-optimal in terms
of survival and quality of life. By examining a model of intermittent hormone therapy
coupled with dendritic cell vaccines, we are able to prolong both the life and quality
of life of the patient. We found that, keeping total yearly dosages the same, more
frequent injections are conducive to managing prostate cancer for a longer period of
time. We extrapolate this idea by modifying the model to include a ‘continual’ dosage,
as if administered through an intravenous fluid.
In our model, there are several parameters which are patient specific, or do not
have accepted literature values. We examined the effect of varying values of e1, the
killing T-cell efficiency. Predictably, increasing e1 led from androgen-independent
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relapse, to stable limit cyclical behavior, and when increased enough, total eradication
of the disease. This parameter measures how effective dendritic cell vaccine therapy
will be - if e1 is small, the therapy will be negligible. e1 also acts to elongate the cycle
times for a stable cyclical disease, which means increased time for the period when the
patient is not undergoing androgen deprivation therapy. We performed bifurcation
analysis on parameter e1 to examine the various behaviors that exist in the system.
As our simulations only considered the case where e1 = e2, we could also investigate
how the dynamics change when we allow these values to be different. Additionally, we
examined m2, the rate at which androgen independent cells switch back to androgen
dependent cells in an androgen-rich environment, such as when a patient is removed
from androgen suppression therapy. We notice that increasing m2, the rate at which
androgen independent cancer cells may switch back to becoming androgen dependent
has the effect of delaying the eventual onset of fatal androgen independent cancer.
Additionally, for mathematical analysis, we simplify the model to have continuous
androgen suppression, in order to determine the effect of continual dosages. We notice
there are two possible equilibria – cancer-free equilibrium and an androgen-independent
(fatal) cancer equilibrium. If our continual dosage is greater than a determined critical
value, the cancer-free equilibrium exists and it is stable. If our continual dosage is
lower than that critical value, the cancer-free equilibrium is unstable and a cancerous
equilibrium is born (stability unknown). These findings have biological significance.
In previous papers it has been determined that for a 30-day vaccine, it is necessary for
a large values of e1 to ensure cancer-free progression (Portz and Kuang, 2012). In this
analysis, we could have smaller values of e1 that still resulted in stable disease-free
equilibrium. For patients with less effective immune systems (lower e1 values), it is
possible to eradicate cancer with higher presence of dendritic cells. As dendritic cell
vaccines are not known to have an adverse effect on the human body, it is possible that
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for patients with weakened immune systems, a tailored dose could be administered.
We further examined the limiting cases of behavior for this system, by allowing
several parameters to go to quasi-steady state. We were able to determine requirements
for global stability – or the guarantee of elimination of prostate cancer in some cases.
Additionally, we were able to determine further conditions for the global stability of
the endemic equilibrium.
Despite the insights that this model has afforded us, there is still much to be
done. Future work may include comparing the model with available patient data.
This will allow us to determine the efficacy of this model at predicting behavior of
the prostate cancer. We will also be able to explore the patient-specific parameters
and the effect these have on final outcome. Additionally, we would like to be able to
compare our model with other patient-data validated models. Local stability of the
endemic equilibrium of the full system should also be studied in detail. Additionally,
we could further investigate how the simulation outcomes are affected by allowing
e1 6= e2.
This section of my thesis was truly the only chapter that involved much analysis.
This project taught me the importance of keeping strong with your mathematical
roots, even if it is tempting to only work on projects that involve real data. There is
no data available to corroborate my model because this combination of treatments
has not yet been studied. This is where the power of mathematics lies: we can fully
investigate the expected potency of altering dosing structures without requiring clinical
data. We can form hypotheses as to what combination, and in what amounts, can
have a strong effect on disease outcome. Of course, I would have loved to test my
models with data, and I hope that one day mathematicians can work more closely
with physicians, in hopes of predicting patient trial outcomes before they happen.
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6.5 The Future of Mathematics in Oncology
Cancer is a very complex process that involves knowledge from the molecular
levels up through cellular levels and tissue. Additionally, depending on the type of
cancer, certain models are more applicable than others. As you examine the work
performed in previous chapters, it is apparent that the tie binding my work together is
the fact that the models are applied to cancer. The models and methods are markedly
different: single PDE, systems of PDE’s and systems of ODE’s are all incorporated in
separate chapters. Additionally, the methods for analyzing these models were very
different, depending on what data (if any) was available. The heterogeneity of cancer
growth requires us researchers to think and to be able to determine which models are
most effective for modeling a specific type of cancer and why.
Mathematics will continue to play a large role in oncological understanding and
practice. With a public push towards personalized medicine, mathematics may become
a more important tool in modeling treatment options. These models can be used by
doctors and patients, allowing patients to once again regain control of their treatment.
Models can bridge the gap between physician and patient: if a physician can show
the patient what their tumor is expected to look like in six months if they choose no
treatment, treatment A, or treatment B, both can make an effective decision together.
Although this point is still very far into the future, the work performed in this thesis
aims to assist the future mathematicians who strive to achieve this goal.
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APPENDIX C
COMPUTER CODE FOR CHAPTER 2
150
1 function [errortot] = x0parest_pdepe_vardiff_later(params ,necinfo)
2
3 % X0PAREST_PDEPE_VARDIFF_LATER returns an error estimate from the
4 % Stein et al data compared with the parameters that are imput for
5 % density -dependent diffusion
6 %
7 % ERRTOT = X0PAREST_PDEPE_VARDIFF_LATER(PARAMS ,NECINFO) solves the
8 % density -dependent diffusion equation
9 % u’=d/dx(D1-D2*u^n/(a^n+u^n)dudx)-vidudx+g(1-u/umax),
10 % for parameters PARAMS given in order (D1, D2, a, n, g, vi), and
11 % necinfo basic settings for simulations -- in order
12 % (a, b, dx, T, dt), where x goes from a to b in with stepsize dx,
13 % final time T, incrementing by dt. The initial condition assumes
14 % day 0 with 210 microns at 95% capacity. The solution is obtained
15 % using pdepe
16
17 % This code requires the user to have ’ic.mat ’, which is a matrix
18 % of Stein et. al data cell density profile on day 3 (location ,
19 % cell count) as well as ’invasiverad3c.mat ’ whcih is a matrix of
20 % Stein et. al data on invasive radius location (day , location).
21 % Either can be generated by using grabit.
22
23 % Written by Erica Rutter (Sept 2014)
24
25
26 m=0;
27
28 % Parameters
29 D1 = params (1);
30 D2 = params (2);
31 aval = 10^ params (3);
32 nval = params (4);
33 g = params (5);
34 vi = params (6);
35 umax = 4.2*10^8;
36
37 % Necessary info to set up simulation
38 a = necinfo (1);
39 b = necinfo (2);
40 dx = necinfo (3);
41 T = necinfo (4);
42 dt = necinfo (5);
43 nt=ceil (1/dt);
44
45 % Ensuring the optimized aparameters are non -negative and D1>D2
46 if(D1 <0| abs(D1)<abs(D2)|g<0|vi <0|aval <0|nval <0)
47 errortot =10^15;
48 return
49 end
50
51 x=a:dx:b;
52 t=0:dt:T;
53
54 % loading data taken from Stein et. al paper using grabit
55 load(’day0starter.mat’) %uniform blob density at 210 microns
56 load(’ic.mat’) %radius at day 3
57 load(’invasiverad3c.mat’) % invasive radius from Stein et. al paper
151
58
59 invraddata=invasiverad3c (:,2) /10000; % correcting units
60 celldensity3=ic(5:21 ,:); % radius at day 3 for invasive cells only
61
62 ic(1:4 ,2)=umax; % ensuring that the middle does not go above umax
63
64 umax =1; % simulations are scaled form 0 to 1
65 sol = pdepe(m,@pdex1pde ,@pdex1ic ,@pdex1bc ,x,t,[],aval ,nval ,D1 ,D2 ,g,
umax ,vi);
66
67 % Extract the first solution component as u.
68 u = sol(:,:,1);
69
70 soln=u*4.2*10^8; % rescaling
71
72 % Find invasive radius front
73 n=length(invraddata);
74 solndata=zeros(n,1);
75 for k =1:n
76 index=max(find(soln (1+nt*(k) ,:) < 1*10^7 ,1 ,’first ’) ,1);
77 solndata(k)=x(index -1);
78 end
79
80 % Find error in density profile at day 3.
81 for j=1: length(ic(:,2))-1
82 indexl=find(x < ic(j,1) ,1,’last’);
83 indexs=find(x > ic(j,1) ,1,’first’);
84 if((x(indexl)-ic(j,1)) < (x(indexs)-ic(j,1)));
85 index2=indexl;
86 else
87 index2=indexs;
88 end
89 if (j < 5)
90 diff(j)=sqrt((ic(j,2)-soln (151, index2)))^2/ic(j,2);
91 else
92 diff(j)=sqrt((ic(j,2)-soln (151, index2))^2)/ic(j,2);
93 steincomp(j-4)=sqrt((ic(j,2)-soln (151, index2))^2)/ic(j,2);
94 % can only compare to stein for migratory cells
95 end
96
97 end
98
99 % caclulate total error
100 errrad=sum(sqrt(( invraddata -solndata).^2)./ invraddata);
101 errdens =(sum(diff));
102 errortot =1/( length(invraddata)+length(ic(1:21 ,2)) -7)*( errrad+errdens
);
103
104
105 %calculate the errors for just the migratory cells
106 errdenscomp =(sum(steincomp));
107 errortotviastein =1/( length(invraddata)+length(celldensity3 (:,2)) -7)
*( errrad+errdenscomp);
108 errortotviasteinnoscale =( errrad+errdenscomp);
109
110
111 % Calculate Error Generated by Stein et. al mdoel
152
112 load(’steinsimdensity.mat’)
113 load(’steinsim3c.mat’)
114 errdenstein =(sum(sqrt(( steinsimdensity (:,2)-celldensity3 (:,2)).^2)
./( celldensity3 (:,2))));
115 errradstein =(sum((sqrt ((( invraddata -steinsim3c (:,2) /10000)).^2) ./(
invraddata))));
116 errortotstein =1/( length(invraddata)+length(celldensity3 (:,2)) -5)*(
errradstein+errdenstein);
117
118
119 %% Plotting the graphs
120
121 load(’steinsimdensity.mat’)
122 load(’steinsim3c.mat’)
123 figure;
124 figureHandle=gcf;
125 set(gca ,’FontSize ’ ,20);%,’fontWeight ’,’bold ’)
126 set(findall(gcf ,’type’,’text’),’FontSize ’ ,30);%,’fontWeight ’,’bold ’)
127 plot (1:7, invraddata ,’k+’ ,1:7, steinsim3c (:,2)/10000 ,’r*’ ,1:7,solndata
,’b-’,’linewidth ’ ,3)
128 xlabel(’time(days)’)
129 ylabel(’invasive radius (cm)’)
130 xlim ([1 ,7])
131 title(’Invasive Radius comparison ’)
132 legend( ’Experimental Data’, ’Stein et. al Simulations ’,’Our
Simulations ’ ,2)
133 set(gca ,’FontSize ’ ,20);%,’fontWeight ’,’bold ’)
134
135
136
137 figure;
138 figureHandle=gcf;
139 set(gca ,’FontSize ’ ,20);%,’fontWeight ’,’bold ’)
140 set(findall(gcf ,’type’,’text’),’FontSize ’ ,30);
141 plot(celldensity3 (:,1),celldensity3 (:,2),’k+’,steinsimdensity (:,1)
/10000 , steinsimdensity (:,2),’r*’,x,soln (151 ,:),’b-’,’linewidth ’
,3)
142 xlim ([0.03 ,0.1])
143 xlabel(’distance from core (cm)’)
144 ylabel(’cell population ’)
145 title(’Tumor Cell Density Profile at day 3’)
146 legend(’Experimental Data’, ’Stein et. al Simulations ’,’Our
Simulations ’)
147 set(gca ,’FontSize ’ ,20);%,’fontWeight ’,’bold ’)
148
149
150
151 figure;
152 set(gca ,’FontSize ’ ,20);%,’fontWeight ’,’bold ’)
153 set(findall(gcf ,’type’,’text’),’FontSize ’ ,30);
154 plot(ic(:,1),ic(:,2),’k+’,steinsimdensity (:,1)/10000 , steinsimdensity
(:,2),’r*’,x,soln (151 ,:),’b-’,’linewidth ’ ,3)
155 %xlim ([0.03 ,0.1])
156 xlabel(’distance from core (cm)’)
157 ylabel(’cell population ’)
158 title(’Tumor Cell Density Profile at day 3’)
159 legend(’Experimental Data’, ’Stein et. al Simulations ’,’Our
153
Simulations ’)
160 set(gca ,’FontSize ’ ,20);%,’fontWeight ’,’bold ’)
161
162
163 % --------------------------------------------------------------
164 function [c,f,s] = pdex1pde(x,t,u,DuDx ,aval ,nval ,D1,D2,g,umax ,vi)
165 c = 1;
166 f = (D1 -(D2*u.^nval)./( aval^nval+u.^nval)).*DuDx;
167 s = g*u.*(1-u)-vi*DuDx;
168 % --------------------------------------------------------------
169 function u0 = pdex1ic(x,aval ,nval ,D1,D2,g,umax ,vi)
170 load(’day0starter.mat’);
171
172 u0 =0.95* interp1(day0starter (:,1),day0starter (:,2),x)/(4.2*10^8);
173
174 % --------------------------------------------------------------
175 function [pl,ql,pr,qr] = pdex1bc(xl,ul,xr,ur,t,aval ,nval ,D1,D2,g,
umax ,vi)
176 pl = 0;
177 ql = 1;
178 pr = ur;
179 qr = 0;
154
APPENDIX D
COMPUTER CODE FOR CHAPTER 3
155
1 function [errortot] = updated_error_twoequations_ode_parest(newparam
,necinfo)
2
3 % UPDATED_ERROR_TWOEQUATIONS_ODE_PAREST returns an error estimate
4 % from the Stein et al data compared with the parameters that are
5 % imput for a 2 population go or grow model.
6 %
7 % ERRTOT = UPDATED_ERROR_TWOEQUATIONS_ODE_PAREST(PARAMS ,NECINFO)
8 % solves the 2 population equations
9 %
10 % M’ = D(d^2M/dx^2)+epsilon*k*T/(T+KM)*P-k*KP/(T+KP)*M-mu*M
11 % P’ = g*P*(1-T/Tmax)-epsilon*k*T/(T+KM)*P+k*KP/(T+KP)*M
12 %
13 % for parameters params given in order (D1,g,k,mu,Km,Kp,epsilon),
14 % and necinfo for basic settings for simulations -- in order
15 % (a, b, dx, T, dt), where x goes from a to b in with stepsize
16 % dx, final time T, incrementing by dt. The initial condition
17 % assumes day 0 with 210 micron spread. The solution is obtained
18 % using Crank -Nicholson for the diffusion term , and forward
19 % differencing for logistic growth and switching
20
21 % Written by Erica Rutter (Nov 2014)
22
23 %% parameters
24 param.Tmax = 4.2*10^8;
25 param.D1 = newparam (1);
26 param.g = newparam (2);
27 param.k =newparam (3);
28 param.mu = newparam (4);
29 param.Km = newparam (5)*param.Tmax;
30 param.Kp = newparam (6)*param.Tmax;
31 param.epsilon = newparam (7);
32 n=1;
33
34 if(param.D1 <0| param.g<0| param.k<0| param.mu <0| param.Km <0|param.Kp
<0| param.epsilon <0)
35 errortot =10^15;
36 return
37 end
38
39 %% initialization parameters
40 a = necinfo (1);
41 b = necinfo (2);
42 dx = necinfo (3);
43 T = necinfo (4);
44 dt = necinfo (5);
45 nx=ceil(b/dx);
46 nt=ceil (1/dt);
47
48
49 % % load data/IC
50 load(’day0starter.mat’) %uniform blob density at 210 microns
51 load(’ic.mat’) %radius at day 3
52 load(’invasiverad3c.mat’)
53
54 %
55 invraddata=invasiverad3c (:,2) /10000; % scaling to cm
156
56 celldensity3=ic(5:21 ,:); % radius at day 3 for invasive radius in
figures
57 ic(1:4 ,2)=param.Tmax;
58
59 dim =2;
60 x=a:dx:b;
61 t=0:dt:T;
62 dimens =[x;x];
63
64 Uplot=zeros(length(t),length(x),dim);
65 X = length(x);
66
67 % migratory functions
68 mig_diffusion = @(u) param.D1+0.*u;
69 mig_diffusiondiff = @(u) 0.*u;
70 migtoprofswitch=@(up,um) param.k*(( param.Kp).^n./((up+um).^n+param.
Kp^n)).*um;
71 mig_fisher = @(up,um) -param.mu*um;
72
73 advection=@(u) 0*u;
74
75 % proliferating functions
76 prof_diffusion = @(u) 0*u;
77 prof_diffusiondiff= @(u) 0.*u;
78 prof_fisher = @(up,um) param.g*up.*(1-(up+um)/param.Tmax);
79 proftomigswitch=@(up,um) param.epsilon *((up+um).^n./((up+um).^n+
param.Km^n)).*up;
80
81 % IC and BC functions
82
83
84 prof_IC = @(x) 0.95* interp1(day0starter (:,1),day0starter (:,2),x);
85 mig_IC = @(x) 0*x;
86 leftBC = @(t,u) 0*t
87 rightBC = @(t) 0*t;
88
89 migUprev=feval(mig_IC ,x);
90 profUprev=feval(prof_IC ,x);
91 Umig=migUprev;
92 Uprof=profUprev;
93
94 migImain_diagonal=zeros(length(x) -2,length(x) -2);
95 migIlower_diagonal=zeros(size(migImain_diagonal));
96 migIupper_diagonal=zeros(size(migImain_diagonal));
97 migImatrix=zeros(size(migImain_diagonal));
98 migEmain_diagonal=zeros(length(x) -2,length(x) -2,2);
99 migElower_diagonal=zeros(size(migImain_diagonal));
100 migEupper_diagonal=zeros(size(migImain_diagonal));
101 migEmatrix=zeros(size(migImain_diagonal));
102
103 Uplot (1,:,1)=profUprev;
104 Uplot (1,:,2)=migUprev;
105
106 %parameters for simulation
107 mu = 0.5; % 0.5 for Crank -Nicholson , 1 for FE , 0 for BE
108 c1 = dt/dx^2;
109 c3 = dt/dx;
157
110 soln=zeros(length(t)-1,length(x));
111
112 for m = 1: length(t)
113
114 b1mig = feval(mig_diffusion ,Umig);
115 advmig = feval(advection ,Umig);
116 fishmig = feval(mig_fisher ,Uprof ,Umig);
117 switchpopmig=feval(migtoprofswitch ,Uprof ,Umig);
118
119 b1prof = feval(prof_diffusion ,Uprof);
120 advprof = feval(advection ,Uprof);
121 fishprof= feval(prof_fisher ,Uprof ,Umig);
122 switchpopprof=feval(proftomigswitch ,Uprof ,Umig);
123
124
125 migImain_diagonal=sparse(diag (1+mu*(2*c1*b1mig (2:end -1))));
126 migIlower_diagonal= sparse(diag((-mu*(c1*b1mig (3:end -1)))
,-1));
127 migIupper_diagonal = sparse(diag((-mu*(c1*b1mig (2:end -2)))
,1));
128 migImatrix = sparse(migImain_diagonal + migIupper_diagonal +
migIlower_diagonal);
129
130 migEmain_diagonal = sparse(diag(-(1-mu)*(2*c1*b1mig (2:end -1)
)-c3*advmig (2:end -1)));
131 migElower_diagonal = sparse(diag (((1-mu)*(c1*b1mig (3:end -1))
) ,-1));
132 migEupper_diagonal = sparse(diag (((1-mu)*(c1*b1mig (2:end -2))
+c3*advmig (2:end -2)) ,1));
133 migEmatrix = sparse(migEmain_diagonal + migEupper_diagonal +
migElower_diagonal);
134
135 Umig (2:X-1) = migImatrix \ (migUprev (2:X-1)’ + migEmatrix*
migUprev (2:X-1)’ ...
136 + dt*fishmig (2:X-1) ’-dt*switchpopmig (2:X-1) ’+dt*
switchpopprof (2:X-1) ’);
137
138 Uprof (2:X-1) = profUprev (2:X-1) ’+dt*fishprof (2:X-1) ’-dt*
switchpopprof (2:X-1) ’+dt*switchpopmig (2:X-1) ’;
139
140 % Ensure boundary conditions
141 Uprof (1)=0;
142 Uprof(end)=0;
143 Umig (1) =0;
144 Umig(end)=0;
145
146 Uplot(m,:,1)=Uprof;
147 Uplot(m,:,2)=Umig;
148
149 migUprev=Umig;
150 profUprev=Uprof;
151
152 end
153
154 soln=Uplot (:,:,1)+Uplot (:,:,2);
155
156 % %Find invasive radius front
158
157 migfront =1*10^7;
158 n=length(invraddata);
159 solndata=zeros(n,1);
160 for k =1:n
161 index=max(find(soln (1+nt*(k),nx:end) < migfront ,1,’first ’) ,1);
162 solndata(k)=x(index+nx -1);
163 end
164
165 % %Find density profile at day 3.
166 for j=1: length(ic(:,2))-1
167 indexl=find(x < ic(j,1) ,1,’last’);
168 indexs=find(x > ic(j,1) ,1,’first’);
169 if((x(indexl)-ic(j,1)) < (x(indexs)-ic(j,1)));
170 index2=indexl;
171 else
172 index2=indexs;
173 end
174 if (j < 5)
175 diff(j)=sqrt((ic(j,2)-soln (151, index2)))^2/ic(j,2);
176 else
177 diff(j)=sqrt((ic(j,2)-soln (151, index2))^2)/ic(j,2);
178 steincomp(j-4)=sqrt((ic(j,2)-soln (151, index2))^2)/ic(j,2);
179 end
180 end
181
182 % %caclulate errors
183 errrad =(sum(sqrt(( invraddata -solndata).^2)./ invraddata));
184 errdens =(sum(diff));
185 errdenscomp =(sum(steincomp));
186 errortot =1/( length(invraddata)+length(ic(1:21 ,2)) -8)*( errrad+errdens
)
187
188 %stein cmpare
189 errortotviastein =1/( length(invraddata)+length(celldensity3 (:,2)) -8)
*( errrad+errdenscomp)
190
191 %stein err
192 load(’steinsimdensity.mat’)
193 load(’steinsim3c.mat’)
194 errdenstein =(sum(sqrt(( steinsimdensity (:,2)-celldensity3 (:,2)).^2)
./( celldensity3 (:,2))));
195 errradstein =(sum((sqrt ((( invraddata -steinsim3c (:,2) /10000)).^2) ./(
invraddata))));
196 errortotstein =1/( length(invraddata)+length(celldensity3 (:,2)) -5)*(
errradstein+errdenstein)
197
198
199
200 %% Plotting the graphs
201
202 figure;
203 figureHandle=gcf;
204 set(gca ,’FontSize ’ ,20);
205 set(findall(gcf ,’type’,’text’),’FontSize ’ ,30);
206 plot (1:7, invraddata ,’k+’ ,1:7, steinsim3c (:,2)/10000 ,’r*’ ,1:7,solndata
,’b-’,’linewidth ’ ,3)
207 xlabel(’time(days)’)
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208 ylabel(’invasive radius (cm)’)
209 xlim ([1 ,7])
210 %title(’Invasive Radius comparison ’)
211 legend( ’Experimental Data’, ’Stein et. al Simulations ’,’Our
Simulations ’ ,2)
212 set(gca ,’FontSize ’ ,20);
213
214
215
216 figure;
217 figureHandle=gcf;
218 set(gca ,’FontSize ’ ,20);
219 set(findall(gcf ,’type’,’text’),’FontSize ’ ,30);
220 plot(celldensity3 (:,1),celldensity3 (:,2),’k+’,steinsimdensity (:,1)
/10000 , steinsimdensity (:,2),’r*’,x,soln (151 ,:),’b-’,’linewidth ’
,3)
221 xlim ([0.03 ,0.1])
222 xlabel(’distance from core (cm)’)
223 ylabel(’cell population ’)
224 %title(’Tumor Cell Density Profile at day 3’)
225 legend(’Experimental Data’, ’Stein et. al Simulations ’,’Our
Simulations ’)
226 set(gca ,’FontSize ’ ,20);
227
228
229 figure;
230 set(gca ,’FontSize ’ ,20);
231 set(findall(gcf ,’type’,’text’),’FontSize ’ ,30);
232 plot(ic(:,1),ic(:,2),’k+’,steinsimdensity (:,1)/10000 , steinsimdensity
(:,2),’r*’,x,soln (151 ,:),’b-’,’linewidth ’ ,3)
233 xlabel(’distance from core (cm)’)
234 ylabel(’cell population ’)
235 %title(’Tumor Cell Density Profile at day 3’)
236 legend(’Experimental Data’, ’Stein et. al Simulations ’,’Our
Simulations ’)
237 set(gca ,’FontSize ’ ,20);
238
239 end
160
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Abstract. Glioblastoma multiforme is an aggressive brain cancer that is ex-
tremely fatal. It is characterized by both proliferation and large amounts of
migration, which contributes to the difficulty of treatment. Previous models
of this type of cancer growth often include two separate equations to model
proliferation or migration. We propose a single equation which uses density-
dependent diffusion to capture the behavior of both proliferation and migration.
We analyze the model to determine the existence of traveling wave solutions.
To prove the viability of the density-dependent diffusion function chosen, we
compare our model with well-known in vitro experimental data.
1. Introduction. Glioblastoma multiforme is a malignant form of brain cancer
with an especially grim prognosis—mean survival time from detection is less than
15 months (Norden and Wen [20]). Glioblastoma are characterized not only by
intense proliferation, but also by excessive migration. This leads to an inability
to effectively treat the tumors, as surgical resection is able to remove the core of
the tumor, but not the migratory cells. This erratic behavior makes modeling all
aspects of glioblastoma growth difficult.
Early models of glioblastoma growth include reaction-diffusion equations which
are able to accurately capture the proliferating tumor core. Tracqui et al. [30]
formulated the earliest reaction-diffusion model to describe glioblastoma growth
and diffusion, also with therapeutic intervention. Swanson et al. [29] continued
with these reaction-diffusion models, accounting for a spatially dependent diffusion
model in an attempt to model more heavily the migratory behavior of the tumor
cells.
A landmark mathematical model introduced by Stein et al. [27] advocated for
the separation of glioblastoma cells into two separate populations: the proliferating
core cells and the migratory cells. Their model was based off of observations from in
vitro experiments involving the spreading of two human astrocytoma cell lines that
form tumor spheroids. In addition to the standard reaction-diffusion terms in the
equation for migratory cells, the Stein et al. [27] model includes a radially biased
motility term corresponding to convection to account for the situation where cells
detect the location of the tumor core and actively move away from it. Our goal is
to formulate a single equation which captures both the migratory and core tumor
2010 Mathematics Subject Classification. Primary: 92C50, 35C07; Secondary: 35K57.
Key words and phrases. Biomathematical modeling, glioblastoma, traveling waves, tumor
growth simulation.
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characteristics as accurately as the dual-equation approach, by using a density-
dependent diffusion term.
One of the fundamental questions with in vitro tumor growth is how fast is the
tumor growing? Can we estimate how far the tumor will spread after a certain
amount of time? We want to quantify tumor spread, not just computationally, but
also analytically. To this end, we will need to analyze the traveling wave solutions.
Traveling wave solutions have been studied in models of glioblastoma growth
with multiple cell populations and constant diffusion, such as in Pe´rez-Garc´ıa et
al. [23] and Harko and Mak [8]. Traveling wave solutions also arise in density-
dependent reaction-diffusion equations, and numerous density-dependent diffusion
functions have been studied by, for example, Atkinson et al. [2], Murray [18], Witel-
ski [31], Sa´nchez-Gardun˜o and Maini [24], Harris [9], Pedersen [22], Maini et al. [13],
Sa´nchez-Gardun˜o et al. [25], Ngamsaad and Khompurngson [19], and Kengne et
al. [11]. More generally, traveling wave solutions for convective-reaction-diffusion
equations were studied in Malaguti et al. [14, 15, 16] and Gilding and Kersner [7].
Minimal speeds for various diffusion and convective terms were estimated.
In this article, we study a nondegenerate convective-reaction-diffusion equation
model of glioblastoma tumor growth. The existence of traveling waves is analyzed
and the minimum wave speed is corroborated by simulations. We perform a sensitiv-
ity analysis on the parameters in the model to detect how variations in parameters
effect the numerical solution. Lastly, we optimize the parameters in order to vali-
date the model with in vitro experimental data. We show that this single equation
model fits the data as well as the previously posed two-equation model of Stein et
al. [27].
2. Model formulation. Multiple mathematical models have attempted to explain
and predict the proliferation and migration of the glioblastoma tumor cells in vitro
and in vivo with varying success (see the review paper by Martirosyan et al. [17]
and references therein). The growth and diffusion of malignant glioma are governed
by many processes including, but not limited to, random diffusion, chemotaxis,
haptotaxis, cell-cell adhesion, cell-cell signaling, and microenvironmental cues such
as oxygen and glucose. Our proposed model is a variation on the in vitro mathe-
matical model of Stein et al. [27]. We briefly discuss the original experiment and
mathematical model and then the reasoning behind our alterations.
In Stein et al. [27], two human astrocytoma U87 cell lines are implanted into
gels—one with a wild-type receptor (EGFRwt) and one with an over expression of
the epidermal growth factor receptor gene (∆EGFR). The resulting spheroids were
left to grow over 7 days and imaged every day. We show a summary of the results of
the experiment for the invasive and proliferating cell radii on days 0, 1, 3, and 7 in
Figure 1. The tumor core radius was measured to be where pixels had an intensity
of < 0.12 and the invasive radius as the half-maximum for the image averaged over
the azimuthal angle.
The mathematical model proposed by Stein et al. [27] describes the movement
of the invasive, or migratory, cells (ui) for the EGFRwt cell line and the ∆EGFR
cell line based on the experiment described above. The radius of the tumor core,
consisting of the less mobile cells, is modeled as increasing at a constant rate based
on the in vitro experimental data. The model of Stein et al. [27] assumes that the
tumor cells leave the tumor core and become invasive cells to invade the collagen
gel. The behavior of invasive cells is described by the model in a way that can
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Day 0 Day 1 Day 3 Day 7
Figure 1. The radius of the core proliferating (black) and migra-
tory (red dashed) cells for the experiment for EGFRwt strain from
Stein et al. [27] on days 0, 1, 3, and 7. The domain is a 3 mm by
3 mm square.
be quantitatively compared to the experimental measurements. The invasive cell
population is governed by the following ad hoc partial differential equation
∂ui(r, t)
∂t
= D∇2ui︸ ︷︷ ︸
diffusion
+ gui
(
1− ui
umax
)
︸ ︷︷ ︸
logistic growth
− νi∇r·ui︸ ︷︷ ︸
taxis
+ sδ(r −R(t))︸ ︷︷ ︸
shed cells from core
, (1)
where ui represents the invasive cells of the tumor at radius r and time t (Stein et
al. [27]). The forces acting upon the invasive cell population are random diffusion,
logistical growth, taxis, and cells being shed from the core of the tumor. Taxis
refers to the active biased motility of invasive cells away from the tumor core which
Stein et al. [27] attributes to possibly chemotaxis or haptotaxis. This taxis term
was found to be more necessary for the highly invasive EGFRwt strain compared
to the less invasive ∆EGFR strain.
As the core of the tumor increases, cells are shed from the front of the expanding
core to become invasive cells. Parameter D is the diffusion constant, g is the growth
rate, umax is the carrying capacity, νi is the degree at which cells migrate away from
the core, s is the amount of cells shed per day, and δ is the Dirac delta function.
The radius of the tumor core is modeled by R(t) = R0 + νct, where R0 is the initial
radius of the tumor core and νc is the constant velocity at which the tumor core
radius increases.
The experimental data in Stein et al. [27] suggests that the invasive cell radius
also spreads at a constant velocity. However, the assumption that the tumor core
radius increases at a constant rate and the existence of the Dirac delta function in
equation (1) is rather artificial and makes traveling wave analysis of the invasive
cells very difficult. We therefore extend the model of Stein et al. [27] to alleviate
some of these issues.
We build our model from a similar base. We keep the logistic growth term, as we
know that the tumor cells grow in number, and logistic growth is sensible. We also
keep the taxis term, since it is apparent that glioblastoma tumor cells do migrate
away from the tumor core (Stein et al. [28]). Since we are trying to model the tumor
core in addition to the invasive cells, we do not need to consider the cell shedding
term. Although many current cancer cell migration models are based on reaction-
diffusion equations, most of those models consider diffusion to be constant or as
a function of space. Some cell migration models have included density-dependent
diffusion, such as the wound healing model of Cai et al. [4].
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Figure 2. The density-dependent diffusion function D(u∗), where
u∗ = uumax , from Equation (3) for D1 = 0.5, D2 = 0.4, and various
a and n. As u∗ increases, D(u∗) decreases from its maximum D1
to its minimum D1 −D2.
We consider a density-dependent convective-reaction-diffusion equation, which
implies that the amount of random diffusion depends on how many cells are present.
Our governing equation for the tumor cells u(x, t) is thus
∂u
∂t
= ∇ ·
(
D
(
u
umax
)
∇u
)
︸ ︷︷ ︸
density-dependent diffusion
+ gu
(
1− u
umax
)
︸ ︷︷ ︸
logistic growth
− sgn(x)νi∇ · u︸ ︷︷ ︸
taxis
, (2)
where we consider the equation in Cartesian coordinates but assume there is radial
symmetry. Parameters g and νi are as in equation (1), but now they are in relation
to the entire tumor cell population instead of just the invasive cell population.
There are many functions that could serve as the density-dependent diffusion
D(u∗), where u∗ = uumax . Experimental work from Stein et al. [27] suggests that
diffusion is large for areas where the cell density is small (the migrating tumor
cells), but diffusion is small where the cell density is large (the proliferating tumor
cells). This relation could possibly be explained by cell–cell adhesion (Armstrong
et al. [1]). To capture this behavior, we set
D(u∗) = D1 − D2(u
∗)n
an + (u∗)n
. (3)
For biologically relevant parameters, we assume that D1, D2, g, a, and νi are all
positive, n > 1, and D2 ≤ D1 to avoid “negative” diffusion, which is a problem
both biologically and numerically. See Figure 2 for an illustration of the density-
dependent diffusion function (3) for various a and n. The parameter n governs how
steeply the function decreases and the parameter a governs the u∗ value at which
the transition is occurring at half maximal rate. D1 and D2 govern the range of the
function.
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As we consider the biology of tumor growth, we recall that glioblastoma tumor
cells must be considered as two differing populations. The proliferative cells are
assumed to remain somewhat stationary and diffuse slowly but grow in population
quickly. On the other hand, the migrating cells diffuse very quickly, traveling very
far in a short amount of time, but do not grow in population as quickly. Since the
proliferating cells are the tumor core cells, they occur when cell density is very high,
and the migrating cells are where the cell density is very low. For our application,
we choose D2 ≤ D1, which allows diffusion to be small for proliferating cells and
larger for migrating cells.
3. Traveling wave speed analysis. In this section we analyze the existence of
traveling wave solutions of (2) using phase plane analysis.
Rewriting (2) in one-dimensional Cartesian coordinates, the governing equation
is
∂u
∂t
= D
(
u
umax
)
∂2u
∂x2
+
1
umax
D′
(
u
umax
)(
∂u
∂x
)2
− νi ∂u
∂x
+ gu
(
1− u
umax
)
. (4)
Rescale by writing
t∗ = gt, x∗ = x
√
g, u∗ =
u
umax
, (5)
set
v =
νi√
g
, (6)
and, omitting the asterisks and dividing through by gumax for simplicity, the equa-
tion (4) becomes
∂u
∂t
= D(u)
∂2u
∂x2
+D′(u)
(
∂u
∂x
)2
− v ∂u
∂x
+ u (1− u) . (7)
A traveling wave solution of (7) is a solution of the form
u(x, t) = w(x− kt), (8)
where k ≥ 0 is the speed of the traveling wave and the function w(z) is defined on
the interval (−∞,∞) and satisfies the boundary conditions
lim
z→−∞w(z) = 1, limz→∞w(z) = 0. (9)
Substituting ansatz (8) into (7) results in the second-order ordinary differential
equation
w′′(z) +
1
D(w(z))
(
(k − v)w′(z) +D′(w(z))(w′(z))2 + w(z)(1− w(z))
)
= 0, (10)
which we may write in this form because the function D as in equation (3) is always
positive.
Rewriting (10) as a system of first-order ordinary differential equations by setting
y := dw/dz,
w′ = y, (11a)
y′ =
−1
D(w)
(
(k − v)y +D′(w)y2 + w(1− w)
)
. (11b)
This system has two equilibrium points, (w, y) = (0, 0) and (w, y) = (1, 0).
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The Jacobian matrix evaluated at (1, 0) is
J(1, 0) =
(
0 1
1
D(1)
−(k−v)
D(1)
)
, (12)
from which we have det J(1, 0) = −1D(1) < 0, and thus (1, 0) is a saddle equilibrium
point.
The Jacobian matrix evaluated at (0, 0) is
J(0, 0) =
(
0 1
−1
D(0)
−(k−v)
D(0)
)
, (13)
from which we have det J(0, 0) = 1D(0) > 0 and assuming that k > v, then
tr J(0, 0) = −(k−v)D(0) < 0 and (0, 0) is a stable node or spiral. Since a stable spi-
ral cannot result in physiologically relevant solutions, we obtain the condition
k ≥ kmin = 2
√
D1 + v, (14)
which in terms of the original dimensional equation (4) is
k ≥ kmin = 2
√
D1g + νi. (15)
We will prove the following main result.
Theorem 3.1. There exists a traveling wave solution (8) of the partial differential
equation (7) with boundary conditions u(x, t) → 1 as x → −∞ and u(x, t) → 0 as
x→∞ with 0 < u(x, t) < 1, whose orbit connects the steady states u ≡ 0 and u ≡ 1
if and only if (14) is satisfied.
To do so, we need to construct a positively invariant region in which to trap the
unstable manifold of the saddle point. Figure 3 illustrates a positively invariant
trapping region and the heteroclinic orbit connecting the two equilibrium points for
a set of physiologically relevant parameters.
Since the horizontal (w′ = 0) nullcline is the horizontal axis {y = 0}, the flow
across this line (when w ∈ (0, 1)) is perpendicular in the negative y direction. Define
the line
T1 = {(w, y) : 0 ≤ w ≤ 1, y = 0}. (16)
Next, consider the line that corresponds to the eigenvector corresponding to the
more negative eigenvalue of the linearized system at (0, 0), i.e.,
y(w) = α0w, (17)
where we define
α0 =
1
2D(0)
(
−(k − v)−
√
(k − v)2 − 4D(0)
)
. (18)
Note that α0 < 0.
Lemma 3.2. The flow at any point along the line y(w) = α0w, for w ∈ (0, 1],
crosses that line in the positive y direction for k sufficiently small.
Proof. The normal vector to the graph of (w,α0w) pointing in the positive y direc-
tion is (−α0, 1). Restricting the vector field to points along the line y(w) = α0w
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Figure 3. Phase Portrait of the system (11) with parameter val-
ues (37). The solid green curve is the unstable manifold, the
dashed blue curve is T1 (16) the vertical nullcline, the dotted or-
ange line is T2 (28) corresponding to the eigenvector of linearized
system at (0, 0), and the dash-dotted purple line is T3 (30). Ar-
rows show direction of flow. The nondimensional wave speed
k = 2
√
D1 + v = 2
√
D1 + νi/
√
g ≈ 0.0047746.
results in the system
w′ = α0w, (19a)
y′ =
−1
D(w)
(
(k − v)α0w +D′(w)α20w2 + w(1− w)
)
. (19b)
We choose k such that the inner product (−α0, 1) · (w′, y′) ≥ 0 along the graph
of (w,α0w), and thus
− α20w −
1
D(w)
(
(k − v)α0w +D′(w)α20w2 + w(1− w)
)
≥ 0, (20)
which can be rearranged as
− α0w
D(w)
(
α0D(w) + (k − v) +D′(w)α0w + 1− w
α0
)
≥ 0. (21)
Since α0 < 0 and D(w) > 0 for w ∈ (0, 1], then − α0wD(w) > 0 and the inequality
becomes
α0D(w) + (k − v) +D′(w)α0w + 1− w
α0
≥ 0. (22)
Since (22) must hold for all w ∈ [0, 1], then we obtain the condition
k ≥ v − max
w∈[0,1]
{
d
dw
(
D(w)(α0w)
)− w(1− w)
α0w
}
. (23)
However, since α0 depends on k, substitute (18) into (23), and after tedious algebraic
manipulation the inequality becomes
k ≤ v + min
w∈[0,1]
{
D(w) + wD′(w)−D1(1− w)√
w(D(w) + wD′(w)−D1)
}
. (24)
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Consider the function
h(w) =
D(w) + wD′(w)−D1(1− w)√
w(D(w) + wD′(w)−D1)
. (25)
The minimum of h(w) is attained in the interior of the domain [0, 1] if h′(w) = 0
for some w ∈ (0, 1). This means that either (i) D1(1 +w)− ddw (wD(w)) = 0 or (ii)
D1 −D(w) +w ddw (wD′(w)) = 0. In case (i), this means that the diffusion function
must be of the form D(w) = D1(1 +w) +
C1
w , where C1 is an arbitrary constant. In
case (ii), the diffusion function must be of the form D(w) = D1+C1
w2−1
w +iC2
w2−1
2 ,
where C1 and C2 are arbitrary constants. Since our diffusion function (3) is of
neither of these forms, the minimum cannot be attained in the interior of [0, 1] and
must be attained at either of the endpoints w = 0 or w = 1.
Since h(w) tends to infinity as w → 0 (assuming that parameter n > 1), then
the minimum occurs at w = 1, and thus if the condition
k ≤ v + D(1) +D
′(1)√
D(1) +D′(1)−D1
= v +
(a+ 1)2D1 + (1 + a+ an)D2
(a+ 1)
√
(1 + a+ an)D2
(26)
is satisfied, then the lemma holds.
Since
2
√
D1 ≤ (a+ 1)
2D1 + (1 + a+ an)D2
(a+ 1)
√
(1 + a+ an)D2
, (27)
the flow across the line
T2 = {(w, y) : 0 ≤ w ≤ 1, y = α0w} (28)
is in the positive y direction for at least the minimum wave speed k. For larger
speeds, the nonlinearities of the system require that T2 be nonlinear such that
k ≤ v − max
w∈[0,1]
{
d
dw
(
D(w)f(w)
)− w(1− w)
f(w)
}
, (29)
is satisfied for some function f where f(0) = 0 and f(w) ≤ 0 for w ∈ (0, 1]. The
minimum wave speed is determined by taking the infimum on the set of functions
f (Sa´nchez-Gardun˜o et al. [25]).
Also due to the nonlinearities of the system and the behavior of the system
near (1, 0), it is difficult to use the eigenvector of the linearized system at (1, 0) as
a portion of the boundary of the trapping region, as is standard for the Fisher–
Kolmogorov equation (Chicone [5]). Instead, define
T3 = {(w, y) : w = 1, α0 ≤ y ≤ 0}. (30)
The flow across this line is in the negative w direction. Thus, if we define the
triangle T defined by the boundaries T1, T2, and T3, then T is a positively invariant
set.
We now prove our main result.
Proof of Theorem 3.1. We first show that the unstable manifold of the saddle point
(w, y) = (1, 0) has nonempty intersection with T for all time.
The vertical (y′ = 0) nullclines are the solutions to the quadratic equation
D′(w)y2 + (k − v)y + w(1− w) = 0, (31)
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which are
y+(w) =
1
2D′(w)
(
− (k − v) +
√
(k − v)2 − 4D′(w)w(1− w)
)
, (32a)
y−(w) =
1
2D′(w)
(
− (k − v)−
√
(k − v)2 − 4D′(w)w(1− w)
)
. (32b)
Since k > v, the slope of the y+ nullcline at w = 1 is
y′+(1) =
1
k − v > 0, (33)
and the eigenvector of the linearized system corresponding to the positive eigenvalue
at the saddle point (1, 0) is
~η =
1, 1
2
−(k − v)
D(1)
+
√(
k − v
D(1)
)2
+
4
D(1)
T . (34)
All trajectories that leave the point (1, 0) in the region R = {(w, y) : 0 ≤ w ≤
1, y ≤ 0} have the tangent vector ~η at (1, 0). Comparing the slope of eigenvector
~η and the slope of the y+ nullcline at the point (1, 0), we find that the slope of ~η is
less than the slope of y+. Therefore, trajectories leaving point (1, 0) leave above y+.
Since the flow across the nullcline y+ is perpendicular in the negative w direction,
and y+ is contained in T near w = 1, the unstable manifold of the saddle at (1, 0)
has nonempty intersection with T .
Thus, the unstable manifold of the saddle at (1, 0) remains in the region T for all
time, and furthermore, the ω-limit set of the corresponding orbit is also in T . Since
w′ = y ≤ 0 within T , by the Poincare´–Bendixson theorem, there are no periodic
orbits or equilibrium points in the interior of T . The ω-limit set must be contained
in the boundary of T , and therefore, the ω-limit set is (0, 0).
Hence, there exists a heteroclinic orbit connecting the equilibrium points (w, y) =
(0, 0) and (w, y) = (1, 0) as long as the condition (14) is satisfied, which implies that
a traveling wave solution exists.
Thus, we should expect in our numerical simulations that the wave speed of the
invasive cells is constant and satisfies condition (15).
4. Computational results. In order to show that the proposed model is viable,
we compare numerical simulations with experimental data and the traveling wave
analysis. A sensitivity analysis as well as a parameter optimization to fit the exper-
imental data is performed. Finally, the simulated wave speed is compared with the
minimum wave speed (15) derived in the previous section.
Experimental data provided in Stein et al. [27] includes the density profile of cells
on day 3 and the invasive radius of the cells measured from days 1 through 7 for both
the U87WT and U87∆EGFR cell lines. The data was obtained via GRABIT [6], a
MATLAB program which extracts data points from an image file. We concentrate
on the U87WT cell line because we want to show our model is effective even for the
strongest migratory cells. All simulations are performed with the U87WT cell line
in mind and are compared to the U87WT data.
The numerical simulations are run over a large spatial domain and boundary
conditions specify that there are no tumor cells at the boundaries, in other words,
u(x, t) = 0 when x = ±1 cm. This ensures that the tumor can freely move within
the domain. Stein et al. [27] does not model the tumor core cells in the invasive cell
170
1166 TRACY L. STEPIEN, ERICA M. RUTTER AND YANG KUANG
−0.4 −0.2 0 0.2 0.40
1
2
3
4
5 x 10
8
distance from core (cm)
ce
ll 
po
pu
la
tio
n
 
 
Our Simulation
Experimental Data
Stein et. al Simulations
0.04 0.06 0.08 0.10
1
2
3
4
5
6
7 x 10
7
distance from core (cm)
ce
ll 
po
pu
la
tio
n
 
 
Our Simulation
Experimental Data
Stein et. al Simulations
1 2 3 4 5 6 70
0.05
0.1
0.15
0.2
time(days)
in
va
si
ve
 ra
di
us
 (c
m)
 
 
Our Simulation
Experimental Data
Stein et. al Simulations
Figure 4. Numerical solution of the density-dependent diffusion
glioblastoma model (2) with diffusion function (3) and optimized
parameter values (37) compared to experimental data from Stein
et al. [27] and their simulations. The density profile is from day 3
of the experimental data.
equation (1), and the initial cell density for their simulations was zero. However,
our model (2) contains all tumor cells. From Stein et al. [27], the initial core tumor
radius is 210µm and the maximum cell density is umax = 4.2 × 108 cells/cm3, and
thus we assume that initially the cell density is 95% of umax for the initial core
tumor radius of 210µm and zero elsewhere.
The governing equation (2) is discretized using the Crank-Nicolson method for
the density-dependent diffusion term and first-order forward differencing for the
advection and logistic growth terms. For the advection term on the left hand
side, first-order backward differencing is used. A limited spatio-temporal study was
conducted to determine the largest possible spatial step and time steps which would
still produce accurate results. Our method was compared with results from the
MATLAB program pdepe [26] to ensure the solutions were accurate. See Figure 4
for a typical simulation that is compared to the experimental data and model of
Stein et al. [27].
The governing equation (2) with diffusion function (3) has six parameters that
are unknowns: D1, D2, a, n, g, and νi. Estimated ranges for some of these pa-
rameters can be obtained from Stein et al. [27]. In particular, the migratory
diffusion (diffusion when the density u is small), D1, is estimated to be on the
order of 10−4 cm2/day. The growth rate g ∈ (0, 1)/day and the taxis constant
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νi ∈ (0, 0.02) cm/day. However, for a and n, there is no precedent to compare with.
We perform a sensitivity study to determine if the model error is insensitive to
any of the changing parameters. If we are able to determine that a parameter is
insensitive, we will be able to fix its value and not include it as a free variable for
parameter optimization.
The error function that we aim to minimize is based on the χ2 error function
used in Stein et al. [27] but modified to account for the experimental data that was
made available and uses relative errors for each point. The modified error function
that takes into account both how fast the tumor is spreading, by measuring the
invasive radius at each day, and also the density of cells by comparing the spatial
profile of cells on day 3 is
err =
1
(N +M)− q − 1
[
N∑
t=1
|rdata(t)− rsimulation(t)|
rdata(t)
+
M∑
i=1
|udata(3, xi)− usimulation(3, xi)|
udata(3, xi)
]
, (35)
where N is the total number of days for which there is invasive radius data, so
N = 7, M is the total number of cell density data points at day 3, so M = 17,
and q is the number of parameters being optimized which, in this case, q = 6.
The first sum in (35) compares the invasive radii of the experimental data, rdata(t),
and the simulation, rsimulation(t). The second sum compares the cell density at
day 3 at experimental data point xi for the data, udata(3, xi), and the simulation,
usimulation(3, xi). We use relative errors because the data covers many different
orders of magnitude: the cell density is on the order of 107–108 cells/cm3 and the
invasive radius is on the order of 0.01 cm.
4.1. Parameter sensitivity. The parameter sensitivity analysis was performed
for the six parameters D1, D2, a, n, g, and νi such that each was in a physiologically
relevant range. The set of base parameters chosen that result in a reasonable match
to the data were
D1 = 10
−4 cm2/day, D2 = 9.99× 10−5 cm2/day, a = 0.1 cells/cm2,
n = 1, g = 0.5/day, νi = 0.01 cm/day. (36)
These base parameters are not chosen for their excellent fit to the data, rather they
are chosen in order to have error that is not too large and to allow for variations to
still remain in biologically relevant ranges. To test the sensitivity of one parameter,
all the other parameters were held constant and the parameter in question was
varied. The results of this sensitivity test is shown in Figure 5.
It is apparent that some parameters are much more sensitive than others, in
particular, D1, g, and νi appear to generate the most sensitivity. The results of this
sensitivity analysis inform us that all parameters are sensitive and we must take
care when we perform our optimization.
4.2. Parameter estimation. The parameters are optimized via the MATLAB
program fminsearch [12] by minimizing equation (35). Various initial parameter
guesses were used as input to ensure parameter values were optimal. The optimized
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Figure 5. Results of a sensitivity analysis with base parameters
(36) using error function (35) (vertical axis).
parameters found are
D1 = 5.5408× 10−6, cm2/day, D2 = 5.3910× 10−6, cm2/day,
a = 0.021188 cells/cm3, n = 1.2848,
g = 0.49120/day, νi = 4.6801× 10−5 cm/day. (37)
Though D1 + D2 is very close to 0, it is still the case that |D1| > |D2| as nec-
essary. To determine the comparable error to the Stein et al. [27] simulations that
use invasive cells as a separate population, we use GRABIT [6] to obtain the simu-
lation data points. Figure 4 shows the results of our simulation with the optimized
parameters compared to the Stein et al. [27] simulations and the experimental data.
In the top left panel of Figure 4, the cell density is plotted on the entire domain
and it indicates that the model is successful in capturing the behavior of both the
tumor core cells and the migratory cells. In the top right panel, the cell density is
plotted on a smaller domain and further verifies that our model with one population
is relatively as accurate as the model of Stein et al. [27] with the separated invasive
cell population and proliferating cell population. In fact, our total error is approx-
imately one-half that of Stein et al. [27] (0.21 compared to 0.45). Even though
the simulated invasive radius (in the bottom panel) does not appear to match the
experimental data as well, overall there is good agreement between our simulations
and the experimental data.
4.3. Wave speed comparison. Now that we have shown that our model can
be utilized, we compare the analytic minimum wave speed (15) to the wave speed
observed in the simulations. To measure the wave speed of tumor spread accurately,
we increase the run-time of the simulation to 200 days and enlarge the spatial
domain to more so mimic an infinite domain, as is used in the traveling wave
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Figure 6. Numerical solution of the density-dependent diffusion
glioblastoma model (2) with diffusion function (3) and optimized
parameter values (37) for days 40, 80, 120, 160, and 200.
analysis. The results of this simulation are shown in Figure 6. The leading edge of
the tumor maintains a constant shape and ultimately moves at a constant rate. To
estimate the wave speed, we ignore the first few days of the simulation so that the
tumor core stably reaches maximum cell density, and then measure the x location
where the cell density is last over 2 × 108 cells/cm3. This is tracked against time,
and the MATLAB program polyfit is used to estimate the slope of the curve for a
linear fit. Using the optimized parameters (37), the minimum wave speed (15) is
kmin ≈ 0.003346 cm/day and the simulated wave speed k = 0.02255 cm/day. While
often the observed simulated wave speed is approximately equal to the analytic
minimum wave speed, here the simulated wave speed is on the order of 10 times
larger than the minimum wave speed.
5. Discussion and further directions. We derived a density-dependent diffu-
sion model for in vitro glioblastoma tumor growth that was validated by existing
experimental data from Stein et al. [27]. We accurately modeled both the prolifer-
ating tumor core as well as the invading migratory cells using only one equation.
This model has the potential to simplify glioblastoma tumor modeling—with only
one equation the analysis is simpler and simulations can be faster. The existence
of traveling waves for this model was studied using phase plane analysis and was
corroborated by simulations. We performed a sensitivity analysis and parameter
optimization to ensure the model describes the behavior of the tumor.
The governing equation has density-dependent diffusion, logistic growth, and
taxis which could possibly be due to chemotaxis or haptotaxis. The chosen density-
dependent diffusion function (3) ensures that when the cell density is large, random
diffusion is small, and when the cell density is small, random diffusion is large, which
could possibly be explained by cell–cell adhesion. This behavior matches how the
migratory cells move further away from the tumor core at a large speed, while
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the core remains proliferating and slowly expanding. The logistic term describes
the growth of the total number of cells. Taxis describes the active and directed
movement of the invasive cells from the tumor core.
A sensitivity analysis indicated that all parameters largely influenced the nu-
merical solutions. We performed a parameter optimization on all six parameters
and showed that the error for the best fit was less than the error generated by the
two-population model of Stein et al. [27]. This implies that monotone decreasing
density-dependent diffusion may better explain the behavior of tumor spheroid cell
migration as opposed to cell shedding of the tumor core.
Through wave speed analysis we were able to determine a minimum wave speed
and conditions necessary for the existence of traveling wave solutions. Numeri-
cal simulations indicated that the observable wave speed is much larger than the
analytic minimum wave speed. We conjecture that for monotone decreasing density-
dependent diffusion functions, the traveling wave solution with minimum wave speed
is unstable.
Furthermore, the observable wave speed appears to depend on other parameters
besides D1, g, and νi. Figure 7 indicates that there is a linear relation between
parameter D2 and the observed wave speed, and parameter n also affects the wave
speed while a does not affect it as much (results not shown). We also note that when
D2 = 0, the observable wave speed equals the analytic minimum wave speed, as
expected. A possible explanation for the difference between the analytic and numer-
ical wave speeds could be that nonlinear diffusion can be considered as contributing
convection with a “velocity” −D′(u)∂u∂x (in one dimension) but the analytic mini-
mum wave speed was obtained after linearizing the system (11). Further work can
be done to investigate finding an expression for the observable wave speed.
Future studies of glioblastoma growth will focus on comparing this model to in
vivo data. The model will need to be extended to include brain geometry, and
furthermore, comparing the model to in vivo data instead of in vitro data may
result in the need to extend the equations to describe more complex behavior such
as tumor cell necrosis, brain tissue type differentiation, and mass effect. Instead
of density-dependent diffusion, it may be more appropriate to implement anistropy
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through diffusion tensor imaging (DTI) such as in the models of Jbabdi et al. [10],
Bondiau et al. [3], and Painter and Hillen [21], depending on the availability of
experimental data. Another direction is to consider a non-local reaction-diffusion
equation instead of density-dependent diffusion with proliferating and dispersing
cell groups in which dispersing cells convert proliferating cells into dispersing ones.
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Abstract. Advanced prostate cancer is often treated by androgen deprivation
therapy, which is initially effective but gives rise to fatal treatment-resistant
cancer. Intermittent androgen deprivation therapy improves the quality of life
of patients and may delay resistance towards treatment. Immunotherapy al-
ters the bodies immune system to help fight cancer and has proven effective
in certain types of cancer. We propose a model incorporating androgen depri-
vation therapy (intermittent and continual) in conjunction with dendritic cell
vaccine immunotherapy. Simulations are run to determine the sensitivity of
cancer growth to dendritic cell vaccine therapy administration schedule. We
consider the limiting case where dendritic cells are administered continuously
and perform analysis on the full model and the limiting cases of the model to
determine necessary conditions for global stability of cancer eradication.
1. Introduction. Prostate cancer is one of the most ubiquitous cancers in males in
the United States, with an expected one in six men diagnosed in their lifetime [23].
The prostate requires androgens, especially testosterone and 5α-dihydrotestosteron
(DHT) to function and continue proliferation. The current treatment protocol is
to suppress androgen, which should lead to inhibited growth of cancer cells as well.
However, although the initial response rates to therapy are excellent, eventually
androgen-independent prostate cancer arises and is most often fatal [33].
Recent research and clinical trials have begun to question whether the efficacy
and comfort of this treatment could be increased by intermittent androgen depriva-
tion (IAD) therapy [6,22,28,37]. Intermittent androgen deprivation therapy works
by administering androgen deprivation therapy until the patient reaches a certain
threshold of prostate specific antigen (PSA), which is a biomarker of the disease.
Upon reaching this threshold, the patient is removed from therapy until their PSA
levels rise above a second threshold, when they are once again put on androgen
2010 Mathematics Subject Classification. Primary: 92C50, 34D20; Secondary: 34D23.
Key words and phrases. mathematical modeling, prostate cancer, androgen deprivation ther-
apy, immunotherapy, dendritic cell vaccine.
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deprivation therapy. This treatment still results in overall androgen suppression
and may improve the quality of life of the individual patient, lessening the un-
pleasant side effects of androgen deprivation therapy [5, 18]. Although it has often
been proposed that intermittent androgen deprivation therapy may increase time
to androgen-independent relapse, this statement remains unproven in clinical trials,
including meta-studies [2,5,39,43]. Of course, there are studies which suggest that
only certain patient groups may benefit from intermittent androgen deprivation
therapy, but determining those groups remains a work in progress [25, 44]. Adding
to the confusion is the fact that there is no consensus in the medical community
on the duration or intervals of the treatment [10]. Some have concluded that the
findings determining that intermittent androgen deprivation therapy is non-inferior
to continual androgen deprivation therapy, are inconclusive due to flawed or incon-
sistent studies [17,34].
Immunotherapy treatments use the body’s immune system to fight against cancer
by enhancing or repressing an immune response in the patient. Dendritic cells are
strongest of the antigen-presenting cells, meaning they ingest antigens and present
the antigen material to naive and memory T cells in the system. These T cells
then target the specific antigen for removal. Dendritic cell vaccines are created by
extracting dendritic cells from the patient, loading the cells with antigens and re-
injecting the dendritic cells into the patient. The target antigen in this case is PAP
(Prostatic acid phosphatase), which has been used in clinical trials [3, 9, 40]. The
dendritic cells then serve to activate the T cells into an immune response against
PAP. Dendritic cell vaccines have been suggested as a method to improve the efficacy
of hormone therapy treatment of advanced prostate cancer. In fact, Provenge is an
FDA-approved dendritic cell vaccine for advanced prostate cancer which has been
shown to extend the life of patients [4, 11].
An emerging field among mathematical oncology is determining optimal dosing
strategies in order to manage cancer. Metronomic therapy, or the use of much lower
dosages of medication more frequently, has been mathematically investigated as a
possible alternative to large dosage strategies [29, 30]. There are many advantages
towards this type of approach: lowering cytotoxicity, lowering costs, and increasing
time until treatment resistance. This strategy aims to manage cancer, rather than
eradicate it.
This research examines the effect of varying the frequency in which the patient
receives dendritic cell vaccines on long term behavior of prostate cancer. We exam-
ine not only the case of discrete injections, but also consider a continuous injection,
as through an intravenous (IV) therapy. We perform analysis on the model to de-
termine biologically realistic parameter values which could result in stable condition
of the disease or the elimination of the prostate cancer, and analytical results are
corroborated with simulations. The parameters which do not have existing litera-
ture values, or are patient-specific, are thoroughly investigated with simulations to
determine what changes to dendritic cell vaccine therapy must be implemented to
delay the onset of androgen independent prostate cancer. Additionally, we exam-
ine the quasi-steady state system and perform a full analysis of the steady states,
determining what conditions are necessary to generate global stability.
2. Model Formulation. There have been many mathematical models that discuss
the evolution and treatment of prostate cancer using androgen deprivation therapy.
In 2004, Jackson [20] formulated a partial differential equation model which featured
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both androgen independent and androgen dependent cancer cells. This model ex-
hibited the effects of androgen independent relapse consistent with experimental
data [20]. Ideta et. al [19] formulated a mathematical model comprised of ordinary
differential equations designed to determine prostate cancer growth while on inter-
mittent androgen therapy. Their model featured androgen concentration, androgen
independent, androgen dependent cancer cells, with a term to model the mutation
rate from androgen dependent to androgen independent in the absence of androgen.
Many have extended upon the model proposed by Ideta et. al. Hirata et. al [15]
extended their model to include two sub-classes of androgen-independent cancer
cells: a subpopulation whose mutation to androgen-independent was reversible, and
a subpopulation who’s mutation to androgen-independent was irreversible. From
this model, they have investigated how to optimize patient treatment protocols
[14, 16]. Additionally, they were able to use the model to classify patients and
determine whether intermittent androgen deprivation therapy would be more or
less effective for each type of patient [13]. Most recently, they have analyzed their
model to find conditions for existence non-trivial periodic orbits for one of the types
of patients [12].
Tanaka et. al [41] extended the Ideta et. al model by incorporating stochasticity,
for more realistic PSA level data. Portz et. al [37] introduced cell quotas to model
how dependent the androgen-dependent and androgen-independent cancer cells are
on androgen concentration. This model has been furthered by other researchers
and compared to previous models [8, 32].
Immunotherapy has also been formulated by mathematicians. Kirschner and
Panetta [24] established a model which quantified the anti-tumor immune response
using populations of T cells, IL2, and tumor cells. Their model also allowed for
incorporation of therapy. In the context of prostate cancer, Kronik et. al [26] for-
mulated a mathematical model which investigated the response of prostate cancer
to dendritic cell vaccines, corroborated with patient data. However, they only con-
sidered one type of tumor cell population and did not account for hormonal therapy.
There has been little work in investigating the combination of dendritic cell vac-
cines with any type of androgen deprivation therapy. Portz and Kuang [27, 36]
examined immunotherapy in conjunction with IAD for prostate cancer which com-
bined the Ideta et. al model [19] with the Kirschner and Panetta [24] model. Their
system of 6 equations included androgen independent cells, androgen dependent
cells, androgen, cytokines (IL-2), activated T cells, and dendritic cells. Recently,
Peng et. al [35] used a 10-dimensional ordinary differential equation model to inves-
tigate how androgen deprivation therapy combines with immunotherapy, including
dendritic cell vaccines. They were able to determine how to synergistically combine
ADT with immunotherapy and fit their model with mouse data. However, their
model did not take into account intermittent androgen deprivation therapy.
Our model is based on the Portz and Kuang [27,36] model described above with
some appropriate modifications. Their results showed that adding dendritic cell
vaccines resulted in an increase in time to androgen independent relapse. However,
the study did not consider how the dynamics of dosage amounts and frequencies
for the dendritic cell vaccines might influence the outcome of the treatment. It
has been hypothesized in a mathematical model that changing the dosages and
frequency of administration of the dendritic cell vaccine may drastically alter the
time to androgen-independent relapse [26].
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Our mathematical model is a population-style model of the interaction between
androgen-dependent cancer cells (X1), androgen independent cancer cells (X2), ac-
tivated T cells (T ), concentration of cytokines (IL), concentration of androgen (A),
and number of dendritic cells (D).
dX1
dt
= r1(A,X1, X2)X1︸ ︷︷ ︸
growth and death
− m1(A)X1︸ ︷︷ ︸
mutation to AI
+ m2(A)X2︸ ︷︷ ︸
mutation from AI
−X1 f1(X1, X2, T )︸ ︷︷ ︸
death by T cell
, (1)
dX2
dt
= r2(X1, X2)X2︸ ︷︷ ︸
growth and death
+ m1(A)X1︸ ︷︷ ︸
mutation from AD
− m2(A)X2︸ ︷︷ ︸
mutation to AD
−X2 f2(X1, X2, T )︸ ︷︷ ︸
death by T cell
, (2)
dT
dt
=
eD
g +D︸ ︷︷ ︸
activation of T cell by DC
− µT︸︷︷︸
death
+ Tf3(IL, T )︸ ︷︷ ︸
activation of T cell by cytokines
, (3)
dIL
dt
= Tf4(X1, X2)︸ ︷︷ ︸
secretion by tumor
− ωIL︸︷︷︸
degradation
, (4)
dA
dt
= γ(a0 −A)︸ ︷︷ ︸
homeostasis of androgen
− γa0u(t)︸ ︷︷ ︸
depletion of androgen if on therapy
, (5)
dD
dt
= − cD︸︷︷︸
death
. (6)
The androgen-dependent cancer cells (AD) are governed by their proliferation
and death (given by r1(A,X1, X2)), their mutation to androgen independent cancer
cells (AI), the mutation from androgen independent cells, and the number killed by
T cells. The AI cancer cells are also governed by proliferation and death, indepen-
dent of androgen, their mutation from AD cells, their mutation to AD cells, and
the number killed by the T cells. The T cell counts are determined by the number
activated by the dendritic cells, their natural death, and clonal expansion. The
concentration of cytokines is determined by their production by stimulated T cells
and a clearance rate. The concentration of androgen in the blood is described by
homeostasis term and deprivation therapy term. The dendritic cells are governed
by their death rate.
The modeling of the intermittent androgen deprivation therapy is governed by
the u(t). Note that if u(t) = 1, we are modeling the ‘on-treatment’ portion of the
therapy, and when u(t) = 0, we model the ‘off-treatment’ therapy. Below are the
detailed equations:
y(t) = c1X1 + c2X2, (7)
u(t) =
{
0→ 1 if y(t) > L1 and dydt > 0,
1→ 0 if y(t) < L0 and dydt < 0.
(8)
In this case, y(t) represents the serum PSA level. When the PSA level decreases
below a certain threshold, L0, the androgen deprivation therapy begins. When the
PSA level increases above another threshold level, L1, the ’on-treatment’ therapy
starts. Note that L0 < L1.
Although our model is similar to the Portz and Kuang model, we include three
major changes which allow for a more realistic model. Firstly, we change the growth
and death functions. The original model incorporated an exponential growth rate
for the androgen independent cell population, which is very unrealistic. We modified
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this growth function to be logistic. Similarly, we change the growth and death for the
androgen dependent cell population. We assume that the lack of androgen affects
the androgen dependent cell population in two ways: lack of androgen lowers the
growth rate, and the lack of androgen actively kills the cell population. This is
a realistic assumption which has been used in other prostate cancer models with
great success [7,21]. We note that when androgen is at its homeostatic level, a0, the
growth rate of androgen-dependent cells is at its highest. As the levels of androgen
decrease, the growth rate of androgen-dependent cells also decreases, and the death
due to lack of androgen increases. When androgen is at its lowest value, 0, there is
no growth of androgen dependent cells, and the highest death rate due to lack of
androgen happens.
r1(A,X1, X2) = r1A
(
1− X1 +X2
K
)
− d1(a0 −A),
r2(X1, X2) = r2
(
1− X1 +X2
K
)
.
(9)
The second major change considers the mutation functions. The original model
assumed that AD cells mutated to AI cells in an androgen-depleted environment.
However, they did not consider the option that AI cells might mutated back to AD
cells in an androgen-rich environment. We include this second mutation term in
our model. If A = a0, we note that there would be no mutation from AD to AI
cell population, as we are at the homeostatic androgen levels. As we decrease the
level of androgen, we increase the rate at which AD to AI mutations occur, until
we reach A = 0, which gives the largest mutation rate m1. For mutation from
AI to AD, we assume a similar, but opposite function. When we have low levels
of androgen, we assume that there is no mutation from AI to AD. However, as
we increase through androgen levels, the mutation rate from AI to AD increases
accordingly. The mutation rate functions are listed below.
m1(A) = m1
(
1− A
a0
)
,
m2(A) = m2
(
A
A+ k4
)
.
(10)
The third major change we consider is using a generic class of functions for the
four immune system interactions. As the immune system is extremely complicated
with many interacting cells, there is not much data to help form a hypothesis on
how these various components of the immune system interact together. In order
to combat this, we consider functions that are generic, but we do want some basic
properties for these functions. Specifically, we assume the following.
(A1): f1(X1, X2, 0) = f2(X1, X2, 0) = f3(0, T ) = f4(0, 0) = 0.
(A2):
∂f1
∂X1
≤ 0, ∂f2
∂X2
≤ 0, and ∂f1
∂T
≥ 0, ∂f2
∂T
≥ 0.
(A3):
∂f3
∂IL
≥ 0, ∂f4
∂Xi
≥ 0, i = 1, 2.
3. Simulations and Observations. There are many potential functions which
could be excellent candidates for our fi, but a logical choice would be a Holling
Type II function. It is reasonable to assume that after a large enough presence of
cancer cells, the death rate would approach a maximum death rate. It is not sensible
183
6 E. M. RUTTER AND Y. KUANG
to use a linear function which would assume the death rate is proportional to the
number of cancer cells. The functions that we propose and use for simulations are:
f1(X1, X2, T ) =
e1T
g1 +X1 +X2
,
f2(X1, X2, T ) =
e2T
g2 +X1 +X2
,
f3(IL, T ) =
e3IL
g3 + IL
,
f4(X1, X2) =
e4(X1 +X2)
g4 +X1 +X2
.
(11)
Explanations for the various parameters and their chosen values , as well as their
respective sources are displayed in Table 1.
As we were unable to find a literature estimate on what the carrying capacity
of the tumor cells would be, we decided to estimate with a brief calculation. The
mean weight of a male prostate is 11 grams (7-16 grams) and the average human
cell has a mass of 1 ng. Thus, we can conjecture that the carrying capacity is on
the order of 10 billion cells.
In previous iterations of the immunotherapy mathematical model, hypothetical
vaccines were administered every 30 days consisting of 0.3 million dendritic cells.
In order to preserve the correct dosage, when the length between vaccinations was
altered, the dosage was also altered accordingly. For the discrete case, variances
from daily vaccinations to vaccinations separated by 120 days were considered.
Simulations are extended to 4000 days to be able to determine long-term behavior of
the prostate cancer. A continuous dose of dendritic cell vaccines was also considered,
as if constantly administered through an IV. All simulations have the same initial
conditions with initial AD count of 15 million cells, AI count of 0.1 million cells, 0
activated T cells, 0 concentration of cytokines (ng/mL) , 30 nmol/mL concentration
of androgen, 0 dendritic cells. We have set the threshold to turn off treatment L0
as 5 and the threshold to begin treatment L1 as 15
ng
mL .
Once graphical results are obtained, it is advantageous to determine numerically
and analytically whether the more successful dendritic cell vaccination timings have
an overall effect.
3.1. Discrete Case. For all numerics, we consider that e1 = e2, which means that
T cells are able to kill AD and AI cancer cells equivalently. We begin by keeping
e1 = e2, the effectiveness with which the T-cells eliminate cancer cells steady at a
value of 0.75, which is reasonable within the range given in Table 1 . We run a
series of simulations, out to 4000 days, varying only the dosage level and frequency
of the dendritic cell vaccine. The vaccination frequencies are varied from daily
vaccinations to 120 days between each injection, and the dosages are varied from
0.01 to 1.20 million cells, respectively.
Figure 1 displays the PSA levels, androgen dependent (X1) and androgen inde-
pendent (X2) cell densities versus time in days. We can see from the graph that
the androgen suppression is triggered when the level reaches about 15 ngmL , and is
discontinued when the level reaches about 5 ngmL . As can be seen, the PSA levels
eventually skyrocket, indicating rise of androgen independent cancer. When the
PSA levels grow drastically, it is clear that androgen suppression therapy is no
longer effective. The effect is clear in the corresponding AD and AI graphs: the
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P Biological Meaning Value Source
r1 AD cell proliferation rate 0.025/day [1]
β1 AD cell death rate 0.008/day [1]
K cancer cell carrying capacity 11 billion
k4 AI to AD mutation half-saturation 1.7
r2 AI net cell growth rate 0.006/day [1]
m1
maximum mutation rate 0.00005/day [19]
from AD to AI
m2
maximum mutation rate 0.00015/day [37]
from AI to AD
a0 base level androgen concentration 30 ng/ml [19]
γ
androgen clearance 0.08/day [19]
and production rate
ω cytokine clearance rate 10/day [38]
µ T cell death rate 0.03//day [24]
c dendritic cell death rate 0.14/day [31]
e1 max rate T cells kill AD cancer cells 0-1/day [24]
g1
AD cancer cell saturation level 10 x 109 cells [24]
for T cell kill rate
e2 max rate T cells kill AI cancer cells 0-1/day [24]
g2
AI cancer cell saturation level 10 x 109 cells [24]
for T cell kill rate
e T cell max activation rate 20 x 106 cells/day [24]
g
DC saturation level 400 x 106 cells [40]
for T cell activation
e3 max clonal expansion rate 0.1245/day [24]
g3
IL-2 saturation level 1000 ng/ml [24]
for T cell clonal expansion
e4 max rate T cells produce IL-2 5 x 10
−6 ng/ml/cell/day [24]
g4
cancer cell saturation level 10 x 109 cells [24]
for T cell stimulation
D1 DC vaccine dosage 300 x 10
6 cells [40]
c1 AD cell PSA level correlation 1 x 10
−9 ng/ml/cell [19]
c2 AI cell PSA level correlation 1 x 10
−9 ng/ml/cell [19]
Table 1. Values of parameters (P), explanations, and cited
sources of every parameter used in this mathematical model.
AD cancer cells are eliminated in the infrequent injections, which gives rise to the
more fatal androgen independent cancer. This is exhibited through the AI count,
which skyrockets in the infrequent injection case. The rapid increase of AI cells
indicates that the more fatal androgen resistant prostate cancer has begun. From
these graphs, it is apparent that more frequent injections of the dendritic cell vac-
cine can help the effectiveness of the intermittent hormone therapy, delaying the
rise of androgen independent cancer.
We can see that by increasing the frequency of the injections, but keeping the to-
tal dosage identical, there are vast improvements in the survival time of the patient.
In order to quantify this relationship, we perform numerical analysis to determine
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Figure 1. PSA serum concentration, androgen dependent (AD),
and androgen independent (AI) cell concentrations for various den-
dritic cell vaccine injection times with an e1 = e2 of 0.75. More
frequent injections result delay of the rise of fatal androgen inde-
pendent cancer.
the lowest value of e1 required for the solution to produce a limit cycle. A limit
cycle in this case would represent a stable disease equilibrium, where the cancer is
indefinitely responsive to IAD treatment. Recall that e1, e2 represent the cytotoxi-
city of the T-cells, a measure of how efficient a T cells is at killing the tumor cells.
The biological range, as stated in 1 ranges from 0-1, cancer cells killed per day. A
summary of the limit cyclical behavior is charted in figure 2.
We immediately notice that as vaccine timing is shortened, the minimal value
of e1 necessary to exhibit a stable disease state also decreases. We recall that e1
could be a patient-specific parameter, as it is the maximum rate that T cells kill
cancer cells per day. Thus, for those with weaker immune systems, more frequent
injections could be much more effective. We note that for cases where the vaccine
timing is greater than 30 days, even with values of maximal e1 = 1, there is no stable
disease state. Therefore, infrequent large doses of vaccine are much less effective at
stabilizing the disease. Additionally, we can examine the shape of the limit cycles:
as we increase the frequency of the dosage, we notice that the limit cycles are much
smoother.
3.2. Continuous Case. We have shown that, even for total amount of vaccine be-
ing constant, more frequent dendritic cell vaccine administrations are more effective
than infrequent administrations. If we consider the limiting case of this behavior,
we arrive at the case of a continual injection, as if the patient is always connected
to the vaccine through an IV system. In order to accommodate for the continual in-
jection, we slightly modify the equation (6) representing the dendritic cell numbers
to: dDdt = v − cD, where v is the continual injection rate.
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Figure 2. Limit cycle solutions for androgen dependent X1, and
androgen independent X2 cancer cells. The minimal value of e1
required to produce limit cycle behavior is noted above each solu-
tion. As vaccine timing decreases, minimal e1 necessary to have
stable disease state decreases.
The simulation begins in this case with an initial injection of 0.04 billion dendritic
cells, which is then kept constant throughout the duration of the simulation. For this
continuous case, a variety of values of e1 were considered, to determine if continuous
vaccinations may help eliminate cancer. Figure 3 displays the PSA concentration
for the different cases. We can see that contrary to the discrete case, it is apparent
that even at lower values of e1 = 0.25, the cancer is manageable. In fact, we even
see elimination of cancer for very large values of e1, for e1 > 0.75.
In order to clearly see if the cancer is manageable for lower values of e1 we turn
to the cell counts for AD and AI cancer cells. Figure 3 displays these counts for
the continual dendritic cell vaccinations. It is apparent for the duration of the
simulation, AI cells only become dominant for the e1 values of 0 and 0.25. This
implies that androgen independent cancer is avoidable for a larger range of e1 values
than in the discrete case. This means that despite a weaker auto-immune response,
it may be possible to suppress the growth of androgen independent cancer cells.
Additionally, the treatment cycle lengths are very different depending on the e1
value: as we increase through our e1 value, we see that the length of ‘off-treatment’
is much longer, resulting in more comfort for the patient.
Since we see a full range of behavior as we increase through e1, we take a closer
look at a bifurcation diagram for the parameter. The resulting bifurcation diagram
is shown in Figure 4. We can see that during most biologically relevant parameter
values of e1, which is a range of 0-1, we have cyclical behavior. At the smallest
range of e1 = 0, we have stability of carrying capacity equilibrium. However,
once we increase past e1 = 0, we can see that we have stable cyclical behavior.
As observed in Figure 3, as we increase through e1 we continue observing stable
disease cycles. Finally, for higher values of e1, we notice that the cycles collapse
into a single steady state solution, which is stable. As we continue increasing e1
187
10 E. M. RUTTER AND Y. KUANG
0 500 1000 1500 2000 2500 3000 3500 4000P
SA
 (n
g/m
L)
0
50
100 e1=0
e1=0.25
e1=0.5
e1=0.75
e1=1
0 500 1000 1500 2000 2500 3000 3500 4000
AD
 c
el
ls
0
10
20
time (days)
0 500 1000 1500 2000 2500 3000 3500 4000
AI
 c
el
ls
10-5
100
105
Figure 3. PSA serum level, AD cell density, and AI cell density
for continual dendritic cell vaccinations, with an injection rate 0.04
billion cells for various values of e1. It is apparent that in this
continuous case, a wider range of e1 is able to suppress the growth
of cancer and elongate the cycles of IAD.
past this point, the steady state approaches zero, which represents the eradication
of the disease. We note that in examining the solutions for small values of e1, the
graph appears to be zigzagging. We believe this may be due to the model dynamics
having a long transition time before approaching the limiting periodic state. We
also have interesting dynamics at e1 = 0.24, where we seem to approach a steady
state, before the solution switches back into cyclical behavior.
4. Basic Properties of the System. Although numerically studying the behav-
ior of equations is useful, further information can be gathered by analysis of the
equations themselves. It is also a metric to ensure that the behavior of the solu-
tions have biological meaning. In order to analyze our equations, we assume that
we are in fact continuously suppressing the androgen, instead of intermittent sup-
pression. This assumption will lead to the following change of equation governing
the concentration of androgen:
dX1
dt
= r1(A,X1, X2)X1 −m1(A)X1 +m2(A)X2 −X1f1(X1, X2, T ), (12)
dX2
dt
= r2(X1, X2)X2 +m1(A)X1 −m2(A)X2 −X2f2(X1, X2, T ), (13)
dT
dt
=
eD
g +D
− µT + Tf3(IL, T ), (14)
dIL
dt
= Tf4(X1, X2)− ωIL, (15)
dA
dt
= −γA, (16)
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Figure 4. Birfurcation digram for parameter e1, a measure of
cytotoxicity of T-cells. Maximum PSA level in black, minimum
PSA level in green. Carrying capacity is stable only for e1 = 0.
Immediately after, we have a Hopf bifurcaton and limit cycles,
until we reach e1 ≈ 0.66, after which the disease-free steady state
is stable.
dD
dt
= v − cD. (17)
Proposition 1. Solutions of (12)-(17) that start positive remain positive.
Proof. Solutions for D and A are explicitly solvable, whose solutions are positive.
If solutions do not remain positive there must be some time t1 > 0 such that
X1(t1) = 0, X2(t1) = 0, T (t1) = 0 or IL(t1) = 0. We examine the first case
where X1(t1) = 0. Then X
′
1(t) ≥ −m1(A)X1, ∀ t ∈ [0, t1], or more specifically,
X1(t1) ≥ X1(0)e−m1(A)t1 > 0, which is a contradiction. Similar arguments can be
extended to the remaining variables, ensuring positivity of all solutions.
We now examine the equations in detail to determine equilibrium points and their
respective stabilities. We hope that this will give us as sense of biological meaning.
What values must biological parameters exhibit in order for prostate cancer to be
eliminated?
Proposition 2. The model system (12)-(17) has a disease-free equilibrium E∗0 =
(0, 0, evµ(cg+v) , 0, 0,
v
c ) with growth functions (9), mutation functions (10), and generic
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functions. E∗0 is unstable if r2 > f2(0, 0, T
∗
0 ), where T
∗
0 =
ev
µ(cg+v) , and locally
asymptotically stable if r2 ≤ f2(0, 0, T ∗0 ). When r2 > f2(0, 0, T ∗0 ), a positive en-
demic equilibrium E∗ = (X∗1 , X
∗
2 , T
∗, I∗L, A
∗, D∗) emerges, stability unknown.
Proof. All variables except X2 are easily solved and have only one steady state.
For X2, we can either have X
∗
2 = 0, which exists always, or an X2 that solves
g(X2) := r2 − r2X2K − f2(0, X2, T ∗) = 0. We examine this quantity in more detail
by calculating its sign at X2 = 0:
g(0) = r2 − f2(0, 0, T ∗0 )
where T ∗0 =
ev
µ(cg+v) is the corresponding T
∗ value when X∗2 = 0. Next we calculate
the sign as X2 → K, its maximum possible value:
g(K) = −f2(0,K, T ∗K) < 0
Thus, if r2 − f2(0, 0, T ∗0 ) < 0, there is no biologically relevant X2 value that solves
g(X∗2 ) = 0, since the function f2 is monotonically decreasing in X2. Therefore,
there is only the trivial, disease-free equilibrium E∗0 = (0, 0,
ev
µ(cg+v) , 0, 0,
v
c ) in our
domain.
On the other hand, if r2 − f2(0, 0, T ∗0 ) > 0 then, by the Intermediate Value
Theorem, there must be some X∗2 ∈ (0,K) which solves g(X∗2 ) = 0, giving us an
endemic equilibrium E∗1 = (0, X
∗
2 , T
∗
1 , I
∗
L1, 0,
v
c ), representing androgen-independent
relapse.
Now that the equilibria have been found, we now turn to finding the eigenvalues
of the Jacobian to determine stability. We examine the disease-free equilibrium E∗0 ,
which generates the following matrix:
a1,1 0 0 0 0 0
m1 r2 − f2(0, 0, T ∗0 ) 0 0 0 0
0 0 −µ T ∗0 ∂∂IL f3(0, T ∗0 ) 0
ceg
cg+v
T ∗0
∂
∂X1
f4(0, 0) T
∗
0
∂
∂X2
f4(0, 0) 0 −ω 0 0
0 0 0 0 −γ 0
0 0 0 0 0 −c

where (a1,1 = −d1a0 −m1 − f1(0, 0, T ∗0 ). This Jacobian results in the following set
of eigenvalues, −d1a0 −m1 − f1(0, 0, T ∗0 ), r2 − f2(0, 0, T ∗0 ),−µ,−ω,−γ,−c). Since
we know that all parameters are non-negative, and assuming that all parameters
are in fact positive, we can see that all eigenvalues except one are guaranteed to be
negative. Only r2 − f2(0, 0, T ∗0 ) has the possibility to be negative, positive, or zero.
If r2 − f2(0, 0, T ∗0 ) < 0, we in fact have the cancer-free equilibrium to be stable.
Otherwise if r2 > f2(0, 0, T
∗
0 ), the cancer-free equilibrium is unstable.
We would like to understand biologically what this means. We write our stability
condition as r2 < f2(0, 0, T
∗
0 ) : this means the maximal growth rate of androgen
independent cells is less than the death rate of androgen independent cells due
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to T cells. We observe that since these functions are monotone, in the case of
strictly monotone function, we can invert f2 to find an equivalent condition that
involves T ∗0 . Recalling that T
∗
0 =
ev
µ(cg+v) , this means we can solve for an explicit
solution involving v, our critical dosage parameter. Theoretically, if the remaining
parameters could be measured for a patient, a critical dosage could be calculated.
We note that if given patient specific parameters such as their individual T cell
efficiencies, we are able to calculate a necessary dose level to stabilize the disease-
free equilibrium. In the context of our proposed simulation functions fi, given in
(11), our condition for stability becomes v > cgg2r2µe2e−g2r2µ , which is indeed a critical
dosage value.
5. Global Analysis of Limiting System. As the full system is difficult to per-
form analysis on, we consider the limiting systems by performing a quasi-steady
state approximation. This can give insight into the biology. We begin by assuming
quasi-steady states for androgen, cytokines, and dendritic cells. This is a reasonable
assumption, since the time scales at which these processes occur is much shorter
than that of the populations of cancer cells growing. Then, we use the results of
Thieme [42] to examine the asymptotic behavior of the limiting system. We con-
sider the system when androgen deprivation therapy is continual (A = 0). We will
examine the case where androgen deprivation therapy is continually on thoroughly
and determine necessary conditions of fi(X1, X2, T ) to obtain global stability of
eradication of prostate cancer and conditions for global stability of the diseased
steady state.
We examine the case where androgen deprivation therapy is turned on (A = 0).
We let IL, D, and A go to quasi-steady state. We end up with the following set of
equations:
dX1
dt
= −d1a0X1 −m1X1 −X1f1(X1, X2, T ), (18)
dX2
dt
= r2X2
(
1− X1 +X2
K
)
+m1X1 −X2f2(X1, X2, T ), (19)
dT
dt
=
eD
g +D
− µT + Tf3(IL, T ), (20)
IL =
Tf4(X1, X2)
ω
, (21)
A = 0, (22)
D =
v
c
. (23)
Note that:
dX1
dt
= X1 [−d1a0 −m1 − f1(X1, X2, T )]
≤ X1 [−d1a0 −m1]
≤ −aX1.
(24)
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It is apparent that lim
t→∞X1(t) = 0. Thus we can reduce the system to:
dX2
dt
= r2X2
(
1− X2
K
)
−X2f2(0, X2, T ),
dT
dt
=
eD
g +D
− µT + Tf3(IL, T ),
(25)
which is defined on the subdomain Ω¯ = {(X2, T ) : X2 ≥ 0, T ≥ 0} and is the
limiting system of (18)-(23).
Before we begin the analysis of the system, we would like to ensure that the
behavior of the quasi-steady state system is analogous to the full system. We must
quantify what dynamics are preserved and eliminated by simplifying the system.
We run the system with the same parameters for the full system and for the reduced
system. Figure 5 shows the comparison. We can see that by examining the quasi-
steady state system we do lose some of the dynamics in certain cases, like when
e1 = 0.15. We note that this falls into the regime of ’chaotic’ behavior, so it is
not surprising that we do not have identical dynamics. For all other values of e1,
however, we note that the quasi steady-sate system very closely resembles the full
system, meaning that our results for the quasi-steady state system may be extended
to the full system. We also note that our expected outcome – that X1 goes to zero,
is exhibited in all of the figures.
Theorem 5.1. The disease-free steady state of (18)-(23) is globally asymptotically
stable under the following conditions:
i) µ > f3(IL, T ),
ii) r2 < f2(0, 0, T
∗
0 ),
iii) µ
2(cg+v)
ev >
∂
∂T f3(0, T
∗
0 ).
To prove this theorem, we break down the result into several propositions for
simplicity. We will begin with positivity and boundedness, move to local asymptotic
stability, and end with conditions necessary for global asymptotic stability.
Proposition 3. If µ > f3(IL, T ) then solutions of (18)-(23) remain positive and
bounded.
Proof. We begin with the proof for positivity, examining T first. We note that since
we are assuming that T (t0) ≥ 0, in order for T (t) < 0 for some t, we would require
that dTdt < 0 when T = 0. However,
dT
dt |T=0 = eDg+D > 0 since all parameters are
positive. For X2, since we are assuming that X2(t0) ≥ 0, in order for X2(t) < 0
for some t, we would require that dX2dt < 0 when X2 = 0. However,
dX2
dt |X2=0 =
m1X1 > 0 since we have already proved that X1 stays positive and all parameters
are positive.
We have already proven that solutions remain nonnegative, so we now look to
boundedness. We begin with T :
dT
dt
=
eD
g +D
+ T (f3(IL, T )− µ)
≤ c− g¯T
(26)
where g¯ = min[µ− f3(IL, T )] > 0 by assumption. This implies that T is bounded.
We look towards the boundedness of X2 now. We immediately see that X2 is
bounded above by K.
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Figure 5. Comparisons of the full system and quasi-steady state
system for various values of e1: 0, 0.15, 0.25, and 0.65, assuming
androgen deprivation therapy is constantly on. These values of
e1 show many differing dynamics. The quasi-steady state system
closely approximates the full system in every case, but shows slight
differences in the case of e1 = 0.15
Proposition 4. The limiting system (25) contains two equilibria: the disease-free
equilibrium and a negative equilibrium, under assumption ii): r2 < f2(0, 0, T
∗
0 ). The
disease-free equilibrium is locally asymptotically stable under assumption ii) and iii):
g+D
eD >
∂
∂T f3(0, T
∗
0 ).
Proof. There are two possible equilibria of the system. Following the proof from
Proposition 2: if r2 < f2(0, 0, T
∗
0 ), only the disease-free equilibrium exists, E
∗
0 =
(0, T ∗0 ). The local stability of the disease-free steady state E
∗
0 = (0,
ev
µ(cg+v) ) is
exhibited in the Jacobian:
r2 − f2(0, T ∗0 ) 0
T ∗0
∂
∂X2
f3(0, T
∗
0 ) −µ+ T ∗0 ∂∂T f3(0, T ∗0 )

and the eigenvalues are given by λ1 = r2 − f2(0, 0, T ∗0 ) < 0 as given by the as-
sumptions, and λ2 = −µ + T ∗0 ∂∂T f3(0, T ∗0 ) < 0 (by condition iii), so we have local
asymptotic stability.
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We are now ready to prove the main result for global asymptotic stability.
Proof of Theorem 5.1. Since solutions to the system are positive and bounded, we
immediately see that there can be no limit cycles around our non-negative equilib-
rium, since our only equilibrium is on the boundary. By Poincare-Bendixson, all
solutions tend towards the disease-free steady state, so E∗0 is globally asymptotically
stable.
We can interpret two of these conditions for the global stability in terms of
biology. We can see that the condition r2 < f2(0, T
∗
0 ) can be interpreted as the
maximal intrinsic growth rate of the cancer cells must be less than the death rate
due to the T cells. Recall that this was the condition for local stability of the
full system, so we are unsurprised to see the same condition again. Similarly, µ >
f3(IL, T ) means that we want the death rate of the T cells to be greater than
the production of T cells due to IL. Now that we have examined the conditions
for global stability for the disease-free equilibrium, we also want to explore the
dynamics for the equilibrium that is not disease-free.
Theorem 5.2. The diseased steady state of (18)-(23) is globally asymptotically
stable under the following conditions:
i) µ > f3(IL, T ),
ii) r2 > f2(0, 0, T
∗
0 ),
iii) µ− f3(IL, T ) > −X2 ∂∂X2 f2(X1, X2, T ) + T ∂∂T f3(IL, T )− r2X2K ∀X2, T ≥ 0.
To prove this theorem, we break down the result into several propositions for
simplicity. We will begin with positivity and boundedness, move to local asymptotic
stability, followed by eliminating limit cycles, and end with conditions necessary for
global asymptotic stability.
Proposition 5. If condition i) is satisfied, then solutions of (18)-(23) remain pos-
itive and bounded.
Proof. Positivity and boundedness have already been proven in Proposition 3, and
the results hold for current conditions, as long as we assume condition i).
Proposition 6. The limiting system (25) contains two equilibria: the disease-free
equilibrium, E∗0 , and a secondary equilibrium, E
∗
1 . The secondary equilibrium is
positive (assuming condition ii)). The disease-free equilibrium is a saddle point
(under conditions ii) and iii)).
Proof. The existence of the equilibria follow from Proposition 2, so we know that
under condition ii), if r2 > f2(0, T
∗
0 ), we will have two biologically relevant equilibria:
E∗0 = (0, T
∗
0 ) = (0,
ev
µ(cg+v) ) and E
∗
1 = (X
∗
2 , T
∗
1 ).
The local stability of the disease-free steady state E∗0 is exhibited in the Jacobian:
r2 − f2(0, T ∗0 ) 0
T ∗0
∂
∂X2
f3(0, T
∗
0 ) −µ+ T ∗0 ∂∂T f3(0, T ∗0 )

and the eigenvalues are given by λ1 = r2 − f2(0, T ∗0 ) > 0 by condition ii) and
λ2 = −µ+ T ∗0 ∂∂T f3(0, T ∗0 ) < 0, by condition iii). Thus, the disease-free equilibrium
is a saddle point.
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Now we examine the Jacobian of the diseased equilibrium:

− r2X∗2K −X∗2 ∂∂X2 f2(X∗2 , T ∗1 ) −X∗2 ∂∂T f2(X∗2 , T ∗1 )
T ∗1
∂
∂X2
f3(I
∗
L, T
∗
1 ) −µ+ T ∗1 ∂∂T f3(I∗L, T ∗1 ) + f3(I∗L, T ∗1 )
 .
Thus, the trace is given by
τ = −r2X
∗
2
K
−X∗2
∂
∂X2
f2(X
∗
2 , T
∗
1 )− µ+ T ∗1
∂
∂T
f3(I
∗
L, T
∗
1 ) + f3(I
∗
L, T
∗
1 ) (27)
and the determinant is given by
∆ =
(
−r2X
∗
2
K
−X∗2
∂
∂X2
f2(X
∗
2 , T
∗
1 )
)(
−µ+ f3(IL,∗ T ∗1 ) + T ∗1
∂
∂T
f3(I
∗
L, T
∗
1 )
)
+
(
X∗2
∂
∂T
f2(X
∗
2 , T
∗
1 )T
∗
1
∂
∂X2
f3(I
∗
L, T
∗
1 )
)
.
(28)
In order for E∗1 to be stable we require τ < 0,∆ > 0. Notice that τ < 0 is given
by assuming condition iii). However, we have no idea about the sign of ∆. Given
our information of τ < 0, we know that E∗1 is either a saddle point or a stable
node/spiral.
Proposition 7. The limiting system (25) has no limit cycles as long as condition
iii) is satisfied.
Proof. We will be using the Dulac criterion to establish that there are no periodic
orbits within. Using h(X2, T ) =
1
X2
, we can see that
∆ =
∂
∂X2
[
1
X2
(
r2X2
(
1− X2
K
)
−X2f2(X2, T )
)]
+
∂
∂T
[
1
X2
(
eD
g +D
− µT + Tf3(IL, T )
)]
=
∂
∂X2
[
r2 − r2X2
K
− f2(X2, T )
]
+
∂
∂T
[
eD
X2(g +D)
− µT
X2
+
T (f3(IL, T ))
X2
]
= −r2
K
− ∂
∂X2
f2(X2, T )− µ
X2
+
f3(IL, T )
X2
+
T
X2
∂
∂T
f3(IL, T )
To ensure that there are no periodic orbits, we must prove that this quantity ∆
does not change sign. We begin by re-writing this condition:
X2∆ = −r2X2
K
−X2 ∂
∂X2
f2(0, X2, T )− µ+ f3(IL, T ) + T ∂
∂T
f3(IL, T ). (29)
We know that for X2, T ≥ 0, ∆ < 0 by condition iii). Thus, the Dulac criterion has
ensured that we will have no periodic orbits in our domain.
We are now ready to prove the main result for global asymptotic stability.
Proof of Theorem 5.2. By Proposition 7, we can see that there are no limit cycles
present. Solutions are positive and bounded, and the model system has two fixed
points, one of which is a saddle point. By the Poincare-Bendixson theorem, we know
that there are three possibilities: all solutions tends to a fixed point, all solutions
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tend to a periodic orbit, or there is a homoclinic or heteroclinic orbit which connects
our two fixed points. We have ruled out periodic orbits by Dulac criterion using
condition iii).
Now we must show there is no homoclinic or heteroclinic orbits connecting our
fixed points.
In order to show there is no heteroclinic orbit connecting the two fixed points,
we look towards the stable manifold of the saddle point. Looking back towards our
Jacobian, we can clearly see that the stable manifold is given by the T -axis(
X2
T
)
=
(
0
1
)
. (30)
Due to assumption ii), we notice that near the disease free steady state E∗0 , we have
dX2(t)/dt > 0. These observations preclude the existence of a heteroclinic orbit
connecting E∗0 and E
∗
1 .
The fact that dX2(t)/dt > 0 near E
∗
0 also implies that there is no homoclinic
orbit originating from E∗0 . There can not be any homoclinic orbits originating from
E∗1 if it is stable. The Dulac criteria also rules out homoclinic orbits originating
from E∗1 if it is a saddle.
By Poincare-Bendixson Theorem, the only option remaining is that all solutions
of (25) converge to E∗1 . Thus, E
∗
1 is globally asymptotically stable.
6. Conclusion. Current treatment options for late-stage prostate cancer are sub-
optimal in terms of survival and quality of life. By examining a model of intermittent
hormone therapy coupled with dendritic cell vaccines, we are able to prolong both
the life and quality of life of the patient. We found that, keeping total yearly dosages
the same, more frequent injections are conducive to managing prostate cancer for
a longer period of time. We extrapolate this idea to the extreme by modifying the
model to include a ’continual’ dosage, as if administered through an intravenous
fluid.
In our model, there are several parameters which are patient specific, or do not
have accepted literature values. We examined the effect of varying values of e1, the
killing T-cell efficiency. Predictably, increasing e1 led from androgen-independent
relapse, to stable limit cyclical behavior, and when increased enough, total eradi-
cation of the disease. This parameter measures how effective dendritic cell vaccine
therapy will be - if e1 is small, the therapy will be negligible. e1 also acts to elon-
gate the cycle times for a stable cyclical disease, which means increased time for
the period when the patient is not undergoing androgen deprivation therapy. We
performed bifurcation analysis on parameter e1 to examine the various behaviors
that exist in the system. As our simulations only considered the case where e1 = e2,
we could also investigate how the dynamics change when we allow these values to
be different.
Additionally, for mathematical analysis, we simplify the model to have continu-
ous androgen suppression, in order to determine the effect of continual dosages. We
notice there are two possible equilibria – cancer-free equilibrium and an androgen-
independent (fatal) cancer equilibrium. If our continual dosage is less than a de-
termined critical value, the cancer-free equilibrium exists, but it is unstable. If
our continual dosage is higher than that critical value, the cancer-free equilibrium
is stable and a cancerous equilibrium is born (stability unknown). These findings
have biological significance. In previous papers it has been determined that for a
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30-day vaccine, it is necessary for a large values of e1 to ensure cancer-free progres-
sion [36]. In this analysis, we could have smaller values of e1 that still result in stable
disease-free equilibrium. For patients with less effective immune systems (lower e1
values), it is possible to eradicate cancer with higher presence of dendritic cells. As
dendritic cell vaccines are not known to have an adverse effect on the human body,
it is possible that for patients with weakened immune systems, a tailored dose could
be administered.
We further examined the limiting cases of behavior for this system, by allowing
several parameters to go to quasi-steady state. We were able to determine require-
ments for global stability – or the guarantee of elimination of prostate cancer in
some cases. Additionally, we were able to determine further conditions for the
global stability of the endemic equilibrium.
Despite the insights that this model has afforded us, there is still much to be
done. Future work may include comparing the model with available patient data.
This will allow us to determine the efficacy of this model at predicting behavior of
the prostate cancer. We will also be able to explore the patient-specific parameters
and the effect these have on final outcome. Additionally, we would like to be able to
compare our model with other patient-data validated models. Mathematically, the
local stability of the endemic equilibrium of the full system should also be studied
in detail.
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